

BIOTECH IN BAVARIA – RIGHT ON TRACK

REPORT
2010

including over 250 company
profiles and contact addresses

Where the future becomes reality



HOTSPOTS FOR LIFE SCIENCE STARTUPS

- Lab and office space (S1 & S2)
- Competitive leasing rents
- Furnished, flexible rooms
- In-house estate management
- The center of an impressive research campus
(2 excellent universities TU & LMU, Max Planck Institutes for Biochemistry and Neurobiology, Clinic Großhadern, Gene Center, Biomedical Center, Prion Center, 40 biotech companies)
- Close contacts with investment partners
- Home for more than 50 startups
- Joint location marketing
- Attractive, modern conference rooms also for external booking



**Innovations-
und Gründerzentrum
Biotechnologie IZB**
Martinsried · Freising

Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0) 89 - 700 656 70
Fax: +49 (0) 89 - 700 656 77

we are active
participants in the
CLUSTER
BIOTECHNOLOGY
BAVARIA


www.izb-online.de

Our tenants:

4SC AG (DD) · Adriacell SpA (DD) · AMSilk GmbH (P) · amYmed GmbH (DS) · Bayerische Gewebebank GmbH (P/S) · Bernina Plus & Hartmann Diagnostic Service (DD/DS) · BioM AG (S) · BioM Cluster Development GmbH (S) · BioM WB GmbH (S) · Biontex Laboratories GmbH (P) · ChromoTek GmbH (DS) · Coriolis Pharma (S) · CRELUX GmbH (DD/DS) · DoNatur GmbH (DD) · DPC Pharma Consulting (S) · EKFS Herzchirurgie Prof. Dr. Eissner (DD) · Ella Biotech GmbH (DS) · eticur GmbH (DS) · Exosome Diagnostics Inc. (DS) · Fresenius Biotech GmbH (DD) · FROST LIFESCIENCE (DS/S) · ibidi GmbH (DS) · Kinaxo Biotechnologies GmbH (DD) · Leukocare AG (DS) · MenloSystems GmbH (I) · NanoScape AG (P) · Octapharma Biopharmaceuticals GmbH (DD/DS) · Omegamatrix GmbH (DS) · origenis GmbH (DD/DS) · Patentquadrat Patentanwaltskanzlei (S) · Prionics Deutschland GmbH (S) · Proteros biostructures GmbH (P/S) · quattro research GmbH (DD/DS) · R&D Biopharmaceuticals GmbH (DD/DS) · RSA Consulting GmbH (S) · SiNatur GmbH (DD) · SIRION Biotech GmbH (P/S) · Smart Move GmbH (I) · Smartec Ingenieur Büro GmbH (S) · SpheroTec GmbH (DS) · SuppreMol GmbH (DD) · that's it GmbH (IT-S) · THE WORKING GROUP Unternehmensberatung (S) · TRION Research GmbH (DD/DS) · VELUMETRIX GmbH (S) · Vesalius Biocapital (VC) · aromaLAB AG (S) · ATRES engineering biogas (S) · Euroderm GmbH (P) · GENidee · gimbio mbH (P/S) · HDBI Hans-Dieter-Belitz-Institut (P/I) · Pieris AG (DD) · UGT Umwelt-Geräte-Technik GmbH (P) · vertis Biotechnologie AG (DD/DS) · XL Protein (DD/P) · CEM Chemieschule Dr. Elhardt GmbH · Café Freshmaker · Kindertagesstätte BioKids

DD = Drug Discovery · DS = Diagnostic Services · I = Instruments · IT-S = IT-Services · S = Services · VC = Venture Capital · P = Products

status: april 11



Welcome to the world of insights

Instrumentelle Analytik | Labortechnik | Biotechnologie | analytica Conference

Keine andere Messe weltweit deckt das Themenspektrum der Labors in Industrie und Wissenschaft in solch einer Breite und Tiefe und in einer solchen Größenordnung ab.

Jetzt informieren
und anmelden:
Messe München GmbH
Tel. (+49 89) 9 49-1 14 88



analytica 2012

17.–20. APRIL | NEUE MESSE MÜNCHEN

www.analytica.de/2012

Imprint

Editorial staff: Almut Graebisch, Georg Kääß, Bianca Reuter

Data collection: Sabine Jordan

Company Profiles: Lina Paulenz

Layout-Design: aimcom, Munich, www.aimcom.de

We thank the Bavarian companies in supporting this survey and many more colleagues at Bio^M and the different regional organizations of the Bavarian Biotechnology Cluster.
May, 2011

Contact

Prof. Dr. Horst Domdey, Managing Director

Spokesman of the Bavarian Biotechnology Cluster

Dr. Mathias Lamparter, Cluster Manager

**The Bavarian and the Munich Biotechnology Cluster
are managed by:**

Bio^M Biotech Cluster Development GmbH

Am Klopferspitz 19 a

D-82152 Martinsried

Phone: +49 (0)89-89 96 79-0

Fax: +49 (0)89-89 96 79-79

E-Mail: info@bio-m.org

Internet: www.biotech-bavaria.de



The layout, graphics and other contents of this brochure of the Bavarian Biotechnology Cluster are protected by copyright law.

Content

Preface	06-07
■ Prof. Dr. Horst Domdey – Spokesman, Bavarian Biotechnology Cluster	
The Companies in the Bavarian Biotechnology Cluster	08-10
■ Facts and Figures – An Annual Comparison	
Employment	12-13
■ Jobs in Biotechnology Companies	
More about Employment	14-16
■ White/industrial Biotechnology	
Products and Pipeline	17-18
■ Drug Development	
Mergers, Deals, Cooperations, Financing	19-23
■ M&A Activities 19	
■ Deals and Cooperations 19-20	
■ Financing 21-22	
■ Revenues 23	
■ Summary 23	
German Centers for Health Research	24-25
Bavaria – A Region of Implementation	26-28
Company Profiles	29-117
in alphabetical order	

About this survey:

For the following report, a biotechnology company has been defined as a company, which develops and/or manufactures products on the basis of state-of-the-art molecular biological methods. But as “conventional” pharmaceutical companies are increasingly also using such methods, it is often difficult to differentiate between biotech and pharma. Traditional phytopharmaceutical companies and manufacturers of homeopathic products are however not included in this compilation. We distinguished the parameters specific to each sector and conducted separate surveys for biotech companies, pharmaceutical companies, (clinical) contract research organizations (CROs), contract manufacturing organizations (CMOs), suppliers and others with activities in the biotechnology sector. In the case of the biotech companies, a distinction was once again made between small and medium-sized companies (SME) having their headquarters in Bavaria, and branch offices and subsidiaries of national and international biotech companies (biotechnology companies, non-SMEs). The term “non-SME” therefore does not say anything about the actual size of this branch office.

The data forming the basis of this report are based on the evaluation of a written survey carried out by Bio^M Biotech Cluster Development GmbH at the beginning of 2011 of approx. 327 Life Science companies throughout Bavaria. Based on the questionnaires returned and intensive follow-up telephone calls it was possible to achieve a response rate of almost 81%. Possible deviations from previously published figures are the result of additional data obtained in this survey that also may refer to previous years. The period under review for this report is the year 2010.

Published in May 2011

Dear Reader,

PROF. DR.
HORST DOMDEY

Spokesman, Bavarian
Biotechnology Cluster



The Bavarian biotech branche is looking optimistically to the future, but it is still up to the politicians to improve the regulatory framework and to promote in this way the innovation process. "We do not need a bailout" – these were the self-confident words we used, at least with regard to Bavarian biotechnology, in February 2009. And now, two years later, the entire German biotechnology sector is in fact fairly optimistic, as is confirmed not only by current surveys commissioned by the Federal Ministry of Education and Research (BMBF) and conducted by Bio Deutschland and the biotech magazine |transcript/BIO-COM, but also by the Ernst & Young Biotechnology Report for Germany 2010.

Let's take a brief look back in time: for biotechnology (and the pharma industry) the year 2009 was in fact a rather good one, which we were able to confirm in our previous year's report for Bavaria. Especially the topic of "health" found a niche that, for all the mood of crisis, was least affected. But it remained open how the situation would develop in 2010. Had the situation bottomed out, might the collateral damage caused by the world of finance possibly just have been delayed and the impact on the biotechnology and pharmaceutical sector is yet to come?

So we were very keen what 2010 would bring for our sector at the final count. Times of crisis are, after all, also times of opportunity, as Rahm Emanuel, the present mayor of Chicago and former Chief of Staff in the White House once said: "Never waste a crisis – it can turn into joyful transformation". And it looks as if the Bavarian companies have also taken this topic to heart. Last year

in particular, we saw at least the beginning of a process of transformation in which company mergers were undertaken, not as a last resort, but as a strategic and future-oriented measure that came from a position of strength. As a result, Bavarian biotechnology may not have any hefty increase in growth to report and yet behind an at least slightly upwards trend in terms of the number of companies and employees and a more pronounced upward trend as regards the sales figures, there is reasonable consolidation, in the case of some companies a focus on content and solid financing for the future. In these respects, Bavarian companies are especially successful in comparison with the rest of Germany. As various surveys for the whole of Germany have shown, in 2010 there was a flow of investments of around € 600 million into German biotech companies – and around half of this sum fortunately went into Bavarian companies! This 200 % increase compared to 2009 is no reason for us to break into joyous hosannas, however: investors' moods tend to keep changing. And if one also considers that around 80 % of the amount of private investment in Germany as a whole comes from 3 major consortia of investors or "family offices", one might just as well argue that they are likely to have invested enough money for the time being and can be expected to exercise some restraint in the coming years. And then this increase would simply just have been a (gratifying) one-off effect after all. One should also consider more carefully the fact that these and other investors seem to focus only on a very small group of biotech companies. Most companies are still fighting more or less desperately either to be noticed by the financial world at all or, even at the level of cooperation agreements with big pharma.

But the situation in the pharmaceutical industry has also changed in past months: with the sword of Damocles hanging over their heads in the form of expiring patents on their megasellers, an increasing number of top pharmaceutical companies are undergoing a radical restructuring, a restructuring, which last year alone has cost more than 50,000 people their jobs worldwide. According to a current study by Challenger, Gray & Christmas, the global cuts made by pharmaceutical industry have amounted to around 300,000 jobs since 2000. Of course, most of the job cuts affect sales, for example because a potential drug could not be put on the market within the required deadline – and

yet qualified staff still seem to be finding good jobs, perhaps even in the up-and-coming generic drug business. Even so, people begin to sit up and take notice when giants like Pfizer, Roche and AstraZeneca also start to cut back radically on their R&D staff and close entire research and production plants (or blow them up as AZ is doing in Delaware).


Given such phases of radical change, does this mean that biotech companies now have the best opportunities, as it were, for selecting ideal partners in the pharma industry? This will probably remain the very special exception. I think that the uncertainty on the pharma side – and this is precisely the mood we find there at the moment – as to how to deal with the approaching “patent cliff”, does not exactly make it any easier for biotech companies but in fact more difficult. In their biotechnology report last year Ernst & Young called for new “rules of the game”, which they urged the players to take to heart. What we have at the moment, however, is a rather wild, unregulated procedure, and fellow players who themselves no longer know exactly what they are supposed to do and perhaps not even who has commissioned them to do it.

Sometimes one has the impression that the pharmaceutical companies now want to move into the fast lane to even “overtake” the biotech industry so they can obtain more direct access themselves to scientific innovations in academic institutions by thoroughly reinforcing their early pipeline in the long term. But is this not the original and actually ideal role of biotech companies, namely to function as a kind of transmission belt for transferring pharma innovations from the academic scene to the pharmaceutical industry? So what is the future position of our sector on a playing field that, given the current competition, is at present undergoing a radical change itself? Everything will eventually fall into place, new players will take on a greater role than before, and the structures will become clearer. “Diagnostics”, which has long been underrated, will scale unprecedented heights as part of personalisation and prevention. And then we must hope that the biotech sector as a whole will have taken the right measures and will be firmly on track for forthcoming developments.

As far as the Bavarian companies are concerned, I look to the future with optimism here. According to our survey these companies are “right on track”. There will be more detailed information about this on the following pages.

I would like to conclude by taking you on a brief excursion into the world of science:

There is something quite new from the Federal Ministry of Education and Research (BMBF) and the Ministry of Health (BMG). Together, they have set up a programme worth billions for health research in which, among other things, they are pressing on with the establishment of the German Health Research Centers (see p. 24-25), as they are called. Again, what is particularly gratifying is the sensational performance of Bavaria and the Munich location in all six indication areas, in which it is now planned to intensify research. But this obvious close collaboration between the Ministry of Education and Research and the Ministry of Health is so important, most of all because it promises an improvement in the dovetailing of innovation funding with the rules and conditions introduced by the health system before market entrance. What would now also be desirable would be a similar close collaboration between the Ministry of Education and Research and the Ministry of Finance, because the consistent obstruction of the risk-capital sector through unreasonable anti-innovation legislation tends to prevent the results of research from being transformed into innovative and marketable products. The companies themselves did their homework in the years of crisis – what is required now is for the Federal Government to take suitable innovative steps to ensure that Germany is not just a location for “ideas” but is also a location for implementing those ideas.



Horst Domdey

The Companies in the Bavarian Biotechnology Cluster

Facts and Figures – An Annual Comparison

“Biotech in Bavaria – right on track” is the slogan we have selected for the 2010 Report of the Bavarian Biotechnology Industry. The aftermath of a global financial and economic crisis has not left the industry completely unharmed – and yet the companies have held their ground brilliantly.

Anxieties about the future of entire economic sectors, for which more and more, and larger and larger, “safety nets” have been devised, seem to have lost their power to scare us in view of the current emotions of sympathy and grief caused by the tsunami and the nuclear disaster in distant Japan. It may well be that we have just got used to the situation of one European country after the next having to seek shelter under a financial safety net, that probably more and more billions of Euros will be required to guarantee Europe’s major basics of economy.

In Germany, these economic fears may also have been pushed into the background because 2010 saw a tremendous recovery in many sectors leading to an unexpected increase of 3.5 % in Germany’s gross domestic product over the previous year. The last time Germany witnessed such a growth was the year of the reunification more than 20 years ago. In 2009, the actual year of the crisis, the GDP had dropped by around 4.5 %. So, the overall economic signs in Germany seem to be very positive at the moment. Does this mean that we have already reached the pre-crisis level again? Could it be that through the impetus of crisis management our position is now even better than before? As always, the situation will be different, depending on the different sectors, and often, if we simply look at the average figures, we lose sight of the realignments, the new developments, the shift in weight from the former champions of the respective sector to newcomers.

Having introduced so, the summaries and overviews we are able to present for the Bavarian biotechnology sector here provide a picture of pleasant stability. And yet there


are hidden details which only reveal on closer inspection that there have been changes in Bavaria or that certain changes are just about to happen.

Number of Companies

According to our criteria (see page 5), the number of biotech SMEs in Bavaria now amounts to 168 (+ 4 compared to 2009). 129 of these are located in the Greater Munich Area. With 25 biotech SMEs the Regensburg/Eastern Bavaria region has the second-largest company cluster in Bavaria.

In total, there were 13 newly established companies (12 in and around Munich, 1 in Northern Bavaria). This


BIOTECH/PHARMA COMPANIES IN BAVARIA



UNESCO World Heritage
Old Town Regensburg
www.regensburg.de

BioPark Regensburg

Successful Innovation Centre on the Danube



In 2009 BioPark Regensburg celebrated its 10 year anniversary. In this period 254 million Euro was invested in the development of the "Life Sciences" and 33 companies were founded. Currently there are 22 leaseholders with 500 employees located in the BioPark – almost fully booked out. This includes successful companies like Antisense Pharma GmbH, Genent AG and AMGEN Research GmbH.

From Sept. 2011 new state-of-the-art laboratory and office space available again direct on the Uni Campus

From September 2011 another 6,000 m² of state-of-the art office and laboratory space (S1/S2) will be available in BioPark III. An in-house childcare centre, direct connection to the motorway (A3), very good university infrastructure and integration with the service and company network of BioRegio Regensburg on-site will enrich the excellent location factors.

See www.bioregio-regensburg.de or fon: +49 941 920 46-0



Member of

CLUSTER
BIOTECHNOLOGIE
BAYERN

BIO**PARK**
REGENSBURG GMBH


continuingly positive start-up trend is also reflected in the latest Ernst & Young Report 2010 for Germany, which lists 8 new companies from Bavaria alone among the 17 in Germany as a whole (the different figures are due to the different ways in which the companies are allocated to industrial sectors and hence their inclusion in the statistics). Apart from these company foundations, there were also 6 companies that ceased to operate (owing to insolvency, sale or closure).

The number of companies in the group of (clinical) contract research organisations (CROs) and the number of pharmaceutical companies have not changed compared with the previous year.

A more general look at the companies relevant to the biotechnology industry must not leave out the suppliers, service providers and a few other companies. On the contrary, the 30 companies that may fall under the heading “Others” and therefore seem to be slightly less important, not only generate large turnovers but also big employment figures. It is these companies in particular which, being “product-driven” companies, have fortunately fought their way superbly through the times of crisis.

The raw figures and the criteria on which the collection of data is based may deviate from those of other surveys so that a feasible comparison may be possible only if one and the same author has conducted the survey. The

BAVARIAN BIOTECH SME IN 2010



fact remains, however, that Bavaria is the location with the largest number of biotechnology companies in Germany as confirmed in the biotechnologie.de survey as well as the Report of Ernst & Young.

Company Foundations

13 newly established companies (biotech-SMEs) started operating in Bavaria in 2010:

COMPANY FOUNDATIONS

COMPANY	CATEGORY
Agrolytix	Agro, Food, Environment
AVIRU	Therapeutics & Diagnostics
ethris	Therapeutics & Diagnostics
Exosome Diagnostics	Therapeutics & Diagnostics
GNA Biosolutions	DNA/Protein Analytics
HolsboerMaschmeyer-Neurobiochemie	Therapeutics & Diagnostics
MAB Discovery	Therapeutics & Diagnostics
iThera Medical	Devices & Reagents
leon-nanodrugs	Therapeutics & Diagnostics
LivImplant GmbH – Regenerative Medicine	Therapeutics & Diagnostics
ProJect Pharmaceuticals	Preclinical Services
SpectraMab	Therapeutics & Diagnostics
Wimasis	Bioinformatics

We explicitly included the relocation of the European subsidiary of the US company Exosome Diagnostics (headquarters in New York City) in this list of “company foundations” after it started its research and development work in the IZB in Martinsried. This relocation from the USA is one of last year’s particular highlights and seems to have whetted the appetite of a number of other US companies which are now (in spring 2011) also looking for premises in Bavarian that are suitable for establishing a subsidiary. At the same time, Exosome Diagnostics covers an important future field which is developing rapidly. Gratifyingly, however, there are therapeutics developers among the company foundations as well, something that had become very rare in recent years. More detailed descriptions of the business fields of these and all other Bavarian companies of our sector can be found in the extensive Annex.

In other words, since 2006, Bavaria has seen more than 40 newly established biotech SMEs.

4 Strong Partners

for Personalized Medicine

- Excellent Universities and Research Institutes
- 350 Life Science Companies
- World renowned Hospitals
- Professional Cluster Management

Employment

Jobs in Biotechnology Companies

Compared to the previous year, there has been a slight increase (+ 89) in the number of employees in all biotechnology companies, an increase (+ 1% over 2009) that is more or less evenly distributed between SMEs and non-SMEs. Taking all biotech companies together, i.e. including the subsidiaries of international companies – of which the German Roche Diagnostics in Penzberg is also listed in this table under “Biotech non-SMEs”, the number of employees amounts to a good 9700. There are 5959 employees working in these subsidiaries (the number has remained almost unchanged compared to 2009), and of these more than 4500 are working for Roche Diagnostics in Penzberg alone. Even such a small increase is by all means remarkable after the even higher increase in 2008, the first year of the crisis, and also in 2009, the second year of the crisis. This illustrates the stability of the Bavarian biotechnology and its “ability to recuperate” after the negative effect of the substantial staff reductions (around 100 people) made by MediGene AG (with the goal to concentrate its business strategy) and the complete closure of IDEA AG.


The total number of employees in Bavarian biotechnology SMEs now amounts to 3723 (previous year: 3665; + 1.6 %) of which around 2750 work in the Greater Munich area. The Nuremberg/Erlangen region, with Novartis Pharma Germany and almost 2000 employees, is a further strong pharmaceutical bastion in Franconia, in addition to the major location of “red biotechnology” in and around Munich and especially to the south of Munich. The Regensburg/Eastern Bavaria region scores with the interdisciplinary approach pursued by BioPark Regensburg and has around 900 employees in the biopharmaceutical sector. According to surveys carried out in Regensburg by BioPark Regensburg GmbH itself there were even around 2500 employees in this region in 2010 if one includes medical technology and further related disciplines (that are otherwise not considered in this survey).

Apart from the Regensburg based “Danube Valley” and the new “Medical Valley” in Erlangen/Nuremberg, which has also been selected as one of the “Leading-Edge

cluster” along with Munich (see page 26), there is another Bavarian valley of note in the field of “red biotechnology” namely the valley of the Würm. Starting at the Lake Starnberg the meandering river Würm (which has given its name to an entire ice-age period) flows northwards through towns like Gauting, Gräfelfing and Planegg/Martinsried. More than 80 biotech companies employing almost 1900 people (1700 of which are in biotech SMEs) are domiciled in this region, the cradle of modern Bavarian biotechnology, where the excellent science campus of Max-Planck-Institutes and the Ludwig-Maximilians University (LMU) still sets the pace for future development. Around 50 companies with approximately 600 employees can be found at the Innovation and Start-up Center for Biotechnology (Gründerzentrum IZB) in Martinsried alone.

Looking back even further, one can state that since 2006 the number of employees in Bavarian biotech SMEs has increased by 24 %, and in the “non-SMEs” by 15 %.

NUMBER OF EMPLOYEES IN THE BAVARIAN BIOTECH CLUSTER



* More detailed figures about employment on the following pages.

Total Number of Employees in the Bavarian Life Science Industry

Although it is relatively easy to collect statistical data in the field of biotechnology – notwithstanding the different definitions in Munich, Berlin, Mannheim or Wiesbaden, the task becomes far more difficult when we come to the broader field of the so-called Life Sciences. This chapter therefore focuses on companies from this complex field that are more closely related to “red biotechnology”. This does not include Bavaria’s many successful medical technology companies.

A not at all negligible percentage of local Life-Science jobs are offered by the so-called (clinical) contract research organisations (CROs). An additional 2540 people work for a total of 60 CROs across the length and breadth of Bavaria. The group what we have called “other biotech companies”, which includes suppliers, trading companies and other service providers such as, for example, contract

manufacturing organisations (CMOs) also make a significant contribution to employment and economic strength. The 30 companies that have been included in our statistics also employ more than 2050 people. And finally there are the 35 companies of the Bavarian **pharmaceutical industry**, currently employing almost 10,000 people. In all three categories above there has been continuous growth over the past years. Taking the bio-pharmaceutical industry and biotechnology in Bavaria together, we arrive at a total of around **24,300** employees in 2010, an increase of more than 3 % compared to 2009!

In addition to these jobs in industry, there are also around 10,000 people working in the Life-Science departments of Bavarian research institutions. Thus altogether, the entire life science sector provides more than **34,000** jobs in science and industry throughout Bavaria.



Engineering
the Medicines
of Tomorrow

A LEADING PIPELINE OF ANTIBODY DRUGS

MorphoSys has established world-leading technologies to develop superior antibody drugs and immunodiagnostic components, including the industry-proven HuCAL® libraries and arYla™. Together with its pharmaceutical partners, MorphoSys is establishing a leading biopharmaceutical pipeline against a broad range of severe diseases. Today’s more than 75 distinct drug programs – including 17 programs in clinical evaluation – illustrate the significant contribution MorphoSys will make to human healthcare.

www.morphosys.com

morphosys

More about Employment

The companies specialising in the development of therapeutics and/or diagnostics and the accompanying platform-technology providers have the largest percentage of employees in the category of small and medium-sized biotechnology companies. This sector employs 1993 people, more than 50 % of all employees in the SMEs. The charts on the next few pages provide an overview on the distribution of company sizes for the Bavarian companies. It shows that a large percentage of biotech SMEs is still small (most of them being also very young). This distribution remains relatively constant owing to the establishment of numerous start-ups in past years. "White" biotechnology (included in "Agriculture, Food, Environment"), on the other hand, is just starting to develop as entrepreneurial field, so the number of SMEs active in this field is still relatively low. But big chemical companies have started efforts in this field.

White (or Industrial) Biotechnology in Bavaria

Since the 1980s biotechnological research and application have found their way into Bavarian chemical companies, with Munich's Wacker Chemie AG* being one of the first to focus on biotechnological production. According to its own market surveys, Wacker is the world's market leader for biotechnologically manufactured cyclodextrins and cysteines produced by fermentation. The amino acid cysteine is an especially good illustration of the fact that there is no clear-cut distinction between "white" and "red" biotechnology, because this substance is the raw material used as an expectorant in many cough mixtures in the form of modified acetylcysteine. Wacker's technologies and production methods are also used by biotech companies for the development of new drugs. Among other things, Wacker is currently developing new biotechnological methods for the cost-efficient production of basic chemicals like ethylene and acetic acid from renewable raw materials. Acetic acid and ethylene are the base substances for vinyl acetate which Wacker uses among other things to produce polymer binders.

Wacker's restructured Biosolutions division contributes a good 3 %, or approximately € 150 million, to the overall sales of almost € 5 billion reported by Wacker Chemie AG for 2010. The dynamic development displayed by this hundred-year-old company, especially in the recent past, can be seen by the overall sales, which have almost doubled in the last six years.


Bavaria's second largest chemicals company, Süd-Chemie AG*, which has been in existence for more than 150 years, has also recognized biotechnology as a field with a great future. One focus of Süd-Chemie's business activities are catalysts for the manufacturing and refinement of primary, petrochemically derived products, for example, olefins, and aromatics like styrene. The company also offers catalysts for alkane dehydration and for the purification of olefins. Therefore it was hardly surprising, when the company decided to start research on biotechnological production methods in the field of fuel production. The company is now moving from the laboratory stage to the next level in the form of a pilot plant that uses an innovative technology for the production of cellulose ethanol from plant residue: Süd-Chemie is currently investing around € 20 million in the construction of a demonstration plant for bio-refining straw into ethanol. This plant, which will start operating by the end of 2011, will convert around 4500 tons of straw into as much as 1000 tons of ethanol every year. Süd-Chemie can draw on its know-how in the field of catalysts for this optimised and now highly efficient conversion process – with the difference that this time it is using biocatalysts (a very special cocktail of enzymes produced by a yeast strain that the company has developed itself) to convert the different cellulose components of the straw into ethanol. These new fields of business at Süd-Chemie may well have been a decisive factor when the Clariant company (Switzerland) decided to acquire Süd-Chemie AG in Spring 2011 for about € 2 billion.

It is of course not only the big Bavarian chemical companies that are active in the field of white biotechnology; there are also Bavarian SMEs that can announce their first successes. For example, the

(*The sales and employment figures reported by these two chemical companies have not been included in the calculations or charts, not even in part.)

Martinsried based AMSilk GmbH received an award as one of the five most innovative biotechnology SMEs in Europe at the end of 2010. AMSilk produces in bacterial culture and processes high performance materials based on spider silk. This innovative product has unique properties such as mechanical strength, chemical stability and biocompatibility and is completely biodegradable at the same time. AMSilk is able to manufacture spider silk in large quantities and to develop it into coatings, silk particles, films, nonwovens and fibres, in order to improve existing products or to generate completely new products. Investors were quick to take an interest in this promising combination of "bionics" (mimicking natural processes) and biotechnology. In Spring 2011 AMSilk

DEVELOPMENT OF STAFF NUMBERS IN BIOTECH COMPANIES



We set things in motion - and keep them moving

Clinical Research Services

- Data Management
- Biostatistics
- E-Clinical Services
- Clinical Trials Phase I - IV and NIS




Contact: Rudolf Köhne-Volland, phone +49 (0) 89 829265-222, rkvolland@metronomia.net, www.metronomia.net

announced the successful conclusion of a further round of financing amounting to € 5 million.


Bavaria's realignment towards sustainable "bio-production" is, on the one hand, receiving support from the scientific community through the establishment of a new Research Center for White Biotechnology at the Technische Universität München. The aim here is to bring the TU's biological, chemical and engineering faculties together with the scientific institutions for renewable raw materials in Weihenstephan und Straubing and also to

offer appropriate new courses of study to attract the next generation of scientists. On the other hand, Bavaria's White Biotechnology is profiting from a dynamic network of science and industry, which is successfully coordinated by the BioMWB, a Bio^M spin-out. As part of the "BioIndustrie 2021" initiative the Bavarian white biotechnology consortium - initiated in the Bavarian Biotechnology Cluster - has received funding of € 5 million from the Federal Ministry of Education and Research (BMBF) and an additional € 5 million from the Bavarian Ministry of Economic Affairs. Currently R&D projects with a total project volume of more than € 28 million are being funded. In addition, proposals for further R&D projects of a comparable volume have been submitted to various funding organizations. Further € 10 million are being invested in technical and structural measures and € 43 millions in plant constructions (see also page 28).

SIZE OF BIOTECH SME BY NUMBER OF EMPLOYEES IN 2010



NUMBER OF EMPLOYEES IN THE BIOTECH SME IN BAVARIA (2010)



Products and Pipeline

Drug Development

Bavarian's Biotech drug development companies are still doing their homework. Many Bavarian companies have achieved substantial milestones in clinical development. MorphoSys AG (Martinsried) has successfully enlarged the number of clinical compounds by more than 100 % during 2010, from eight at the beginning of the year to 17 compounds by the end of 2010.


Compared to last year the number of preclinical drug candidates decreased by 22 % to 66 preclinical candidates. One reason for this shrinking effect could be the limited financing situation for Bavarian Biotech companies as well as boosting their pipeline through late-stage drug candidates. Pieris AG (Freising/Weihe-Stephan) announced in April 2010, its first positive preclinical data on c-Met Anticalin drug program. PRS-110, which targets the c-Met receptor, has shown positive dose dependent response in xenograft mouse model. In October 2010, the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug application for BiTE antibody MT111/MEDI-565 developed by Micromet Inc (Munich/Bethesda, US). The licensee company Medimmune, Inc. will start a clinical phase I beginning of 2011 in patients with gastrointestinal cancer.

Fortunately, the companies have achieved important milestones to start their clinical phase I. 38 clinical drug candidates are currently in clinical phase I. In comparison to last year, the number of clinical phase I studies increases by 81 %. For example, Corimmun GmbH (Martinsried) has successfully completed its clinical phase I studies with its lead candidate COR-1 for cardiovascular diseases. During this clinical phase I study, no drug related side effects occurred and pharmacokinetic and pharmacodynamic studies demonstrate a favorable profile with dose-dependent efficacy. COR-1 is a cyclic peptide developed for the personalized treatment of heart failure and targets the auto-immune mechanism of antibodies directed against the β 1-adrenergic receptor in these patients.

Moreover, Pieris AG has started clinical phase I for its lead program PRS-050 in June 2010, an anti-VEGF Anticalin for cancer treatment. The clinical phase I has started at three sites in Germany and the first patients have been dosed. SuppreMol GmbH (Martinsried) has

DRUG PIPELINE IN BAVARIA

number of drug candidates



started in April 2010 its clinical phase Ib/Ila trial with its lead candidate SM101 in Idiopathic Thrombocytopenic Purpura. The first patient treatment in the multi-centric, randomized, double-blind, placebo-controlled, dose escalating study has been initiated in Poland.

Wilex AG (Munich) has successfully completed its clinical phase I dose escalation study for its MEK inhibitor WX-554 in June 2010. This study demonstrates for the first time activity and safety in humans. MorphoSys AG (Martinsried) announced the first patient was treated with its lead compound MOR103 in January 2010 in clinical phase Ib/Ila for rheumatoid arthritis. In June 2010, MorphoSys licensed the antibody MOR208 from Xencor and started clinical development in the United States for chronic lymphocytic leukemia patients.

During the year 2010, 38 clinical drug candidates have been in clinical phase II. In comparison to last

year, the number of clinical phase II candidates has grown by 124 %. The increasing number of clinical phase II candidates represents a maturing development process within the Bavarian Biotech Cluster.

4SC AG (Martinsried) has announced several positive results from its clinical phase II studies. In September 2010, 4SC AG published initial clinical data for Resminostat, a pan-histone deacetylase inhibitor from the ongoing phase II SHELTER study in hepatocellular carcinoma. In October, the company announced further initial phase II data from Hodgkin Lymphoma patients of the ongoing SAPHIRE study with Resminostat. In November and December 2010, 4SC AG continued to present the first primary endpoint with response rate of 88.5 % for the treatment of patients with Crohn's disease and ulcerative colitis. Finally, the company has completed enrolment of its COMPONENT phase II b study with Vidofludimus in rheumatoid arthritis patients.

In September 2010, Micromet has started its clinical phase II study with its lead candidate BiTE antibody Blinatumomab (MT103) which will conduct in adult patients with relapsed or refractory B-precursor Acute Lymphoblastic Leukemia (ALL) to demonstrate efficacy, safety and tolerability of Blinatumomab.

MediGene AG (Martinsried) has successfully completed its clinical phase II of EndoTAG-1 for the treatment of breast cancer patients.

11 clinical programs in clinical phase III have been in development during 2010. This development describes an increase of 120 % compared to 2009. Antisense Pharma GmbH (Regensburg) published its clinical phase IIb study G004-AP 12009 with Trabedersen in the Journal of the American Society for Neuro-Oncology. These published positive data support the pivotal Phase III study (SAPPHIRE) in recurrent refractory AA patients (anaplastic astrocytoma). In August 2010 the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug authorization for clinical studies with Trabedersen in the US. This important milestone enables the company to include US American clinics in this and further studies.

Agennix AG (Martinsried/Heidelberg) has expanded its clinical phase III FORTIS-M registration trial in non-small cell lung cancer. The enrollment will be completed in the first half of 2011. Besides this, the company has plans to initiate clinical Phase II/III with Talactoferrin in severe sepsis in early 2011. Important clinical data from Talactoferrin from clinical Phase II trial in severe sepsis was presented at Sepsis 2010 International Symposium. Phase II results of Talactoferrin in severe sepsis reduces all-cause mortality compared to placebo over longer term at 3 months and at 6 months.

PHASE II	PHASE III	APPROVED
<p>4SC: Hepatocellular carcinoma, Hodgkin's Lymphoma, mild to moderate rheumatoid arthritis, Inflammatory bowel disease (IBD)</p> <p>Activaero: Asthma</p> <p>Affectis: Depression</p> <p>Agennix: Diabetic foot ulcers, Severe Sepsis</p> <p>Avontec: Asthma, Psoriasis</p> <p>Bavarian Nordic: Advanced prostate cancer, Smallpox</p> <p>Donatur: Periarthritis</p> <p>IDEA: Onychomycosis, Skin Pain and Inflammation</p> <p>MediGene: Breast cancer, Pancreatic cancer, Rheumatoid Arthritis</p> <p>Micromet: Adult r/r acute lymphoblastic Leukemia, MRD-positive acute lymphoblastic leukemia, Solid tumors</p> <p>MorphoSys (with Roche): Alzheimer's diseases</p> <p>MorphoSys (with Novartis): Oncology</p> <p>MorphoSys (with Centocor): Immunology, Oncology</p> <p>MorphoSys: Rheumatoid Arthritis</p> <p>Scil Technology: Periodontitis</p> <p>SuppreMol: Idiopathic Thrombocytopenic Purpura</p> <p>Trion Pharma /Fresenius Biotech: Metastatic Breast cancer EU/US, Gastric cancer EU, Ovarian Cancer EU/US, Malignant Ascites EU</p> <p>Vasopharm: Traumatic brain injury</p> <p>Wilex: Advance non-metastatic pancreatic cancer, Breast cancer</p>	<p>Agennix: Non small cell lung cancer, Prostate Cancer</p> <p>Antisense Pharma: Glioma (Trabedersen®)</p> <p>Curacyte: Septic Shock (Hemoximer®)</p> <p>Fresenius Biotech: Stem cell transplantation, Immunology therapy</p> <p>IDEA: Osteoarthritis</p> <p>Wilex: non-metastatic clear cell renal cell cancer (antibody and diagnostic antibody, Rencarex®, Redectane®)</p>	<p>Fresenius Biotech: Transplantation (ATG-Fresenius S)</p> <p>MediGene: Genital warts (Veregen®), Prostate Cancer (Eligard®), Rosacea, inflammatory lesions (Oracea®, sold)</p> <p>Trion Pharma/Fresenius Biotech: Malignant Ascites (EU, Removab®)</p>

Mergers, Deals, Cooperation, Financing

Bavarian Biotech companies are a step further in their maturing process. Especially during the last year many Bavarian companies were very active regarding joint ventures with national and international companies. The companies have continued to strengthen their patent portfolio and to focus on commercialization and outlicensing opportunities. In 2010, several licensing agreements have been successfully closed and many research and development cooperations have been started as well as existing long term partnerships have been pursued. All in all, Bavarian biotech companies made very good progress in realizing their individual growth strategies.

M&A Activities

In April 2010, GENEART AG (Regensburg) announced the merger with the US-based Life Technologies Corp. Life Technologies acquired during the last year 100 % of GENEART shares through its German subsidiary Applied Biosystems Deutschland GmbH. Life Technologies Corporation is a public-listed global biotechnology tools company focusing on consumables and services for researchers. Geneart is now a technology brand in the portfolio of Life Technologies with about 200 employees in Regensburg serving customers in synthetic biology. FGK Clinical Research GmbH (Munich) has acquired the assets from the Hungarian CRO BlankaMedika in August 2010. This acquisition is part of FGK Clinical Research expansion strategy in Europe for providing integrated services for clinical studies in European countries. Furthermore, MorphoSys (Martinsried) acquired the private German company Sloning BioTechnology GmbH (Puchheim) in October 2010, which has developed new methods for synthetic biology based on Sloning's state-of-the-art technology. This transaction enhances the assembly and quality of protein libraries. Sloning's technology will significantly support MorphoSys' therapeutic and diagnostic antibody programs. Sloning's shareholders received a € 19 million cash payment upon signing.

In November 2010, WILEX AG (Munich) announced two transactions. First, WILEX announced the acquisition of all shares of Heidelberg Pharma AG (Heidelberg) for € 19,2 million. Thus WILEX is able to use Heidelberg Pharma's novel antibody drug conjugate platform technology for therapeutic antibodies in cancer treatment. Shortly later WILEX announced the signing of

an agreement with Siemens Healthcare Diagnostics to acquire the assets of Oncogene Science (Cambridge, MA, USA) for approximately € 500.000 in cash. Oncogene Science focuses on the development, manufacturing and commercialization of oncology biomarker assays, especially for measuring proteins in blood. This acquisition has provided WILEX access to commercial products, in particular specific companion diagnostics, in oncology.

Just in early 2011 KINAXO (Martinsried) has been acquired by Evotec AG (Hamburg) for about €12 million (cash and shares). It is intended to grow and fully integrate the Kinaxo site in Munich, as Evotec Munich. With the acquisition of Kinaxo, Evotec is expanding its drug discovery platform with cutting-edge technologies. Furthermore, Evotec adds proprietary technologies for drug response prediction as well as drug efficacy and safety assessment, especially in the key indication area oncology.

Deals and Cooperations

Boehringer Ingelheim and Priaxon (Munich) entered into a worldwide collaboration to research and develop mdm2/p53 inhibitors for the treatment of cancer. Priaxon is providing its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigate inhibition of protein-protein interactions. Together with upfront payments, Priaxon will be eligible to receive from Boehringer Ingelheim € 86 million milestone payments in the future.

MorphoSys AG (Martinsried) and Rinat Neuroscience Corp, a US based subsidiary of Pfizer Corporation signed a non-exclusive licensing agreement for the acquired platform technology Slonomics. Furthermore, MorphoSys' research and diagnostic antibody unit AbD Serotec entered into a licensing cooperation with the Institute of Cancer Research in UK, which provides AbD Serotec with worldwide exclusive rights to commercialize the prototypic BrdU antibody clone for research applications. In addition, AbD Serotec signed another licensing agreement with VU University Medical Center (Amsterdam) and with the University College of London to get worldwide access to Anti-PTH antibodies for research purposes. In addition, MorphoSys has also signed a collaboration and licensing agreement with Absynth Biologics, a UK based Biopharmaceutical

Company. MorphoSys has started its own research and development program focusing on new targets against infectious diseases by using its HuCaL PLATINIUM Technology. Absynth Biologics will be responsible for testing relevant disease models.

Several interesting drug discovery joint ventures started in 2010; in particular KINAXO Biotechnologies GmbH (Martinsried) supports several drug discovery programs of Bristol-Myers Squibb. Moreover, in September 2010 KINAXO also entered into a long term partnership with Daiichi Sankyo Company Limited. Daiichi Sankyo will use KINAXO's chemical proteomics platform technology to refine its own cancer drug programme.

In September 2010, Pieris AG (Freising) signed a collaboration and licensing agreement with Sanofi-Aventis and Sanofi-Pasteur. Pieris will employ its Anticalin technology to discover new Anticalin-based drugs against multiple targets, which will be further developed by Sanofi-Aventis and Sanofi-Pasteur. Pieris will start with two selected targets, but this multiyear collaboration includes also the option for additional targets.

Another collaboration has been started in September 2010 by Proteros biostructures GmbH (Martinsried) signing a collaboration agreement with Johnson & Johnson. Under this agreement, Proteros has started to discover small molecule lead compounds against a specific target by using its integrated lead discovery approach.

In July 2010, Intana Bioscience GmbH (Martinsried) has initiated a joint venture with Johnson & Johnson. Intana will provide its proprietary Fluorescent Cross Correlation Spectroscopy technology platform to identify small molecule inhibitors.

Another Bavarian Biotech Service company has entered into collaboration with a German Pharmaceutical company: Eurofins Medigenomix (Ebersberg) will support the Pharmacogenetics and Pharmacogenomics division of Boehringer Ingelheim (Biberach).

During the year 2010, many Biotech Companies in Bavaria have boosted their expansion strategy, for example in August 2010 Proteros biostructures GmbH (Martinsried) has started its new wholly owned subsidiary, Proteros Inc. in Maryland (USA).

Major big player, Roche Diagnostics (Penzberg) invested € 136 million for its new Diagnostics Operation Complex, which will be focused on research and development of new diagnostics for personalized healthcare.

Commercialization and outlicensing opportunities represent very important milestones for each Bavarian Biotech company. MediGene AG (Martinsried) sold its European rights for marketing and distribution of Eligard® to Astellas Pharma Europe Ltd in July 2010. MediGene AG will obtain a total of € 25 million in cash from Astellas in three tranches and additional royalties on future product sales. Regarding MediGene's product Veregen®, the management has signed two licensing and supply agreements for the commercialization and marketing of Veregen® with companies in China and South Korea. In April 2010, MediGene divested its oncolytic Herpes Simplex Viruses program to Catherex, Inc., a private US Biotech Company. In return, MediGene has received a 40 % stake in Catherex becoming in this way main shareholder of Catherex.

Micromet Inc. intensified its cooperation with Boehringer Ingelheim regarding Micromet's BiTE antibody against multiple myeloma. Together, they have entered into a collaboration agreement for research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma. Under the terms of agreement, Boehringer Ingelheim will pay Micromet an upfront cash payment of € 5 million and Micromet has the opportunity to obtain development and regulatory milestone payments of up to € 50 million and future royalties on product sales outside the US.

Financing

Beginning of the year 2010, Antisense Pharma GmbH (Regensburg) has received fresh capital of € 13 million from its existing shareholders, MIG Fonds and Global Asset Fund and others. Through this financing further clinical development of the lead candidate Trabedersen will be pushed.


Agennix AG (Martinsried/Heidelberg) announced the closing of a private placement with existing shareholders. The company raised approximately € 9.8 million by selling new shares. This capital increase enables Agennix to continue with the full-scale enrollment in Phase 3 FORTIS-M trial in non-small cell lung cancer and to fund ongoing development activities of Talactoferrin. Later in 2010, Agennix could secure a € 15 million loan* by one of its major shareholders, dievini Hopp BioTech holding to fund the company's corporate operations in 2010. In addition to the loan, Agennix has closed its second capital increase in October 2010, supported by new and existing shareholders. The company has raised another € 76 million in net proceeds by offering 20,588,705 new shares. By this capital boost, the company will support the initiation of a Phase III trial with Talactoferrin in severe sepsis. Finally, the Agennix U.S.

subsidiary has been awarded approximately \$ 490,000 in grants under the Qualifying Therapeutic Discovery Project program.

Micromet, Inc. (Munich) closed a public offering of its common stock in March 2010 and obtained net proceeds of approximately \$ 75.3 million. Additionally, Micromet, Inc. announced in November 2010, its second public offering during this year, with \$ 70.5 million by offering additional 9.9 million shares of its common stock.

Affectis Pharmaceuticals AG (Martinsried) has successfully closed a financing round with € 3.3 million in March 2010 (the third tranche of its Series D financing round), supported by existing investors LSP, Aescap Venture, KfW bank, Bayernkapital and EMBL Ventures. Affectis will use this money to support its European Phase IIa trial with Cimicoxib in depression.

EXTERNAL FINANCING AND DEALS



Lophius Biosciences GmbH (Regensburg) published in the first half of the year 2010 successfully closed financial opportunities. In May 2010, Lophius closed its second financing round with approximately € 1.6 million. S-Refit, the new lead investor and Bayern Kapital as well as High-Tech Gruenderfonds supported this second financing round.

ChromoTek GmbH (Martinsried), a Biotech service company focusing on the discovery and development of innovative fluorescent nanoprobe has received € 400.000 from High-Tech Gruenderfonds and Bayernkapital to boost research and development activities for their Chromobody technology platform.

Corimmun GmbH (Martinsried) closed successfully its second financing round with MIG AG as lead investor, Bayern Kapital, Bio^M AG, High-Tech Gruenderfonds and KfW Bank. The company obtained € 7.45 million for the proof of principle studies in man with its lead candidate COR-1 and with the platelet inhibitor revacept.

In a new financing round (series D), SuppreMol GmbH (Martinsried) has received € 15.5 million. The new financing round was supported by new and existing shareholders. SuppreMol will promote the clinical studies of SM101 and the development of a GMP production system.

In December 2010, Wilex AG (Munich) has received a subordinated loan* of € 10 million, payable in two tranches, provided by its two main shareholders dievini Hopp BioTech holding GmbH & Co.KG and UCB Pharma S.A..

4SC AG (Martinsried) has been awarded a € 5.8 million grant as part of a research consortium financed by the European Union for the identification of new drugs for the treatment of Rheumatoid Arthritis.


Revenues

For reasons of comparison, the following figures focus on the business data published by Bavaria's biotechnology companies listed at the stock exchange. Their sales reported for 2010 amount to € 179.4 million, a result that is approximately the same as that of last year (2009: € 184.6 million). The R&D investments of these companies come to around € 133 million for the previous year (2009: around € 141 million).

Total sales in 2010 for the majority of companies that are not listed can only be roughly estimated at around € 215 million, based on the reported figures (65 % feedback of biotech SMEs). If one adds the sales of the companies that did not report any figures (one third), the sum of all sales generated by Bavaria's private biotech SME's in 2010 amounts to around € 284 million.

Taken together, the sales figures of Bavarian biotech companies (SMEs) thus show a clear upward trend for 2010 with more than € 450 million and a plus of approximately more than 10 %. The major part of this increase was generated by private biotech companies.

REVENUES TOTAL IN MIO. €, LISTED COMPANIES



Summary

In the past 5 years, the Bavarian biotechnology sector showed further signs of stabilisation and a very positive level of development that is above average when compared to the established biopharmaceutical industry. An increase in the number of employees of 24 % since 2006, double-digit growth rates almost every year in terms of sales, and an unbroken entrepreneurial spirit with more than 40 start-ups in the past five years are definitely positive signs that innovative ideas resulting from superb scientific research at universities, clinics and the non-university research institutions of the Fraunhofer

Society, the Helmholtz Association and the Max Planck Society have fallen on fertile ground here and will continue to do so.

The Bavarian State Government has also set the right course for the future by providing accompanying measures such as investments in infrastructure, buildings for science and education and the furtherance of research cooperations in all fields of the life sciences:

Biotech in Bavaria remains "right on track"!

German Centers for Health Research

For a new national research strategy the Federal Government will place its emphasis on networking and invests € 5.5 billion in six “National Centers for Health Research” by 2014.

These six “centers” are in fact networks of different locations consisting of universities, university clinics and non-university research institutes that are bundling their technical expertise for purposes of researching the pathogenesis of the major common diseases. Through close cooperation between research and industry the aim is to apply medical findings more quickly, thus achieving an improvement in the treatment of patients on the one

hand, and, through targeted prevention measures, preventing an increase in patient numbers on the other. In most of the “national centers” an institute of the Helmholtz Association of German Research Centers is linked to academic institutes or hospitals in the network.

The new priorities of national health research are described in a brief overview below. Munich is the only location in Germany that is involved in all 6 national centers, with (at least) one research institution or as coordinator:

■ German Center for Neurodegenerative Diseases – Dt. Zentrum für Neurodegenerative Erkrankungen (DZNE)

The center was founded in 2009 and has locations in Munich, Tübingen, Bonn, Witten, Magdeburg, Dresden, Rostock/Greifswald and Göttingen. Translational research concentrates on Parkinson’s and Alzheimer’s disease.

■ German Center for Diabetes Research – Dt. Zentrum für Diabetesforschung (DZD)

Also established in 2009, the center comprises partners in Munich, Tübingen, Düsseldorf, Potsdam and Dresden. Thematically, the focus is on the complex development mechanisms of diabetes and the accompanying prevention research. The aim is a targeted therapy that takes account of a patient’s individual predispositions – the genome as well as the metabolome.

■ German Consortium for Translational Cancer Research – Dt. Konsortium für Translationale Krebsforschung (DZK)

The selected partner institutes were announced in November 2010. They are located in Munich, Tübingen, Heidelberg, Freiburg, Essen, Frankfurt/Mainz, Dresden and Berlin. The aim is to develop personalized therapies for various types of cancer (especially pancreatic cancer and intestinal cancer, acute leukaemia and lymphomas) by finding joint signalling pathways.



Source: BMBF/BIOCOM ©

■ **German Center for Cardiovascular Research –
Dt. Zentrum für Herz-Kreislaufforschung (DZHK)**

The locations selected were Munich, Heidelberg, Frankfurt am Main, Göttingen, Hamburg/Lübeck, Berlin and Greifswald. The Munich partner in the DZHK is the Munich Heart Alliance which has dedicated its work in particular to translating basic research into clinical research and application. In the same way as the research locations of the other German centers in Munich, the DZHK intends to cooperate closely with Munich's "m⁴ Leading-Edge Cluster programme" and with the m⁴ Biobank Alliance there.

■ **German Center for Infectious Diseases Research –
Dt. Zentrum für Infektionsforschung (DZIF)**

The locations selected were Munich, Tübingen, Heidelberg, Gießen, Cologne/Bonn, Braunschweig/Hannover and Hamburg. The aim is to derive new strategies for combating resistant bacteria from an improved understanding of pathogens and infections.

■ **German Center for Lung Research –
Dt. Zentrum für Lungenforschung (DZL)**

The locations selected were Munich, Heidelberg, Gießen/Marburg, Hanover and Borstel. The thematic focus will include asthma and allergies, chronic obstructive pulmonary disease and lung cancer, and especially the prediction and stratification of these diseases.

Seit 35 Jahren in Martinsried

- eigene Produktion von Laborgeräten
- Service Ihrer Laborgeräte

Wir zertifizieren Ihre Laminar Flows,
CO₂ Inkubatoren, Autoklaven und Zentrifugen.

WWW.UNIEQUIP.COM



UNIEQUIP Laborgeräte & Vertriebs GmbH

Fraunhoferstr.11 · 82152 Martinsried

Tel: 089/8575200 · Fax: 089 8561304 · E MAIL: info@uniequip.de

Bavaria – A Region of Implementation

Success strategy of cooperative networks between science and industry

The foundation of the “Gene Center” Munich in 1984 – one of four national genetic research centers of this type – meant that Bavaria was breaking new ground. For the first time (more than 25 years ago) an idea was being put into practice that today is praised everywhere as a future trend: “public private partnership”. In addition to substantial core funding from the Federal and the Bavarian Government there was also a partner in big industry (including the then Hoechst AG, today’s Sanofi aventis). The aim being to achieve an internationally leading position in a newly emerging scientific field like molecular biology with joined forces and adequate finance – and not just to finance buildings made of glass and concrete, but to generate genuine added value for the location.

These first scientific work groups at the Gene Center Munich under the supervision of Prof. Winnacker were at the same time attractive to others who were scientifically interested in the application, as well as being the nucleus for independent business spin-offs. And these spin-offs in turn laid the foundation for the positive development of the Munich Biotech Cluster, which is also shown in its attractiveness to outside investors: since then, around € 3 billion has been invested privately in Munich’s biotechnology companies!

The active partnership between scientific institutions and industry is now experiencing a second spring – some decades after the Gene Center initiative. Again the Federal Ministry of Education and Research is supplementing this by supporting such new cooperation networks from science and industry, and has meanwhile been joined by the Federal Ministry of Economics and Technology (BMWt) with special initiatives like its *Central Innovation Programme SME* (ZIM). The best-known example of this new approach is the so-called “Spitzencluster-Wettbewerb” (Leading-Edge Cluster competition) organised by the BMBF. By the end of 2011/beginning of 2012, the plan is to select a total of 15 regional concepts, each of which will receive € 40 million (and at least the same sum from industrial partners) right across all branches of industry. So far, Bavaria was able to make its mark with two concepts selected from the fields of biotechnology/pharma and medical technology/diagnostics in 2010. They have now been working on specific projects for several months. We

present here a short overview of future concepts in Munich (“Munich Biotech Cluster m⁴ – Personalized Medicine and Targeted Therapies: a New Dimension in Drug Development”) and Erlangen/Nuremberg (“Medical Valley European Metropolitan Region Nuremberg – Medical Technology for the Future”).

Leading-Edge Cluster Munich Biotechnology

Munich currently has 100 partners from industry and academia supporting a joint concept for developing new drugs whose efficacy and safety are meant to be increased by targeted patient stratification. These include major players in the sector like Roche Diagnostics in Penzberg and Novartis Pharma in Nuremberg as well as local biotech companies such as MorphoSys, Trion Pharma, Kinaxo, Priaxon, Proteros, Supremol and many more. The cooperation partners from science do research at Ludwig-Maximilians University (LMU) and at Technical University Munich (TUM), the two university clinics, the Helmholtz Center Munich as well as in other institutions in the Greater Munich Area.

The successful implementation of Personalized Medicine requires exchange and discussion among all partners along the medical value creation chain: Close cooperation between academia and industry will enable new therapies and technologies to reach market maturity more quickly. The aim is to secure and increase the region’s economic strength and the number of jobs through the lead in innovation. Driven on by Bio^M GmbH’s cluster management, these ambitious goals are now being implemented. 32 cooperation projects are today receiving support. In most of these projects a biotech company cooperates with one or more academic research groups. The projects are dedicated to drug development, clinical trials, new diagnostic methods or the development of platform technologies. The indications addressed are primarily cancer, cardiovascular diseases and autoimmune diseases.

There are also 5 structural projects under way, which will create framework conditions beneficial to the entire cluster. One of these projects is the **m⁴ Biobank Alliance** which will provide easier and central access to Munich's biosample resources for academic and industrial users. Also under development are joint quality standards for the collection and storage of indication-specific tissue and non-tissue samples and their linkage to clinical data. The **m⁴ Trial Service Center** will offer consultancy and services during the early clinical phases and serve as the first point of contact for biotech SMEs that want to embark upon the clinical phase. As far as the structural projects are concerned, the two Munich universities and the university clinics are all pulling together. This is also necessary in order to make scattered resources more easily accessible and to create completely new bases for cooperation with industry. www.m4.de

Leading-Edge Cluster Medical Technology Erlangen-Nuremberg

Medical technology in the service of optimum healthcare is the vision of the Franconian metropolitan region with the aim of developing and marketing products, services and solutions. In the medium term this will significantly

increase effectiveness and efficiency in prevention, diagnostics, therapy and rehabilitation. The long-term goal of the Medical Valley EMN is to optimise the structures in healthcare overall. To achieve this, it brings all the players together – policy-makers, payers, hospitals, general practitioners, the health economy, industry. The common aim is to develop an international model region for optimal healthcare.

The key themes being addressed in the partnership cooperation projects can be subsumed under the five main groupings:

■ **Imaging Diagnostics:**

Improved technology for early detection of diseases and monitoring of therapy, special focus on integrated breast cancer diagnostics

■ **Intelligent Sensor Systems:**

Developing miniaturised sensor modules for mobile use outside of the hospital (remote diagnosis and treatment) to provide reliable measurements of relevant vital data for chronic obstructive pulmonary disease (COPD), cardiac insufficiency or chronic kidney failure.



www.m4.de · www.bio-m.org



www.medical-valley-emn.de

■ **Therapy Systems:**

These research and development projects are aimed at improving the control of drug therapy by means of dosing systems and measures for avoiding undesired (side-) effects by combining pharmacogenomics, population pharmacokinetics and pharmacodynamics.

■ **Ophthalmology:**

Companies from the cluster that are globally active and technological leaders in the field of eye disorders are developing laser applications for refractive surgery, artificial lenses and diagnostic systems.

■ **Horizontal innovations for product and process optimisation:**

Along with major technological themes, the cluster is also generating horizontal innovations for product and process optimisation. www.medical-valley-emn.de

Next Stop: Synthetic Biology

The latest example of a concept like that of the Gene Center Munich is a new institute ('Technikum') for "white/industrial biotechnology" at Technische Universität München (TUM) with partners from industry in Garching near Munich. Situated on the university campus, this institute is able to offer, right from the

beginning, contract research for industry in addition to its own research, for example, for optimising production methods or for efficiently separating and purifying bio-products. In this way, it is not only the companies that benefit from the exchange of their know-how and the results of state-of-the-art research (and the researchers from the industry's standards): the training of students in the field of process engineering and production is also linked with the real (industrial) world.

For TU München the new Technikum of the Research Center for White Biotechnology counts as the nucleus on the way towards a center for industrial biotechnology with a supra-regional aura. For example, the university has launched an initiative under the title "Bauhaus Synthetic Biotechnology". By the term "Synthetic Biotechnology" the initiators understand all technologies that will ensure in the long term that the chemical industry will no longer have to work with oil-based methods. The Bauhaus Concept aims at bundling research from science and engineering more strongly in the Munich region and to coordinate it with the expertise of industrial partners. TUM is planning to establish a central institute for the "Bauhaus Synthetic Biotechnology" in Garching and to integrate institutes in the surrounding area. There are four central themes: with minimal cells the aim is to reduce the large number of metabolic pathways in production organisms and thus customise them for the production process. The other three central themes planned are so-called cell-free syntheses, the development of so-called biohybrid chip-based systems and the development of artificial biomolecules.

After the initially stronger focus on research and development and market approval (especially in drug development), Bavaria is now taking the next logical step towards strengthening and preserving the entire value creation chain in the region or even to expanding it further in the future.

Invented *and* made in Bavaria - this is our mission!



Company Profiles



Contact:
Bettina von Klitzing

Am Klopferspitz 19a
D-82152 Martinsried/München
Phone: +49 (0) 89 700763-0
Fax: +49 (0) 89 700763-29
E-Mail: bettina.von.klitzing@4sc.com
Internet: www.4sc.com



Contact:
Dr. Mihaly Juhasz

Hammersbacher Fußweg 24
D-82467 Garmisch-Partenkirchen
Phone: +49 (0) 8821 9430-271
Fax: +49 (0) 8821 9430-272
E-Mail: M.Juhasz@accelsiors.com
Internet: www.accelsiors.com



Contact:
Dr. Jörg Scheidle

Am Windfeld 35
D-83714 Miesbach
Phone: +49 (0) 8025 2867-0
Fax: +49 (0) 8025 2867-28
E-Mail: info@acino-pharma.com
Internet: www.acino-pharma.com

4SC AG

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Medicinal Chemistry, Molecular Modelling, Small Molecules, Infectious Diseases, Rheumatology, Autoimmune Diseases

4SC AG is a drug discovery and development company focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a small molecule, is currently in a Phase IIb study in rheumatoid arthritis and a Phase IIa exploratory study in inflammatory bowel disease. The company's lead oncology compound, resminostat (4SC-201), a pan histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma and Hodgkin's lymphoma. Two further oncology compounds, 4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties. 4SC was founded in 1997, has 91 employees, and is listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Accelsiors Group International GmbH

CRO

Accelsiors International headquartered in Europe, is composed of an international CRO, drug development consulting and a biopharma development group. With offices in Germany, Hungary, the United States and a partnership in China, India and Latin America, Accelsiors conducts cost effective, time efficient large multi-centric international trials. Accelsiors' comprehensive project experience developed for multinational and US companies, provides reliable data and regulatory support for the filing of products with EMEA and FDA, while counseling clients through all project phases, from planning to implementation, from cloning to filing. Accelsiors intimate involvement with biologics (Peptides, EPO, Ifn-beta, Ifn-alpha, hGH, SR-Forms) and small molecules (GnRH) contributes proven experience to complicated drug development programs.

Acino AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharmacology, Clinical Research, Drug Delivery, Medicinal Chemistry

Acino has specialised in the development, registration and manufacture of generic and innovative pharmaceutical products using sophisticated formulation technologies, for which Acino also holds patents. By focusing on solid oral dosage forms with modified release as well as therapeutic systems for transdermal drug delivery such as patches and biodegradable, subcutaneous implants, Acino supplies the leading companies in the European drug markets. Acino offers the pharmaceutical industry a comprehensive range of services from product development and registration through procurement and contract manufacturing to packaging and logistics. Headquartered in Basel, the Acino Group currently employs a staff of close on 443. In 2010, it generated a total sales revenue of EUR 127,5 million. Acino Holding AG is quoted on the SIX Swiss Exchange (SIX: ACIN).

Activaero GmbH

BIOTECH DEVICES & REAGENTS, MEDTECH

Keywords: Drug Delivery, Devices, Peptide/Protein, Small Molecules, Infectious Diseases, Inflammation, Respiratory Diseases

Activaero GmbH, a technology leader in controlled breathing inhalation devices. These innovative technologies enable safer, more cost-efficient, and effective options for inhaled treatments and are available for clinical trials and pharma partnerships. Under the trade mark of AKITA® Activaero is developing and producing inhalation systems which enable the use of FAVORITE in the therapy of pulmonary diseases and the development of new inhalant drugs. Beyond that, Activaero is a center of excellence in aerosol medicine and supports pharma and biotech companies with its technology and services. Activaero GmbH is located in Gemünden/Wohra, Munich (Germany) and Dublin, Ohio (USA).

Active Motif Chromeon GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals / Reagents, Nanobiotechnology, Microscopy

Active Motif Chromeon provides innovative fluorescent reagents for Life Science research applications including several lines of fluorescent chromophores the Chromeo Dyes, RuLabels and Py-Dyes. Chromeo Dye excitation and emission properties match common excitation sources and filter sets, ideal for microscopy and plate-based assays. RuLabels are phosphorescent ruthenium probes that emit strongly polarized light with a long decay time, which enhances sensitivity and reduces background. The Py-Dyes possess unique physical and spectral properties that make conjugation simple, while greatly reducing background. As alternative to organic dyes, a set of bright and biocompatible fluorescent nanoparticles is offered. They represent excellent tools for increasing the sensitivity of your assays.

Affectis Pharmaceuticals AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: CNS, Drug Development, Inflammation, Small Molecules

Affectis is a pharmaceutical company developing novel drugs for the treatment of psychiatric and neuroinflammatory disorders. The Company has the capabilities to move its proprietary drug candidates from discovery to early clinical stage. Affectis is developing Cimicoxib for the treatment of major depression. The company recently completed a phase IIa study in which Cimicoxib showed consistent advantage over placebo. Affectis is also developing AFC-5128, a novel brain-penetrant and highly potent oral P2X7 antagonist for the treatment multiple sclerosis, and neuropathic pain. AFC-5128 is currently in preclinical development with IND filing planned for 2011.



Contact:
Bernhard Müllinger

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 897969-0
Fax: +49 (0) 89 897969-22
E-Mail: info@activaero.de
Internet: www.activaero.de



Contact:
Dr. Jörg Plümpe

Von-Heyden-Str. 12
D-93105 Tegernheim
Phone: +49 (0) 9403 95449-10
Fax: +49 (0) 9403 95449-15
E-Mail: chromeonsales@activemotif.com
Internet: www.activemotif.com



Contact:
Dr. Luc St-Onge

Fraunhoferstr. 13/4.OG
D-82152 Martinsried
Phone: +49 (0) 89 8932811-100
Fax: +49 (0) 89 8932811-111
E-Mail: info@affectis.com
Internet: www.affectis.com



Contact:
Barbara Müller

Fraunhoferstr. 20
D-82152 Martinsried
Phone: +49 (0) 89 8565-2665
Fax: +49 (0) 89 8565-2610
E-Mail: ir@agennix.com
Internet: www.agennix.com



Contact:
Prof. Dr. Gottfried Brem

Larezhäuserstr. 2-3
D-86567 Hilgertshausen
Phone: +49 (0) 8250 9279040
Fax: +49 (0) 8250 9279049
E-Mail: labor@agrobiogen.de
Internet: www.agrobiogen.de



Contact:
Dr. Karl Fehnle

Münchner Str. 11
D-85540 Haar
Phone: +49 (0) 89 613727-0
Fax: +49 (0) 89 613727-20
E-Mail: cro@algora.de
Internet: www.algora.de

Agennix AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Immune Therapy, Peptide/Protein, Dermatology, Oncology, Small Molecules, Drug Development

Agennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients. The Company's most advanced program is talactoferrin, an oral targeted therapy that has demonstrated activity in Phase 2 studies in non-small cell lung cancer as well as in severe sepsis. Talactoferrin is currently in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers.

Agrobiogen GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Automation, Xenotransplantation, Genomics, Gene Transfer, Transgenic Animals, Agrobiotechnology

Agrobiogen focuses on and is experienced in the application of molecular-genetic techniques in livestock animals (especially molecular-genetic diagnosis and gene transfer). Many transgenic rabbit lines and several cattle clones have been established. As a service for other biotech companies transgenic farm animals are generated using conventional microinjection procedures and nucleus transfer. Gene diagnosis of microorganism toxic to livestock like BVD, as well as parentage control of animals, scrapie resistance genotyping and analysis of DNA markers are offered as a service for breeders, veterinarians and companies. Agrobiogen has developed a simple labour-saving system for collection of tissue samples and extraction of DNA from millions of animals for automatically controlled analyses.

ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH

CRO

Keywords: Oncology, Monitoring, Clinical Research, Infectious Diseases

Algora is a niche CRO successfully operating on clinical trials in Germany. Services include phase II-IV trials as well as large observational studies and range from protocol development to final study reports. Algora manages complete study projects or delivers individual services, such as clinical monitoring, data management or statistical analysis. Experienced in oncology since the first days of the company in 1989, Algora always had a focus on innovative therapies, leading to close relationships to university hospitals and medical societies. Since 1995 another focus developed in large pediatric studies. Customers are pharmaceutical and medical device companies, independent research groups, and other CROs.

AMGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Research, Oncology, Bone / Joint Diseases, Nephrology

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, please visit www.amgen.com or www.amgen.de

AMGEN Research GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Oncology, Neurology, Inflammation, Hematology, Small Molecules, Drug Development

AMGEN, (Applied Molecular Genetics Inc.) was founded in 1980 as one of the pioneers of industrial biotechnology. The company develops, produces and sells biopharmaceutical products that are produced through recombinant DNA technologies as well as small molecule therapeutics. AMGEN Research GmbH was founded in Regensburg in 2000. Basic research is conducted with the aim of identifying new pharmaceutical lead structures for the development of innovative drugs. Low molecular weight compounds are identified by high throughput screening (HTS) procedures. Over 10 million compounds are analyzed every year.

AmplexDiagnostics GmbH – Gesellschaft für molekularbiologische Diagnostik

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, PCR, Infectious Diseases

AmplexDiagnostics GmbH is a privately held company for the development, production and distribution of In Vitro Diagnostics. Our aim is the improvement of the potential of the PCR-technology by implementing the main advantages of this technology into the diagnosis of bacterial infections. Founded in 2002 - Amplex developed its first product (hyplex[®] StaphyloResist) and entered the market already in 2003. Additional systems for the direct detection of multidrug-resistant bacteria (like VRE, ESBL, KPC and NDM-1) are completing our portfolio of PCR-screening tests for nosocomial infections causing bugs. Beside this we offer several PCR-based screening tests for sexual transmitted diseases, EHEC or TBC. For further information please visit our webpage www.hyplex.de or contact us.



Contact:
Dr. Karl-Heinz Grajer

Hanauerstr. 1
D-80992 München
Phone: +49 (0) 89 149096-1600
Fax: +49 (0) 89 149096-2600
E-Mail: karl-heinz.grajer@amgen.com
Internet: www.amgen.de



Research GmbH

Contact:
Mirko Stemmler

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 465-20000
Fax: +49 (0) 941 465-20100
E-Mail: Mirko.Stemmler@amgen.com
Internet: www.amgen.de



Contact:
Dr. Lars Wassill

Werkstr. 2
D-83555 Gars-Bahnhof
Phone: +49 (0) 8073 91693-0
Fax: +49 (0) 8073 91693-33
E-Mail: info@amplexdiagnostics.de
Internet: www.amplexdiagnostics.de



Contact:
Dr. Gerlinde Jänel

Werner-Eckert-Str. 10
D-81829 München
Phone: +49 (0) 89 2000074-11
Fax: +49 (0) 89 2000074-40
E-Mail: gerlinde.jaenel@ams-europe.com
Internet: www.ams-europe.com



Contact:
Axel Leimer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 38156-4430
Fax: +49 (0) 89 38156-3859
E-Mail: info@amsilk.com
Internet: www.amsilk.com



Contact:
Dr. Marian Wiegand

Lochhamer Str. 29a
D-82152 Martinsried
Phone: +49 (0) 89 63854363
Fax: +49 (0) 89 99753425
E-Mail: info@amvac-research.de
Internet: www.amvac-research.de

AMS Advanced Medical Services

CRO

Keywords: Analysis, Pharmacology, Medical Writing, Monitoring, Clinical Research

AMS Advanced Medical Services GmbH is a privately owned independent European mid-size CRO founded in 1997 in Mannheim by 6 partners, 4 of whom are medical doctors. AMS has also offices in London, Vienna and Munich. AMS has an overall staff of 350 people, approx. half of them are in clinical research, the other half in Marketing and Sales services. AMS invented the 1. Internet-Pharmaschool (1.IPS) with trainers and techniques offering tailor-made training concepts for staff in both clinical research and sales. AMS is a full service CRO with significant experience in multiple therapeutic areas and strong medical expertise covering Phase I to Phase IV, non-interventional programs, pharmaco-epidemiology and -economics. Our staff includes 60 CRAs and more than 50 people in DM and Stats.

AMSilk GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Drug Delivery, Tissue Engineering / Cell Culture, Fine Chemicals / Reagents, New Materials

Technology enables the production of tailor-made materials which are unrivaled by most common synthetic materials. AMSilk addresses many applications and industry sectors with new materials enabling new products with previously unachievable features.

AMSilk has developed a unique process to produce biopolymers like spider silk at an industrial scale. These materials form the basis for coatings, films, non-wovens and monofilament fibers. The resulting products are being developed medical, pharmaceutical and industrial applications.

The name AMSilk and the AMSilk Logo are registered trademarks of AMSilk GmbH; Munich.

AmVac Research GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Vaccines, Gene Transfer, Drug Development

AmVac Research is a biotech company developing highly innovative and multifunctional vaccines. The company is using a novel viral vector technology that combines excellent immunogenicity of live viral vaccines with the high safety profile of inactivated vaccines. This technology serves as a platform for the development of several tailor-made vaccines. One main focus of the company is the development of vaccines against respiratory tract diseases caused by viral agents such as RSV or hPIV3 against which no effective therapeutic or preventive means exist. Related to vaccination, AmVac is developing adjuvant candidates which show superior mucosal efficacy.

amYmed GmbH – Referenzzentrum für Amyloidkrankheiten

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Antibody, Devices, Antibody Production Service, Clinical Diagnostics

We provide high precision immunohistochemical classification of the diverse amyloid diseases with respect to specific and causal treatment as a service for patients and physicians.

We are in the process of extending this service by producing and offering test kits in order to enable clinics and institutes of pathology to perform this classification by themselves.

Antisense Pharma GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Antisense/Nucleotides, RNAi & Antisense, Drug Development

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology. The medications specifically block the synthesis of key cancer proteins. Antisense Pharma has clinical trials running that involve patients with brain tumors (phase III), advanced pancreatic carcinoma, malignant melanoma and colorectal carcinoma (phase I/II). Therapies for other indications are under preclinical development. The company has been honored with the German Founder Award and the Bavarian Innovation Award and received the Innovation Prize TOP 100 twice.

Apceth GmbH & Co. KG

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Gene Transfer, Cell Therapy, Gene Therapy, Cardiovascular Diseases, Oncology, Tissue Engineering / Cell Culture

Apceth is a biopharmaceutical company (foundation 11/2007) dedicated to the development and clinical implementation of innovative cell and gene therapeutics based on stem cells for the treatment of malignant and non-malignant diseases. Apceth aspires to set up the highest standards for manufacturing, quality and safety of Advanced Therapy Medicinal Products (ATMPs). The company operates within unique state-of-the-art GMP/S2 facilities comprising separate Cleanroom suites class C and class B/A, Quality Control Units and R&D laboratories. After obtaining the Manufacturing License (§13 of AMG) for production of somatic cell therapeutics in 10/2010, Apceth commenced its first clinical trial Phase I/II for the treatment of critical limb ischemia in 03/2011. As of 2011 Apceth offers contract GMP-manufacturing and associated services for cell-based products.

amYmed

Contact:
Prof. Dr. med. Reinhold P. Linke

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52012638
Fax: +49 (0) 89 52389013
E-Mail: linke@amymed.de
Internet: www.amymed.de



Contact:
Carolin Nolte

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 92013-0
Fax: +49 (0) 941 92013-29
E-Mail: pr@antisense-pharma.com
Internet: www.antisense-pharma.com



Contact:
Dr. med. Christine Günther

Max-Lebsche-Platz 30
D-81377 München
Phone: +49 (0) 89 7009608-0
Fax: +49 (0) 89 7009608-79
E-Mail: c.guenther@apceth.com
Internet: www.apceth.com



Contact:
Dr. Karl-Heinz Molz

Landsberger Str. 476
D-81241 München
Phone: +49 (0) 89 896016-0
Fax: +49 (0) 89 896016-33
E-Mail: apexpkpd@aol.com
Internet: www.apex-research.com



Contact:
Prof. Dr. Gottfried Brem

Larezhhausen 2
D-86567 Hilgertshausen
Phone: +49 (0) 8250 9279010
Fax: +49 (0) 8250 9279019
E-Mail: gottfried.brem@apogene-gmbh.de
Internet: www.apogene-gmbh.de



Contact:
Verena Köpke

Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 741206-80
Fax: +49 (0) 89 741206-88
E-Mail: verena.koepke@assigngroup.com
Internet: www.assigngroup.com

APEX GmbH

CRO

Keywords: Pharmacology, Drug Development, Clinical Research, Pharmacokinetics, Diabetics, Hepatology, Nephrology

- Our Concept... APEX is a highly efficient combination of investigator and CRO. Our aim is to provide our clients with a service which combines the access to patients of an investigator with the expertise to perform a complex, high quality research project of a CRO. We combine high level phase 1 data quality with the typical phase 2/3 study population.
- Our Service... Is the clinical performance of pharmacokinetic and proof-of-concept / PKPD studies.
- Our Study Population... are patients with impaired renal or hepatic function and patients with other chronic stable diseases (diabetes, hypertension, asthma etc.). Since the patients come into our clinic, rather than us having to go to them via their GP's, the data we generate are more complete and accurate, fewer patients are required and the project can be completed faster.
- Our Clients... are international pharmaceutical companies from medium sized to members of the world's top ten.

apoGene GmbH & Co. KG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Xenotransplantation, Knock Out, Tissue Engineering / Cell Culture

apoGene is focused on the field of xenotransplantation. Rabbits and pigs are genetically modified (transfer, knock out and recombination of endogenous genes) for influencing the different steps of the rejection process after xenotransplantation of animals tissues and organs. We are also investigating the expression of endogenous retroviral sequences after xenogenetic transfer. For the development of knock out animals we have developed and patented an alternative strategy, the so called screen-out of homozygote carriers of functional defects in natural or mutagenized populations. The technique will also be very interesting for the establishment of animal models for basic and applied research.

Assign Group

CRO

Keywords: Analysis, Clinical Research, Logistics, Monitoring, Medical Writing, Pharmacology, Toxicology

Assign is a midsize European Contract Research Organisation, offering full service in clinical research from phase I to phase IV. Our expertise includes the design of clinical development plans, study synopsis and study protocol writing, feasibility studies, project management, monitoring, quality management, data management, biostatistics and study drug management including QP release as well as central lab logistics.

Astellas Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Antibiotics, Allergy, Autoimmune Diseases, Immune Therapy, Infectious Diseases, Inflammation

Astellas Pharma Inc. was formed in April 2005 from a merger with Yamanouchi and Fujisawa. Astellas Pharma is Japan's second largest pharmaceutical company and is headquartered in Tokyo. It has operations in Europe, Asia, North America and Japan. Astellas is focused on four key therapy areas: Transplantation, urology, dermatology, and anti-infectives. Astellas employs approximately 3,300 people in Europe across Sales and Marketing, Research & Development and Manufacturing. Astellas has 19 Sales and Marketing Affiliates, 3 plants and 1 R&D site in Europe. Astellas Europe is headquartered just outside London in Staines. The German headquarters are based in Munich. Located here are Sales, Marketing and Medical. The product portfolio includes therapies in transplantation, urology, dermatology, asthma/COPD, cardiology, antibiotics and gastroenterology. Astellas Pharma GmbH Munich employs approximately 350 people including 225 sales representatives.

Aurigon Life Science GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Toxicology, Pharmacology, Drug Development

Aurigon the CRO for efficacy and safety testing, is an independent, privately owned company dedicated to serving the biotech, pharmaceutical, food and chemical industries by providing a comprehensive range of services in bio-analytics, pharmacology, biological activity testing, ADME/PK and regulatory toxicology (rodent and non-rodent) including genotoxicity, immunotoxicity, safety pharmacology, cancerogenicity and reprotoxicity. We have broad experience in working with small molecules, chemicals and biologicals including peptides, antibodies, biosimilars, herbal extracts, nutritionals and cell therapy. With personalized and flexible services we support achievement of our customers needs in expected timelines, investment and efforts. With its headquarter in the south of Munich, Aurigon Life Science operates in state of the art GLP respectively GMP compliant facilities with subsidiary and affiliated laboratories located near Budapest. We are a trusted outsourcing partner for multinational pharmaceutical and chemical groups, food producers and innovative biotechnology companies. We feel committed to life.



Contact:
Dr. Martin Marhoefer

Georg-Brauchle-Ring 64-66
D-80992 München
Phone: +49 (0) 89 4544-1440
Fax: +49 (0) 89 4544-5440
E-Mail: info@de.astellas.com
Internet: www.astellas.de



Contact:
Dr. Gundel Hager

Bahnhofstr. 9-15
D-82327 Tutzing
Phone: +49 (0) 8158 2597-30
Fax: +49 (0) 8158 2597-31
E-Mail: info@aurigon.de
Internet: www.aurigon.de

baseclick

Contact:
Dr. Thomas Frischmuth

Bahnhofstr. 9-15
D-82327 Tutzing
Phone: +49 (0) 8158 903867
Fax: +49 (0) 8158 903894
E-Mail: info@baseclick.eu
Internet: www.baseclick.eu



Contact:
Dr. Thomas Trilling

Kistlerhofstr. 75
D-81379 München
Phone: +49 (0) 89 7857674-0
Fax: +49 (0) 89 7857674-100
E-Mail: office.DE@basileapharma.com
Internet: www.basilea.com



Contact:
Derek Beggs

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 85650030
Fax: +49 (0) 89 85651333
E-Mail: derek.beggs@bavarian-nordic.com
Internet: www.bavarian-nordic.com

baseclick GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Fine Chemicals / Reagents, New Materials, Chip / Array Technology, Nanobiotechnology, PCR

Baseclick GmbH is a young and dynamic start-up company located in Tutzing, south of Munich, close to the biotech campus in Munich-Martinsried. The baseclick IP was generated at the University of Munich in the group of Prof. Thomas Carell. Core technology of our company is the modification of oligonucleotides with click chemistry. Using this method, nucleic acids can be easily labeled with various molecules, amongst them dyes and quenchers, biotin, and more. Multiple modifications with different labels can be done at any position within the DNA/RNA strand, including the termini.

Basilea Pharmaceutica Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Antibiotics, Allergy, Dermatology, Infectious Diseases, Oncology

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The company currently focuses on antibiotics and antifungal as well as oncology and dermatology drugs, targeting the medical challenge of rising resistance and non-response to current treatment options in the hospital and specialty care settings. Basilea Pharmaceutica Deutschland was founded 2007 in Munich. Skin diseases are an area of high medical need. Patients are suffering from disfiguring conditions such as hand eczema. Alitretinoin (Toctino®), a vitamin A derivative offers a significant quality of life improvement in the treatment of adults with severe chronic hand eczema unresponsive to topical corticosteroid.

Bavarian Nordic GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Vaccines, Drug Development

Bavarian Nordic (BN) is a leading international biopharmaceutical company developing innovative vaccines to prevent and treat infectious diseases. The company is capable to meet the growing demand for safe 3rd generation smallpox vaccines due to its proprietary vaccine technology MVA-BN®. BN was founded in 1994 and is headquartered in Kvistgaard, Denmark with subsidiary operations in Martinsried and Berlin, Germany. BN recently founded in the US an operating company, BN ImmunoTherapeutics Inc., for research and development of cancer vaccines. The company employs about 180 people and is listed on the Copenhagen Stock Exchange. More than 450 healthy and immune compromised subjects so far vaccinated with MVA-BN®, suggest an excellent safety and efficacy profile of the vector.

Baxter Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Tissue Engineering / Cell Culture, Vaccines, Immune Therapy, Pain, Oncology, Autoimmune Diseases, Nephrology

Baxter International Inc. (NYSE: BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Beckman Coulter Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: PCR, Automation, Nanobiotechnology, Devices

Beckman Coulter Genomics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Genomics, Drug Development, Pharmacogenetics, Pharmacogenomics, Clinical Diagnostics

Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Our diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs.

Hospital laboratories are our core clinical diagnostic customers. Our life science customers include pharmaceutical and biotechnology companies, universities, medical schools and research institutions. Beckman Coulter has an installed base of more than 200,000 clinical and research systems operating in laboratories around the world.

Beckman Coulter has a leading position in Laboratory Automation. Research & Development as well as Production of our stand alone automation systems, the AutoMate 2500 Family (formerly known as OLA 2500), are located in Munich, Germany.



Contact:
Maria Wiedemann

Edisonstr. 4
D-85716 Unterschleißheim
Phone: +49 (0) 89 31701-0
Fax: +49 (0) 89 31701-277
E-Mail: info_de@baxter.com
Internet: www.baxter.de



Contact:
Dr. Gerhard Gunzer

Sauerbruchstr. 50
D-81377 München
Phone: +49 (0) 89 579589-0
Fax: +49 (0) 89 579589-3503
E-Mail: info@beckmann.com
Internet: www.beckmanngenomics.com



Bernina Plus

Contact:
Dr. Felix Gropp

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52388740
Fax: +49 (0) 89 52388333
E-Mail: gropp@berninaplus.de
Internet: www.berninaplus.de



Contact:
Dr. Kai Lamottke

Richard-Riemerschmid-Allee 27
D-81241 München
Phone: +49 (0) 89 82072564
Fax: +49 (0) 89 529178
E-Mail: lamottke@bicoll-group.com
Internet: www.bicoll-group.com



Contact:
Dr. Silke Martin

Herzog-Heinrich-Str. 2
D-80336 München
Phone: +49 (0) 89 5399-4500
Fax: +49 (0) 89 5399-4505
E-Mail: biobank@blutspendedienst.com
Internet: www.biobank.de

Bernina Plus GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Liposomes, Nanobiotechnology

Bernina develops smart oral drug delivery systems for therapeutic peptides. The proprietary technology is based on artificial envelopes created by lipids. In addition, these nano-particulate natural and synthetic lipids are used in coating and drug elution processes.

Bicoll GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Medicinal Chemistry, Oncology, Drug Development, Infectious Diseases, Natural Compounds, Small Molecules, Nutraceuticals

Bicoll is a biopharmaceutical company, offering pre-clinical support in the area of Drug Discovery from Natural Products and Medicinal Chemistry. To speed up drug discovery processes, Bicoll offers its drug like compound library BILOBAC N, consisting of already fractionated plant extracts, to global clients in drug discovery and related innovative fields. BILOBAC N provides enhanced probability of biological activity and reduced complexity of fine fractions, thus ready to use in client's screening systems. With innovative strategies and a proprietary technology platform, Bicoll is able to rapidly select only the best leads with superior drug-like profiles for further development. Subsequent medicinal chemistry and custom synthesis complete Bicoll's seamless substantial services.

BIOBANK der Blutspender – Blutspendedienst des BRK

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Metabolic Diseases, Diabetics, Cardiovascular Diseases, Autoimmune Diseases, Clinical Diagnostics

With its »Blood Donor BIOBANK«, the Bavarian Red Cross Blood Donor Service offers a unique resource for biomarker research: the world's first blood donor based biobank. A large pool of more than 400,000 active blood donors enables the identification of several thousands of diseased BIOBANK participants per year. Their serial, pre-diagnostic blood samples are a unique resource for investigating markers associated with the onset and progression of diseases. With a collection of more than 3 Mio plasma samples processed and stored using highly standardized, qualified processes (ISO9001:2008 certification) the »Blood Donor BIOBANK« is one of the largest biobank projects worldwide.

Biomax Informatics AG

BIOTECH BIOINFORMATICS

Keywords: Proteomics, Genomics

Biomax provides computational solutions for better decision making and knowledge management in the life science industry. We offer an innovative and powerful solution to accelerate knowledge-driven research processes. We support our customers with a platform that combines software products with knowledge resources, including oncology, nutrigenomics, plant research and functional genomics.

Our flexible and comprehensive solutions provide access to relevant knowledge at the right time & in the right context. We help customers generate value from proprietary and public resources by extracting the knowledge indispensable for efficient data exploration and interpretation. We focus on integrating information to enable a knowledge-based approach to develop innovative life-science products.

Biomed Labordiagnostik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, PCR, ELISA / EIA, Analytical Chemistry

The product range of BIOMED Labordiagnostik GmbH focuses on proven reagents for the in vitro diagnostic since 1976. BIOMED offers system reagents together with calibrators and controls. The reagents are stable, long-lasting, ready-to-use, a guarantee of reliable test results due to maximum test signals, linearity and correlation and available in economical sizes of pack. BIOMED system reagents have a favourable serum-reagent ratio and offer economically relevant benefits which ultimately bring about a quantifiable reduction in costs:

1. Reduced amount of time spent loading the machine,
2. Two to seven additional spaces on the R1 plate,
3. More methods possible on the device,
4. Analysis time shortened by up to 30 minutes.

Using the lyophilised or ready-to-use calibrators and controls achieves reliable control results which conform to RiliBÄK and meet the most demanding requirements.



Contact:
Dr. Shannon Frances

Robert-Koch-Str. 2
D-82152 Planegg
Phone: +49 (0) 89 895574-0
Fax: +49 (0) 89 895574-825
E-Mail: info@biomax.com
Internet: www.biomax.com



Contact:
Claudia Caspers

Bruckmannring 32
D-85764 Oberschleißheim
Phone: +49 (0) 89 3157000
Fax: +49 (0) 89 3153242
E-Mail: info@biomed.de
Internet: www.biomed.de



Contact:
Dr. Jutta Haunschild

Kerschensteiner Str. 11-15
D-92318 Neumarkt
Phone: +49 (0) 9181 2319-0
Fax: +49 (0) 9181 2312-65
E-Mail: info@bionorica.de
Internet: www.bionorica.de



Contact:
Dr. Stephan König

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 324799-50
Fax: +49 (0) 89 324799-52
E-Mail: contact@biontix.com
Internet: www.biontix.com



Contact:
Dr. Alexander von Nieciecki

Weihenstephaner Str. 28
D-81673 München
Phone: +49 (0) 89 2444129-33
Fax: +49 (0) 89 2444129-30
E-Mail: info@bioproof.de
Internet: www.bioproof.de

BIONORICA SE

PHARMA & CHEMICAL INDUSTRY

Keywords: Neurology, Pain, Respiratory Diseases, Oncology, Clinical Research, Analytical Chemistry, Drug Development

Bionorica SE is one of the leading companies in the area of phytopharmaceuticals worldwide. The product range focuses mainly on diseases of the respiratory tract, urinary tract, gynaecological disorders, allergy and on medications for the treatment of pain. As an essential Bionorica follows the principle of phytoneering as gold standard in modern phytotherapy. Phytoneering stands for deciphering the active principle in botanicals (PHYTO) using innovative technologies (engiNEERING) to develop and manufacture the most effective phytopharmaceuticals. The expressed goal is to discover new active substances in order to develop effective drugs with minimized side effects. Bionorica has established an impressive network of scientists working in about 490 renowned universities, institutions and organisations worldwide.

Biontix Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals / Reagents, Gene Transfer, Liposomes, RNAi & Antisense, Gene Therapy, Nanobiotechnology, Microscopy

Biontix is a genetic engineering company offering comprehensive range of products in field of transfection technology. Our new development META-FECTENE EASY is a GLOBAL INNOVATION in this product sector eliminating need for time-consuming optimization, while METAFECTENE SI is a reagent designed for efficient siRNA transfection. A major alternative is the direct transport of proteins into cells; a purpose for which the new reagents in the PROTEOfectene series were specifically developed. Our groundbreaking new Microfection product series enables the outstanding optical properties of μ -Slides in live-cell imaging to enhance the versatility and efficiency of nucleic acid and protein transfection applications. The product portfolio is completed by mycoplasma detection and removal kits.

BioProof AG

CRO

BioProof offers high standard analytics of small molecules and biologicals (LC-MS/MS, HPLC, ELISA, bioassays) according to GLP, pharmacokinetic evaluation and support as well as medical writing (IDB, IMPD, IND etc.). Its multidisciplinary team has excellent expertise in registration-oriented project management at the intersections of chemistry, analytics, formulation, manufacturing, preclinical and clinical development, throughout the whole product-driven development process.

BioProof is a privately owned and independent CRO, founded in 2001. Focusing on development until proof of concept, BioProof is continuously expanding its potential through partnering and networking.

Bio-Rad Laboratories, Inc. USA – Life Science Group CE

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Gene Transfer, Genomics, Proteomics, Peptide/Protein, PCR, Chip / Array Technology

Bio-Rad Laboratories GmbH is a subsidiary of the Bio-Rad Group, one of the leading companies in the field of Life Science and Diagnostics with more than 6,900 employees throughout the world. Bio-Rad Laboratories develops, produces and distributes apparatus and consumables for molecular biological and biochemical research in Life Science, for Clinical Diagnostics and routine applications.

bioregeneration™ GmbH

BIOTECH

Keywords: Tissue Engineering / Cell Culture, New Materials, Nanobiotechnology, Cell Therapy, Clinical Research, Devices

bioregeneration™ GmbH works in the field of tissue engineering using a proprietary technology. The technology comprises of the newly developed biomaterial „Xellulin“, which can be individually shaped and causes no graft-reaction in the human body.

BIOZOL Diagnostica Vertrieb GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Peptide/Protein, Antibody, Small Molecules, Proteomics, Clinical Diagnostics, ELISA / EIA

Biozol Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology and biochemistry, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals und further reagents for cell culture, flow cytometry, immunohistology and cytogenetics. The company represents almost 40 different worldwide known suppliers in Germany. Biozol offers additionally different types of services such as free product search.



Contact:
Martina Fuß

Heidemannstr. 164
D-80939 München
Phone: +49 (0) 89 31884-120
Fax: +49 (0) 89 31884-123
E-Mail: TechSupportLSG.CE@bio-rad.com
Internet: www.bio-rad.com



Contact:
Dr. Günter Bertholdt

Boltzmannstr. 11a
D-85748 Garching
Phone: +49 (0) 89 28910-916
Fax: +49 (0) 89 28910-933
E-Mail: mail@bioregeneration.eu
Internet: www.bioregeneration.eu



Contact:
Dr. Ralf Bäuerle

Obere Hauptstr. 10b
D-85386 Eching
Phone: +49 (0) 89 3799666-6
Fax: +49 (0) 89 3799666-99
E-Mail: info@biozol.de
Internet: www.biozol.de



Contact:
Dr. Bernd Winterhalter

Arnulfstr. 29
D-80636 München
Phone: +49 (0) 89 12142-0
Fax: +49 (0) 89 12142-392
E-Mail: info@b-ms.de
Internet: www.b-ms.de



Contact:
Dr. Alexander Werner

Behringstr. 6/8
D-82152 Planegg
Phone: +49 (0) 89 899650-0
Fax: +49 (0) 89 899650-11
E-Mail: info@bioservice.com
Internet: www.bioservice.com



Contact:
Dr. Tobias Polifke

Simoniusstr. 39
D-88239 Wangen
Phone: +49 (0) 7522 79527-0
Fax: +49 (0) 7522 79527-29
E-Mail: info@candor-bioscience.de
Internet: www.candor-bioscience.de

Bristol-Myers Squibb GmbH & Co. KGaA

PHARMA & CHEMICAL INDUSTRY

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com

BSL-BIOSERVICE Scientific Laboratories GmbH

CRO

Keywords: Analysis, Laboratory, Drug Development, Pharmacokinetics, Toxicology, Pharmacology

Since 1984, BSL BIOSERVICE is world-wide active as an CRO that concentrates on biological trials of pharmaceuticals, biologics, chemicals, agrochemicals, medical devices, cosmetics and food. The internationally accepted approach of the institute with its various accreditations and certifications (GLP, GMP, DIN EN ISO 17025, FDA approved) guarantees high-quality services. Areas of expertise include e.g. ADME and Metabolism, Bioassays, Cell-Based Immunoassays and Immunotoxicological Investigations, Clinical Sample Services, Toxicology, Pharmacology, Microbiology and Analytics. BSL BIOSERVICE also offers comprehensive services for REACH. BSL BIOSERVICE is also active in the development of alternative test methods to animal experiments.

CANDOR Bioscience GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, ELISA / EIA, Chip / Array Technology, Toxicology

CANDOR-The Technology Solution Provider for Optimising your Immunoassays. CANDOR Bioscience provides services and products for optimising and stabilising immunoassays. Due to optimisation you can significantly improve the reliability of results. We are supplier and service provider for diagnostics, GLP laboratories and pharmaceutical industry. CANDOR provides for every application the optimal solution. The innovative LowCross buffer[®] reduces cross reactivities, interference and matrix effects which are characteristic for blood, serum and tissue specimen. All products are available in bulk quantities to manufacturers of test kits. For pharmaceutical research and diagnostics we develop and validate ELISA according to relevant guidances (e.g. FDA). CANDOR is DIN EN ISO 9001:2008 certified.

Carl Zeiss MicroImaging GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Analysis, Tissue Engineering / Cell Culture, Microscopy, Clinical Diagnostics, Clinical Research

Carl Zeiss MicroImaging GmbH offers a broad range of modern and innovative microscope systems and solutions for different fields such as biotechnology, biomedical and clinical research as well as routine and industrial applications. Carl Zeiss MicroImaging employs about 1,750 staff worldwide and has its direct sales force in 130 countries. The company's headquarter is in Jena. At its Munich site Carl Zeiss MicroImaging is focusing on software development, systems for laser microdissection and its application as well as digital slide and automation technology. In addition, in Munich the company is maintaining a unique facility hosting a modern application center and an up-to-date laboratory for biomedical and clinical research, molecular analysis and imaging. Practical courses, workshops and training are held on a regular basis and customer services are offered.

Celgene GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Small Molecules, Hematology, Drug Delivery, Oncology

Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem.

For further information visit: www.celgene.de

cellasys GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Chip / Array Technology, Pharmacokinetics, Drug Development, Tissue Engineering / Cell Culture, Toxicology

cellasys offers system solutions for online analysis of living cells. These include services as research and development, production and maintenance of cell based assays. Furthermore we are consultant for development of applications, data analysis and data interpretation.



Contact:
Dr. Richard Ankerhold

Kistlerhofstr. 75
D-81379 München
Phone: +49 (0) 89 909000-800
Fax: +49 (0) 89 909000-820
E-Mail: info@zeiss.de
Internet: www.zeiss.de/microdissection



Contact:
Aart Brower

Joseph-Wild-Str. 20
D-81829 München
Phone: +49 (0) 89 451519-010
Fax: +49 (0) 89 451519-019
E-Mail: info@celgene.de
Internet: www.celgene.de



Contact:
Dr. Joachim Wiest

Karlstr. 96
D-80335 München
Phone: +49 (0) 89 2000110-74
Fax: +49 (0) 89 2000110-76
E-Mail: wiest@cellasys.com
Internet: www.cellasys.com



Contact:
Dr. med. Peter Geigle

Industriestr. 19
D-63755 Alzenau
Phone: +49 (0) 6023 9181-0
Fax: +49 (0) 6023 9181-33
E-Mail: info@cellmed.de
Internet: www.cellmed.de



Contact:
Dr. Johannes Betz

Am Kleinfeld 11
D-85456 Wartenberg
Phone: +49 (0) 8762 724300
Fax: +49 (0) 8762 724312
E-Mail: info@centronic-gmbh.com
Internet: www.centronic-gmbh.com



Contact:
Dr. Frank Schneider

Landsberger Str. 94
D-80339 München
Phone: +49 (0) 89 895570-0
Fax: +49 (0) 89 895570-15
E-Mail: info@cephalon.com
Internet: www.cephalon.de

CellMed AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Diabetics](#), [CNS](#), [Peptide/Protein](#), [Cell Therapy](#), [Drug Delivery](#), [Drug Development](#)

CellMed is developing encapsulated cellular systems for the delivery of therapeutic substances right in the patient. CellMed uses proprietary encapsulation technology and a cell line based on mesenchymal stromal cells. The cells are designed to secrete the desired proteins or peptides. These systems are produced according to GMP and are currently in clinical trials for the treatment of stroke. The engineered peptide here is a proprietary version of GLP-1 with specific anti-apoptotic properties.

For a second version of the GLP-1 AstraZeneca has an option to exclusively license that version for the treatment of diabetes and obesity.

A „pure“ bead product for cosmetic dermatology has been developed and will be introduced to the market by Merz.

Centronic GmbH

BIOTECH DEVICES & REAGENTS

Keywords: [Clinical Diagnostics](#), [Clinical Research](#)

Centronic GmbH is a German manufacturer, with a certified Quality Management System according to EN ISO 9001:2008 and ISO 13485:2003/AC: 2009, and distributor of a big range of high qualitative clinical chemistry reagents in fluid and lyophilised form for the determination of enzymes, electrolytes, substrates, lipids and proteins. The product range is completed by Latex reagents, controls-calibrators and our registered additive for waterbaths Prothermal. The products are distributed worldwide.

Our team consists of highly engaged scientists from different special fields with an experience of many years in the area of clinical chemistry.

Cephalon GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [Pain](#), [Oncology](#), [Neurology](#), [Hematology](#), [CNS](#)

Cephalon GmbH is the German affiliate of the biopharmaceutical company Cephalon Inc. headquartered in Frazer, Pennsylvania. Cephalon GmbH markets and promotes drugs for the treatment of epilepsy, Parkinson's Disease, narcolepsy, bipolar disorders, breakthrough cancer pain and leukemia with its own sales forces in Germany and Austria.

ChemDiv, Inc.

CRO

Keywords: Clinical Research, Drug Development, Medicinal Chemistry, CNS, Pharmacology, Neurology, Pain

ChemDiv, a global Contract Research Organization (CRO), offers Integrated Discovery outSource™ solutions that cover a complete range of disciplines from medicinal chemistry to clinical development needed to bring new drugs from target to market. With successful 20 years business record and over 500 research associates, the company puts forward unique translational expertise to help accelerate its partners R&D programs. ChemDiv provides Proof of Concept data in less time and at a fraction of the costs typically seen in the industry with keeping the high quality standards, all of which plays a critical role in mitigating risks associated with full scale clinical development.

ChromBios GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Founded in 1998, ChromBios is focused on the field of Molecular Cytogenetics (fluorescence in situ hybridisation, FISH). The company's aims are to provide service and products for chromosome analysis tailored to the needs of the customers. We offer „FISH service“ such as chromosome analysis with „chromosome painting“, mapping of clones, characterisation of cancer cell lines and animal models in genome research. We especially focus on multi colour karyotyping human tumour cells and other transformed cell lines (for example for patent applications). Chrombios also offers multi colour chromosome painting of mouse cells to identify translocations in mouse tumours and to characterise mouse ES cells. Apart from human and mouse, we also provide service in the characterization of chromosomes from other animal model species including rat, hamster, cat, and various live stock animals.

ChromoTek GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, Proteomics, Peptide/Protein

ChromoTek GmbH, a biotech spin-off from the LMU Munich founded in 2008, aims to establish Chromobodies® (highly efficient functional binding reagents for a multitude of immunological and biochemical applications) as superior substitutes for conventional antibodies in areas like proteome analysis, target screening/validation, cell sorting and live cell HCA. On the basis of its technology (patent pending) the team of 5 biologists around CEO Ulrich Rothbauer develops novel analytical and preparative solutions for the biomolecular research market. It has successfully launched the GFP-Trap®, the best commercially available pull-down reagent for GFP and/or GFP fusion proteins.



Contact:
Dr. Anna Niebling

Waldstr. 22
D-82049 Pullach
Phone: +49 (0) 89 74442700
Fax: +49 (0) 89 79367571
E-Mail: aniebling@chemdiv.com
Internet: www.chemdiv.com



Contact:
Dr. Andrea Kofler

Mühlenstr. 1
D-83064 Raubling
Phone: +49 (0) 8035 9849-28
Fax: +49 (0) 8035 9849-30
E-Mail: kofler@chrombios.com
Internet: www.chrombios.com



Contact:
Dr. Ulrich Rothbauer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 787973-10
Fax: +49 (0) 89 787973-11
E-Mail: u.rothbauer@chromotek.com
Internet: www.chromotek.com



Contact:
Dr. Christa Sommerburg

Pionierstr. 2
D-82152 Krailling
Phone: +49 (0) 89 8638933-10
Fax: +49 (0) 89 8638933-99
E-Mail:
christa.sommerburg@clinical-trial-care.de
Internet: www.clinical-trial-care.de



Contact:
Dr. Hans Wolf

Dachauer Str. 37
D-80335 München
Phone: +49 (0) 89 54558355
Fax: +49 (0) 89 557443
E-Mail: germany@clintec.com
Internet: www.clintec.com



Contact:
Dr. Andreas Klostermann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 3187-2662
Fax: +49 (0) 89 3187-3835
E-Mail: info@conogenetix.de
Internet: www.conogenetix.de

Clinical Trial Care GmbH

CRO

Keywords: Clinical Research, Monitoring, Dermatology, Metabolic Diseases, Nephrology, Pain, Rheumatology

Clinical Trial Care GmbH founded in 2001 is a CRO located in the southwest of Munich (Krailling) and provides the full scope of clinical and biometric services required for the conduct of clinical trials of phase II-IV, post marketing surveillance as well as non-interventional or epidemiologic studies. The very experienced, flexible and successful team ensures expert support and a responsive commitment. The CRO is headed by Dr. Christa Sommerburg and Andreas Behr (Geschäftsführer) with a long standing history of clinical research.

ClinTec GmbH

CRO

Keywords: Neurology, Cardiovascular Diseases, Regulatory Affairs, Drug Development, Oncology, Medical Writing, Clinical Research

ClinTec International is a privately owned full service global Clinical Research Organization covering more than 30 developed and emerging countries. It was founded in 1997 by Dr Rabinder Buttar, the company's President & CEO. In 2007, the Global Clinical Research Centre of Excellence was established in Munich recruiting a functional unit of thirty professionals from the former European headquarters of an international pharmaceutical company. It is the global home for standards, tools and industry best-practice in the following functions: Regulatory Affairs, Clinical Research, Data Management & Biostatistics, Medical Writing and Quality Assurance. We are working seamlessly with our clients, understanding their needs and constraints in order to deliver optimal solutions.

conoGenetix biosciences GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Pain, CNS, Peptide/Protein, Drug Development

conoGenetix biosciences GmbH is a biotechnology company that focuses on the development of peptide-based drugs for the treatment of currently untreatable neurological and cardiovascular disorders. These therapeutics - isolated from complex animal venoms - display the advantage of an extremely high specificity resulting in reduced side effects for the patient. Alliances with academic research groups and a network of co-operators throughout the world enhance the company's capabilities of drug discovery and development.

Conreso GmbH

CRO

Keywords: Clinical Research, Logistics, Monitoring, Drug Development

Conreso, established in 1990, BVMA member, offers a wide range of clinical research services. Conreso shows an impressive record of successful FDA inspections and significant contributions to important new product licenses in Europe and the USA. Having recruited more than 30,000 patients between 0 and 17 years of age proves the company's unique expertise in pediatric trials. The Hannover Clinical Trial Center, a joint venture of Conreso and the Medizinische Hochschule Hannover, provides Conreso's clients access to the clinical expertise and the comprehensive diagnostic and therapeutic facilities of one of the leading academic medical institutions in Germany. The Conreso Institute of Veterinary medicine provides all types of veterinary studies.

Corimmun GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Cardiovascular Diseases, Peptide/Protein, Drug Development

CORIMMUN is a spin-off from the universities of Wuerzburg and of Tuebingen. The projects are funded by two grants of the GO-Bio project of the BMBF. Corimmun is financed by the MIG AG, KfW Bank, Bayernkapital, HTGF and Bio^M. The company is developing new drugs to treat congestive heart failure and atherosclerosis, the most common causes of mortality in developed countries. Two innovative products COR-1 and COR-2 are currently in preclinical development. COR-1 is a peptide drug candidate to prevent the auto-antibody-mediated propagation of heart failure. COR-2 is a biological which prevents foam cell formation in atherosclerotic plaques. The founders and management of Corimmun bring together knowledge and reputation in research and clinical medicine together with biotech experience.

Coriolis Pharma

BIOTECH PRECLINICAL SERVICES, MEDTECH

Keywords: Analysis, Antisense/Nucleotides, Vaccines, Peptide/Protein, Drug Delivery

Coriolis Pharma is a globally operating independent service provider for research and development of biopharmaceutical drugs (proteins, peptides, monoclonal antibodies, RNA/DNA etc.) and vaccines. An interdisciplinary team of highly qualified scientists with many years of experience in the development of biopharmaceuticals supported by an expert scientific advisory board provides cutting-edge service and know-how related to the formulation development of biopharmaceuticals. This may involve for example formulation development of (pre-)clinical material through to commercial products, lyophilization processes, stability testing, supply of pre-clinical material, and analytical services using innovative analytical technologies.



Contact:
Jürgen Schäfer

Neuhauser Str. 47
D-80331 München
Phone: +49 (0) 89 236650-0
Fax: +49 (0) 89 236650-50
E-Mail: schaefer@conreso.com
Internet: www.conreso.com



Contact:
Dr. Goetz Münch

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 8565-2010
Fax: +49 (0) 89 8565-2020
E-Mail: info@corimmun.com
Internet: www.corimmun.com



Contact:
Dr. Michael Wiggerhorn

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 5424498-0
Fax: +49 (0) 89 5424498-22
E-Mail: contact@coriolis-pharma.com
Internet: www.coriolis-pharma.com



Contact:
Dr. Michael Schäffer

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 700760-170
Fax: +49 (0) 89 700760-222
E-Mail: schaeffer@crelux.com
Internet: www.crelux.com



Contact:
Dr. Tobias Schmidt

Hubertusstr. 96a
D-82131 Gauting
Phone: +49 (0) 89 8939-9904
Fax: +49 (0) 89 8939-9905
E-Mail: tschmidt@pharmanet.com
Internet: www.pharmanet.com



Contact:
Gudrun Skiba

Konrad-Adenauer-Allee 1
D-86150 Augsburg
Phone: +49 (0) 177 3426021
Fax: +49 (0) 821 34662-22
E-Mail: gudrun.skiba@cros.it
Internet: www.cros.it

CRELUX GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: 3 D Structural Analysis

CRELUX specializes in tailor made protein crystallography and fragment based drug discovery services. The company is a professional and dedicated service provider for the global pharma and biotech industry. Moreover CRELUX is the only completely independent premium crystallography provider fully owned by its founders and directors. We are advancing innovations in protein expression to promote the availability of high quality crystallizable protein. Our XPRESS portfolio of readily available proteins grants turn around times of customer complex structures within a few weeks. Crystallography services from concept to high resolution complex structure are provided under individual agreements following our customer's needs. In addition we are offering end-to-end fragment based discovery services based on our unique screening technology INTRACT.

CRO-PharmaNet Services GmbH

CRO

Keywords: Devices, Medical Writing, Monitoring, Logistics, Clinical Research, Analysis, Drug Development

PharmaNet Development Group, a global, drug development services company, provides clinical development services including consulting, Phase I and bioequivalence clinical studies, Phase II-III clinical development programs, Phase IIIb-IV surveys, registries, and programs, as well as bioanalytical laboratory services through its subsidiaries Anapharm, Anapharm Europe, Keystone Analytical, and Taylor Technology.

CROS DE GmbH

CRO

Keywords: Dermatology, Pharmacovigilance, Analysis, Clinical Research, Oncology, Respiratory Diseases, Medical Writing

CROS NT is a contract research organisation (CRO) providing outsourced services for Clinical Data Management, Statistics, Pharmacovigilance, Medical Writing and Hosting for Pharma-Life Sciences Solutions across all phases of drug development.

Established in 1992, CROS NT has completed over 780 studies in a wide range of therapeutic areas like respiratory, oncology, cardiovascular, HIV and Infectious diseases of clinical and observational studies. Our clients and partners include pharmaceutical, biotechnology, medical device and academic organizations in Europe and USA. CROS NT Headquarters is in Verona, we have offices in Milan and Augsburg and currently employ 45 people.

Curacyte AG

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Cardiovascular Diseases, Multi organ failure, Peptide/Protein

Curacyte AG and its US subsidiary Apex Bioscience, Inc. are focussed on the clinical development of a hospital therapeutic based on human haemoglobin. Hemoximer (PHP, pyridoxalated haemoglobin polyoxyethylene) is currently examined in a multi-European, placebo-controlled Phase III trial in patients suffering from distributive shock.

CYTOX, biologische Sicherheitsprüfungen

CRO

Keywords: Microscopy, ELISA / EIA, Toxicology, Tissue Engineering / Cell Culture

CYTOX provides biological testing service for the medical device and pharmaceutical industry by using in vitro toxicological testing procedures according to ISO 10993 as well as FDA-compliant processes. Next to classical 2D cell culture testing systems we use organotypical 3D cell culture systems especially in the area of skin irritation testing and REACH applications.

DAIICHI SANKYO EUROPE GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Antibiotics, Drug Development

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly € 5.9 billion in fiscal year 2008, DAIICHI SANKYO is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo, and its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries and has been one of the strongest Japanese pharmaceutical companies located in Europe since it set up European production facilities and marketing offices in 1990. The company's research activities focus on the areas of cardiovascular diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to develop medications that are „best“ in their class or to create new classes of pharmaceutical drugs.

For more information, please visit: www.daiichi-sankyo.eu



Contact:
Dr. Ulrich Delvos

Grillparzerstr. 14
D-81675 München
Phone: +49 (0) 89 2000-14210
Fax: +49 (0) 89 2000-14279
Internet: www.curacyte.com



Contact:
Dr. Dietmar Scheddin

Gottlieb-Keim-Str. 60
D-95448 Bayreuth
Phone: +49 (0) 921 1511-254
Fax: +49 (0) 921 1511-255
E-Mail: info@cytox.de
Internet: www.cytox.de



Contact:
Olaf Lamberz

Zielstattstr. 48
D-81379 München
Phone: +49 (0) 89 7808-0
Fax: +49 (0) 89 7808-202
E-Mail: service@daiichi-sankyo.eu
Internet: www.daiichi-sankyo.eu



Contact:
Dr. Michael Davids

Roentgenstr. 3
D-93055 Regensburg
Phone: +49 (0) 941 948228
Fax: +49 (0) 941 9468119
E-Mail: antibodies@dabio.de
Internet: www.davids-bio.de

DEFINIENS®

Understanding Images

Contact:
Eva Tietz

Trappentreustr. 1
D-80339 München
Phone: +49 (0) 89 231180-0
Fax: +49 (0) 89 231180-90
E-Mail: etietz@definiens.com
Internet: www.definiens.com



Contact:
Dr. Ulf Henseling

Seeshaupter Str. 27
D-82393 Iffeldorf
Phone: +49 (0) 8856 803605
Fax: +49 (0) 8856 803607
E-Mail: DiaServe@t-online.de
Internet: www.diaserve.de

Davids Biotechnologie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Allergy, Immune Therapy, Antibody, Proteomics, ELISA / EIA, Tissue Engineering / Cell Culture, Antibody Production Service

Davids Biotechnologie is a made in Germany manufacturer for custom antibodies. Monoclonal antibodies are developed from mice and men. Polyclonal antibodies are developed from rabbit and other rodent and also from egg yolk from hen and quail. Davids Biotechnologie produces antibodies in cell cultures with hybridoma techniques and from transient transformed cells. Monoclonal antibodies as well as polyclonal antibodies will be purified by affinity purification methods and by ion exchange and size exclusion chromatography beside other methods in our lab. Cell culture based assays for optimizing medication and dietary supplement are developed and is applied together with medical practitioners.

Definiens AG

BIOTECH BIOINFORMATICS

Keywords: Analysis, Toxicology, Oncology, Microscopy, Automation, 3 D Structural Analysis, Drug Development

Definiens is the number one Enterprise Image Intelligence company for analyzing and interpreting images on every scale - from microscopic cell structures to satellite images. Based on human cognitive perception processes, Nobel laureate Prof. Gerd Binnig developed the Definiens Cognition Network Technology® to extract intelligence from images. Definiens enables Life Science organizations to analyze and interpret vast numbers of images accurately and consistently. By automating image analysis processes, Definiens improves the measurement of cell assays, the examination of tissue samples and the interpretation of non-invasive imaging, enabling high-content screening and digital pathology.

DiaServe Laboratories GmbH

BIOTECH DEVICES & REAGENTS

DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories. The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories.

DoNatur GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatology

DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases.

Dr. Nibler & Partner

CRO

Keywords: Medical Writing, Pharmacology, Clinical Research, Devices, Drug Development

Legal requirements for pharmacovigilance are continuously rising. The fulfillment turns out to be a major burden for small and medium sized enterprises.

We provide a complete pharmacovigilance full-service solution:

- 24-hours availability for receipt of adverse event reports by phone, fax or e-mail
- Literature screening and -review
- Data entry and MedDRA coding
- Follow-up by medically qualified personnel (MD, RN)
- Scientific assessment by experienced physicians
- Authority reporting either electronically or on paper
- SUSAR reporting
- Preparation of periodic reports: PSUR and ASR
- Preparation and maintenance of risk management plans
- Implementation and optimization of your pharmacovigilance system
- SOP preparation or revision
- Audits and guidance through inspection

Dr. R. Pflieger GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Dermatology, Antibiotics, Pharmacokinetics, Pharmacology, Clinical Research, Drug Delivery

Dr. R. Pflieger GmbH is a medium sized German pharmaceutical company located in Bamberg (Bavaria) with a staff of 300 employees. Established in 1945 as a private company, it is nowadays exclusively owned by the Doktor Robert Pflieger Foundation, which aims are the exclusive sponsoring of charitable and social projects and the support of medical research.

The company is currently selling about 35 medicinal products with emphasis in urology, gynaecology and dermatology and has GMP approved production facilities.

The international business is focused on the antimuscarinic drug trospium chloride which was developed by the Dr. R. Pflieger and is approved for treatment of overactive bladder.



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: info@donatur.de
Internet: www.donatur.de



Contact:
Dr. Reinhard Nibler

Fürstenriederstr. 105
D-80686 München
Phone: +49 (0) 89 56823726
Fax: +49 (0) 89 92185265
E-Mail: mail@dr-nibler.de
Internet: www.dr-nibler.de



Contact:
Dr. Peter Topfmeier

D-96045 Bamberg
Phone: +49 (0) 951 6043-0
Fax: +49 (0) 951 6043-29
E-Mail: info@dr-pflieger.de
Internet: www.dr-pflieger.de



Contact:
Dr. Dirk Scholl

Am Coulombwall 3
D-85748 Garching
Phone: +49 (0) 89 289-12720
Fax: +49 (0) 89 289-12704
E-Mail: info@dynamic-biosensors.com
Internet: www.dynamic-biosensors.com



Contact:
PD. Dr. Hans-Peter Klenk

Poebinger Fussweg 7a
D-82340 Feldafing
Phone: +49 (0) 8157 9963-164
Fax: +49 (0) 8157 9963-162
E-Mail: info@egene-biotech.de
Internet: www.egene-biotech.de



Contact:
Dr. Peter Frischmann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 70939316
Fax: +49 (0) 89 70939440
E-Mail: info@ellabiotech.com
Internet: www.ellabiotech.com

Dynamic Biosensors

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Vaccines, Small Molecules, Peptide/Protein, Antibody, Proteomics, Chip / Array Technology

Dynamic Biosensors offers a superior new analysis system for molecular interaction. Based on the revolutionary label-free *switchSENSE* technology, we allow researchers to determine affinity and kinetics of molecular interactions with unrivaled sensitivity in real time. As a total novelty in label-free analysis, *switchSENSE* allows to determine molecular size (e.g. formation of aggregates) and conformational changes in real-time as well. While *switchSENSE* is an extremely versatile technology, our current focus lies on protein interaction analysis (antibodies and transcription factors), protein folding and posttranslational modifications.

e.gene Biotechnologie GmbH

BIOTECH BIOINFORMATICS

Keywords: Pharmacogenomics, Genomics

e.gene Biotechnologie GmbH is a service provider in microbial genomics and pharmacogenomics. We perform for our academic and industrial customers complete microbial genome analyses from genome sequencing to annotation and pathway reconstruction.

ELLA Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Research, Antisense/Nucleotides, Genomics, RNAi & Antisense, Chip / Array Technology, PCR, Clinical Diagnostics

Our focus is the synthesis of special oligoribonucleotides for selected projects in diagnostics, chip technologies, genesynthesis and further topics – following quality standards which you would appreciate and expect in your own lab. The guidelines for the synthesis standards can be defined by our customers themselves.

Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners.

Emergent Product Development Germany GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Vaccines, Infectious Diseases

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders.

Emergent Sales and Marketing Germany GmbH

BIOTECH

Keywords: Vaccines, Infectious Diseases

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders.

EMP Genetech

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Peptide/Protein, Clinical Diagnostics, Tissue Engineering / Cell Culture, Drug Development

EMP Genetech conducts development and production of recombinant proteins as a service provider for research departments in industry and academia. For production HEK293 (hn embryonic kidney) cells are being used. These cells are distinguished for the expression of glycosylated, correctly processed and modified proteins. The expressed proteins show excellent bioactivity compared to other expression systems. The biomolecules are produced in serum free culture medium of safe origin. EMP Genetech offers all working steps from cloning of the GOI to chromatographic purification of the produced protein. There are developed stable cell lines of high productivity. These are cultivated as suspension cell cultures in stirred bioreactors usually in a continuous mode. The expression product is purified from cell supernatant or cell extract by classical column chromatographic methods. The bioactivity will be analysed by enzymatic or cell assays.




Contact:
Isabelle Erdelji

Walter-Gropius-Str. 17
D-80807 München
Phone: +49 (0) 89 5506988-0
Fax: +49 (0) 89 5506988-88
E-Mail: erdeljii@ebsi.com
Internet: www.emergentbiosolutions.com



Contact:
Isabelle Erdelji

Walter-Gropius-Str. 17
D-80807 München
Phone: +49 (0) 89 5506988-0
Fax: +49 (0) 89 5506988-99
E-Mail: erdeljii@ebsi.com
Internet: www.emergentbiosolutions.com



Contact:
Dr. Franz X. Welsler

Hebbelstr. 61
D-85055 Ingolstadt
Phone: +49 (0) 841 3796013
Fax: +49 (0) 841 8817185
E-Mail: info@empgenetech.com
Internet: www.empgenetech.com



Contact:
Dr. Werner Deininger

St.-Veit-Weg 2
D-93051 Regensburg
Phone: +49 (0) 941 69818-10
Fax: +49 (0) 941 69818-28
E-Mail: info@entelechon.com
Internet: www.entelechon.com

...EPICEPT GmbH

Contact:
Uschi Lang

Goethestr. 4
D-80336 München
Phone: +49 (0) 89 680872-0
Fax: +49 (0) 89 680872-20
E-Mail: info@epicept.de
Internet: www.epicept.com

EPIGENE

Contact:
Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.epigene.de

Entelechon GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics, Clinical Research, Chip / Array Technology, PCR, Genomics, Antibody Production Service

Entelechon, founded in 1999, is an internationally operating biotech service provider specialized in synthetic biology. Entelechon integrates a strong DNA synthesis platform for genes, bioinformatics software development, protein expression, and molecular biological services. Entelechon provides workflows centered on synthetic biology concepts, such as library screening, protein engineering and creation of artificial metabolic networks. Its bioinformatics expertise focuses on gene optimization and combinatorial biology. The company maintains a network comprised of strategic partnerships with academic institutions and companies. Among Entelechon's long term customers are major international pharma and biotech players.

EpiCept GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Immune Therapy, Hematology, Drug Development

EpiCept GmbH is a subsidiary of EpiCept Corp. (Tarrytown, NY) which is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment and pain management. The Company possesses an approved cancer product and a deep and balanced pipeline of nine clinical product candidates.

EpiCept Corp. is listed on both the NASDAQ National Market and the OM Stockholm Exchange, under the symbol EPCT.

EpiGene GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiGene GmbH, founded in 1999, is a genomics-based research and development company focusing on applications in plant protection. The core competences comprise the molecular characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents at the molecular level and the identification of mutations or differentially expressed genes in pathogens as potential new targets.

EpiLogic GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Genomics, Agrobiotechnology

EpiLogic is a new European wide operating company involved in product development based on genomic analysis of fungal pathogens propagated by wind in agricultural crops (at present: cereals and vine). Pathogen analysis of virulence and fungicide sensitivity are used as decision support for breeding, choice of cultivar and fungicide management to ensure sustainable agriculture. A genotype bank of several pathogens is currently being set up to offer high quality inoculum for selection in laboratory, greenhouse and field. Additionally, methods are under development for analysing and culturing new pathogens.

ethris GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Metabolic Diseases, Dermatology, Bone / Joint Diseases, Gene Therapy, Gene Transfer, Tissue Engineering / Cell Culture, Drug Development

With stabilized, non-immunogenic messenger RNA (SNIM®RNA), ethris GmbH possesses an enabling platform for Transcript Therapies. SNIM®RNA is a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient's body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, life style- or age-related, rare or frequent. ethris develops transcript therapeutics with a focus on regenerative medicine.

eticur) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

eticur) is headquartered in the IZB in Martinsried and cooperates with the Department of Transfusion Medicine and Haemostaseology of the University Hospital of Erlangen. Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. Our priority is to grant the most secure storage, highest quality and extensive testing by highly qualified personnel. eticur) grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute).



Contact:
Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.EpiLogic.de



Contact:
PD Dr. Carsten Rudolph

Ulrich-Haid-Str. 1
D-82229 Seefeld
Phone: +49 (0) 8152 9299-7330
Fax: +49 (0) 8152 9299-7339
E-Mail: info@ethris.com
Internet: www.ethris.com



Contact:
Felix Raslag

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 125981-0
Fax: +49 (0) 89 125981-19
E-Mail: info@eticur.de
Internet: www.eticur.de



Contact:
Dr. Brigitte Obermaier

Anzinger Str. 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-200
Fax: +49 (0) 8092 8289-201
E-Mail: info@medigenomix.de
Internet: www.medigenomix.de



Contact:
Dr. Jutta Huber

Anzinger Str. 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-0
Fax: +49 (0) 8092 21084
E-Mail: info-eu@eurofins.com
Internet: www.eurofinsdna.com



Contact:
Dr. Andreas Jenne

Am Klopferspitz 19a
D-82152 Martinsried/München
Phone: +49 (0) 89 4613363-0
Fax: +49 (0) 89 4613363-20
E-Mail: info@evotec.com
Internet: www.evotec.com

Eurofins Medigenomix GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Pharmacogenomics, Clinical Diagnostics, Clinical Research, Pharmacogenetics, Genomics, Agrobiotechnology

Since foundation in 1998 Eurofins Medigenomix has evolved into a recognized reliable outsourcing partner for the biopharmaceutical industry and academic institutions for high fidelity DNA sequencing incl. GLP sequencing and molecular biological techniques. It expanded successfully with services for DNA forensics, animal and plant breeding, food authenticity testing and for Pharma/Pharmacogenetics, e.g. genotyping, DNA/RNA preparation, polymorphism screening, mutation analysis, expression analysis, exclusive marker set for the general identification of responder/non-responder in the scope of clinical studies. Medigenomix is certified according to ISO 9001 and ISO 17025 and audited by pharmaceutical clients for GLP.

Eurofins MWG Operon

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Small Molecules, PCR, Automation, Antisense/Nucleotides, Genomics

Eurofins MWG Operon, founded in 1990 and member of the Eurofins Group, is an international provider of genomic services established around the core business lines next generation sequencing, custom DNA sequencing, oligo-nucleotides, siRNA and gene synthesis. The company's main mission is focussed on customer convenience and high quality services in industrial scale for the life science industries and academic research institutions around the world.

Evotec AG

BIOTECH PRECLINICAL SERVICES

Keywords: Genomics, Proteomics, Metabolic Diseases, Drug Development, Small Molecules, Inflammation, Oncology

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, Novartis, Ono Pharmaceutical and Roche. The Company's headquarters are located in Hamburg. Additional major technology and research facilities are based in Göttingen (former DeveloGen AG) and Martinsried (former Kinaxo Biotechnologies GmbH), Abingdon, UK and Thane, India. Evotec has more than 550 employees worldwide. For additional information please go to www.evotec.com

EXCELLA GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Medicinal Chemistry, Analytical Chemistry, Small Molecules, Oncology

Excella GmbH has been serving the pharmaceutical industry for more than 35 years with high quality API's and finished dosage forms. Recent investments have directed our focus towards high containment products (including OEB5) and a one-stop-shopping approach. Excella supplies products to the generic industry but although manufactures for big pharma life cycle end products and develops processes for innovative API's and novel solid dosage forms. Services offered range from early product development through registration support to state-of-the-art manufacturing.

Excella's Feucht site has an excellent track record with the FDA and other regulatory agencies since 1983 and is Safebridge certified.

Exosome Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Clinical Research, Genomics, PCR, CNS, Diabetics, Metabolic Diseases

Exosome Diagnostics is a leading developer of blood and urine based molecular diagnostic tests for use in personalized medicine. Exosomes are shed into body fluids such as blood and urine forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary Xosome™ technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. The Company is commercializing both *in vitro* diagnostic and laboratory developed tests for use in companion diagnostics and real-time monitoring of disease recurrence. The Company is located in New York, USA and Munich, Germany and is backed by an international consortium of leading venture capitalists.

Eyesight & Vision GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Ophthalmology

Eyesight & Vision is focused on intraoperative real-time laser diagnostics for refractive eye-surgery.

Our goal is to become the global leader in intraoperative real-time diagnostics for the growing number of patients which desire perfect vision.

Our team of experts in ophthalmic devices works closely with eye doctors, clinical specialists and partners to advance the wavefront guided cataract surgery.

We provide innovative solutions and utilize our advanced technology, to be the first to introduce intraoperative real-time wavefront diagnostics, so that surgeons are able to decide during the cataract surgery which intraocular lens is best to achieve postoperative perfect vision.



Contact:
Dr. Johann Peter Mörsdorf

Nürnberger Str. 12
D-90537 Feucht
Phone: +49 (0) 9128 4045-38
Fax: +49 (0) 9128 4045-81
E-Mail: pmoersdorf.excella@fareva.com
Internet: www.excella-pharma-source.de



Contact:
Dr. Mikkel Noerholm

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 416172-70
Fax: +49 (0) 89 416172-69
E-Mail: munich@exosomedx.com
Internet: www.exosomedx.com



Contact:
Kurt Heiberger

Burkhardtstr. 9
D-90455 Nürnberg
Phone: +49 (0) 911 888035
Fax: +49 (0) 911 888035
E-Mail: k.heiberger@eyesight-vision.de
Internet: www.eyesight-vision.com



Contact:
Albert Stumpf

Aubinger Str. 30
D-82166 Gräfelfing
Phone: +49 (0) 89 895300-24
Fax: +49 (0) 89 895300-25
E-Mail: info@fermcom.de
Internet: www.fermcom.de



Contact:
Martin Krauss

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893119-0
Fax: +49 (0) 89 893119-20
E-Mail: martin.krauss@fgk-cro.de
Internet: www.fgk-cro.de



Contact:
Dr. Edgar J. Fenzl

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893119-22
Fax: +49 (0) 89 893119-20
E-Mail: edgar.fenzl@fgk-rs.com
Internet: www.fgk-rs.com

FermCom Bio-VNT – Biologische Verfahrenstechnik und Netzwerk-Technologie

BIOTECH DEVICES & REAGENTS

Keywords: Monitoring, Devices

FermCom Bio-VNT is a research and development company focused on biotechnology and network applications. FermCom Bio-VNT is in development of an innovative in-situ online-analysis system by using a high-technology bioreactor. With the help of the device for classification of biomolecules in liquid there will be new technologies brought together to a new biosensor system „Multisensor-MiniLab“. The use of bio-chips allows to miniaturize online real-time-analysis. In cooperation with appropriate high-tech partner companies FermCom Bio-VNT creates a national / international network via Internet / Intranet for data tele-transfer. International patent-applications (PCT) are the cornerstone of the company's strategy. FermCom's field of activity is development of a new compact system for non-invasive process-monitoring in the area of biotechnology, fermentation- and environment-analytics.

FGK Clinical Research GmbH

CRO

Keywords: Drug Development, Clinical Research

FGK Clinical Research GmbH is a Europe-based full service Contract Research Organization offering the complete range of clinical development and consulting services to biotechnology and medical device companies. FGK headquarters are in Munich, Germany, with more than 70 highly-skilled and experienced employees working on local and global projects, covering clinical studies Phases II to IV and post-marketing studies. In addition, FGK has subsidiaries in the UK, Hungary, Poland and Czech Republic, and further subsidiaries are planned. FGK has extensive experience in all major therapeutic areas allowing it to effectively design, manage, and analyze development programs and clinical trials.

FGK Representative Service GmbH

CRO

Keywords: Drug Development, Clinical Research

FGK Representative Service GmbH was founded in order to meet legal requirements of sponsor companies which do not have a subsidiary within the European Union and Switzerland, for the purpose of performing clinical research projects in this region. Such a legal representative for clinical drug trials or authorized representative for medical device trials fulfills the obligation that the sponsor companies must be established or represented in the European Union according to Clinical Trials Directive 2001/20/EC. FGK represents in all member states of the EU for drug and medical device trials to enable submissions of regulatory applications to the European authorities and ethics committees. FGK also represents for all applications in drug authorizations and orphan drug designations.

Fresenius Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Hematology, Immune Therapy, Antibody, Cell Therapy, Gene Therapy, Oncology

Fresenius Biotech GmbH - a subsidiary company of the Fresenius Health Care Group - is focused on the development, marketing and commercialization of biopharmaceuticals in the fields of oncology and transplantation medicine. Our current research and development activities are primarily concentrated on the clinical development of immunotherapeutic products based on innovative antibody technologies.

FRIZ Biochem Gesellschaft für Bioanalytik mbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Devices, Infectious Diseases, Chip / Array Technology

FRIZ Biochem develops and produces highly reliable user-friendly and inexpensive biochip systems for applications in medical diagnostics, food testing and pharmaceutical research. Key products are DNA-chips with direct electrical read-out where SNPs (single nucleotide polymorphism) can unambiguously be detected and time-consuming labeling of the target-DNA is no longer necessary. This enables a broad range of simple and fast analyses making the system ideal for biological medical studies.

The company's proprietary combination of micro arrays, electrical detection and semiconductor technology opens the way to compact multiplex analyses directly at a PC without the expensive instrumentation commonly needed.

GE Healthcare Europe GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals / Reagents, Devices, Analytical Chemistry, Genomics, Proteomics

GE Healthcare Life Sciences provides a broad range of products and services for biomolecule separations at all scales. Chief products include:

- ÄKTAdesign™ chromatography systems and BioProcess™ media
- Filtration systems and devices ■ Wave Bioreactor™ and mixers
- Cell separation for isolating and purifying cells, viruses, and sub-cellular particles ■ FastTrak™ BioPharma Services.

Our products are used in the manufacture of the majority of all FDA-approved biopharmaceuticals on the market. GE Healthcare Life Sciences is a part of GE Healthcare, a General Electric company with more than 42,000 employees, providing transformational medical technologies that are shaping a new age of patient care.



Contact:
Dr. Christian Schetter

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 30659-611
Fax: +49 (0) 89 30659-616
E-Mail: christian.schetter@fresenius-biotech.com
Internet: www.fresenius-biotech.com



Contact:
Dr. Gerhard Hartwich

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 724409-0
Fax: +49 (0) 89 724409-10
E-Mail: info@frizbiochem.de
Internet: www.frizbiochem.de



Contact:
Michael Kaleja

Oskar-Schlemmer-Str. 11
D-80807 München
Phone: +49 (0) 7667 833-559
Fax: +49 (0) 7667 833-616
E-Mail: michael.kaleja@ge.com
Internet: www.gelifesciences.com



Contact:
Prof. Dr. Ralf Wagner

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 94276-0
Fax: +49 (0) 941 94276-711
E-Mail: geneart.info@lifetech.com
Internet: www.lifetechnologies.com



Contact:
Dr. Peter Haberl

Lena-Christ-Str. 50
D-82152 Martinsried
Phone: +49 (0) 89 4581901-0
Fax: +49 (0) 89 4581901-5
E-Mail: peter.haberl@genedata.com
Internet: www.genedata.com



Contact:
Dr. Hildegard Haas

Schwanthalerstr. 60
D-80336 München
Phone: +49 (0) 89 543448-0
Fax: +49 (0) 89 543448-20
E-Mail: info@genedia.de
Internet: www.genedia.de

GeneArt AG

BIOTECH

Keywords: Genomics, Combinatorics

Since entering the Gene Synthesis market in 2000 GeneArt has established as the global market leader. GeneArt provides key technologies for Synthetic Biology projects for example for the construction of bacteria which produce complex biopolymers such as biofuels or organisms which degrade environmental toxins. Furthermore the company contributes key technologies necessary to develop and produce new therapeutics and vaccines. Customers also rely on GeneArt services to improve enzymes, such as the ones used as additives in detergents. GeneArt was awarded the worldwide largest gene synthesis contract for the completion of the „Mammalian Gene Collection (MGC) Program“ by the U.S. National Institutes of Health (NIH). In addition, GeneArt produced subgenomic elements for the construction of the first synthetic bacterial genome by the J. Craig Venter Institute. Since December 2010 GeneArt AG is a 100% subsidiary of the U.S.-American Life Technologies Corporation.

Genedata Bioinformatik GmbH

BIOTECH BIOINFORMATICS

Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company's solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), Boston (USA), and Tokyo (Japan).

Genedia AG Biotec Services and Products

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Medicinal Chemistry, Genomics, Antisense/Nucleotides

Genedia AG Biotec Services and Products is a provider of DNA testing services including private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services (full or half sibling testing, grandparents testing, aunt or uncle testing, 1st cousin testing, maternity testing as well as twin testing). An other area is DNA genealogy and anthropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analysis. The forensic area includes DNA identification and banking services forensic testing services especially stain analysis. DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation). DNA testing of animals.

Genelux GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Drug Delivery, Immune Therapy, Oncology

Genelux Corp., San Diego, CA, US, was founded in 2001. Its assets are built on its founder's experience on genetically modified light-emitting bacteria, viruses and mammalian cells:

Luminescent or fluorescently labelled microorganisms, when injected into tumor bearing mice, specifically colonize tumors plus metastases and can be imaged. They grow and replicate within the tumors. Tumors are remitted. These scientific results should enable diagnosis and treatment of cancer, combining in vivo imaging (diagnostics) with bacteria/virus induced tumor regression (therapy), and should add a potent theragnostic alternative to existing therapies and diagnostics.

Genelux GmbH, Bernried, Germany, was established mid 2004 and aims to translate the scientific results into commercial services and products.

Genetic ID (Europe) AG – Labor für gentechnische Analysen

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: ELISA / EIA, Genomics, PCR, Analysis, Laboratory, Transgenic Plants, Agrobiotechnology

Genetic ID is a global leader in testing for the presence of genetically modified organisms (GMOs) in food and agricultural products. In addition Genetic ID also offers Allergen screening.

Founded in 1996, Genetic ID Inc. maintains global headquarters in USA, as well as premier testing laboratories in Japan and Germany, offices in Brazil, and the Global Laboratory Alliance of affiliated laboratories and representatives spanning five continents.

We develop technologies that address all aspects of the GMO-testing segment and provide all clients with the technology, services and information they need to operate in the increasingly high-tech global marketplace.

GeneWake GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Genomics, Oncology, Clinical Diagnostics, Pharmacogenomics

GeneWake GmbH focuses on contract research in the vast field of biomarker analysis for oncology. We specialize in biomarker prescreening for patient stratification to ensure the best possible care for cancer patients. By employing bioinformatical algorithms based on knowledge in pathway structure and microarray data from public sources, it is possible to limit biomarker screening to analysis on a low-density scale. This is not only cost efficient, but also more easily interpreted compared to high-density methods like whole genome microarrays. Samples can be anything from fresh frozen or paraffin embedded tissue to whole blood. A typical output of a study would be a short list of 10-20 potential biomarkers, that are highly likely to carry changes on the DNA or protein level.



Contact:
Dr. Albert Röder

Am Neuland 1
D-82347 Bernried
Phone: +49 (0) 8158 9223-0
Fax: +49 (0) 8158 9223-35
E-Mail: a.roeder@genelux.de
Internet: www.genelux.de



Contact:
William F. Thompson

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 74776-30
Fax: +49 (0) 821 74776-39
E-Mail: info-europe@genetic-id.com
Internet: www.genetic-id.de



Contact:
Dr. Robert Loewe

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 74419-166
Fax: +49 (0) 89 74419-164
E-Mail: info@genewake.com
Internet: www.genewake.com



Contact:
Dr. Korbinian Grote

Bayerstr. 85a
D-80335 München
Phone: +49 (0) 89 599766-0
Fax: +49 (0) 89 599766-55
E-Mail: info@genomatix.de
Internet: www.genomatix.de



Contact:
Dr. Andrea Kücherer-Ehret

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 899890-0
Fax: +49 (0) 89 899890-90
E-Mail: info@gilead-sciences.de
Internet: www.gilead.com



Contact:
Dr. Margit Gieseler

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 907056-78
Fax: +49 (0) 931 907056-79
E-Mail: info@gilyos.com
Internet: www.gilyos.com

Genomatix Software GmbH

BIOTECH BIOINFORMATICS

Keywords: Genomics

Genomatix is one of the world's leading suppliers of technologies to analyze and interpret genomic data. As well as laying the groundwork for microarray experiments and NGS data sequencing analyses, our hardware, software & service solutions help answer the typical questions posed by systems biology. Our approach: combine multiple lines of evidence to perform an integrated meta-analysis.

Instead of looking at single strands of information separately, we access an exceptionally large pool of data from different sources. This wealth of data is continually expanding, so it is continually up to date.

This meta-analysis leads to more relevant results, more precise scientific knowledge and a better chance of understanding the molecular contexts of gene regulation and expression.

Gilead Sciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Gilead Sciences is dedicated to providing accelerated solutions for patients and the people who care for them. The evolution of Gilead - from a promising biopharmaceutical company to a leader in the international development and commercialisation of medicines for life-threatening infectious diseases (viral, fungal and bacterial infections) - is testament to what the company has achieved through disciplined science, visionary thinking and diversified planning. Gilead's headquarter is based in Foster City, California with additional operations in San Dimas, California. Sales and marketing organisations are located in the following cities: Athens, Greece; Cambridge, UK; Lisbon, Portugal; Madrid, Spain; Istanbul, Turkey; Munich, Germany; Paris, France; Dublin, Ireland; Milano, Italy.

GILYOS GmbH

CRO

Keywords: Drug Development, Nanobiotechnology, Antibody, Peptide/Protein, Small Molecules, Analysis

GILYOS is a research-oriented, highly specialized contract service partner in the field of pharmaceutical freeze-drying. Services include, but are not limited to, formulation development for pharmaceuticals (protein, peptide), freeze-drying cycle development, optimization of processes including Quality-by-Design and scale-up from laboratory to production. GILYOS offers a variety of analytical methods to fully characterize drug formulations (liquid and solid state), with special focus on the examination of the physicochemical properties of materials. Moreover, the company offers a full range of consulting services, including technical support for freeze-dryers and sales of equipment.

GKM Gesellschaft für Therapieforschung mbH

CRO

Keywords: Logistics, Analysis, Pharmacovigilance, CRO/CMO, Clinical Research, Monitoring, Medical Writing

GKM Gesellschaft für Therapieforschung mbH is a privately owned full service Contract Research Organisation for designing and conducting clinical trials phase II-IV as well as post-marketing-surveillances. Since 1981, GKM is a much valued partner for many pharmaceutical, biotech and medical device companies. GKM provides flexible services with expert knowledge and dedication to your Projects according to ICH-GCP and international guidelines for research projects. 25 years experience: Cost-effective quality combined with the latest standards and technologies.

- Concept ■ Statistical planning ■ Study material ■ Regulatory services
- Site recruitment ■ Monitoring ■ Clinical trial management
- Quality assurance ■ Data management ■ Medical coding / writing
- Statistical analysis

GlaxoSmithKline GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

Keywords: Respiratory Diseases, Oncology, Dermatology, CNS, Vaccines, Antibiotics

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies with biotech developments in the area of vaccines and biopharmaceuticals. A cooperation with Human Genome Sciences Inc. has led to the sequence and functional analysis of a large number of genes which are the basis of ongoing developments.

GLUCOMETRIX AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Diabetics, Drug Development, Devices, Chip / Array Technology, Peptide/Protein

GlucoMetrix AG was founded in 2001. It has 3 major subsidiaries that concentrate on different aspects of enhancing the quality of life for people suffering from diabetes.

GlucoMetrix NIB GmbH develops medical devices for measuring blood sugar non-invasively, i.e. without puncturing the skin.

GlucoMetrix PVS GmbH develops a new production method for insulin which promises a purer insulin with less side effects.

GlucoMetrix Pharma VV GmbH develops, manufactures and markets medicinal products related to wound healing. These are particularly suited for diabetic wounds.

- Products and Technologies:**
- Development of expression platforms for biomedical products and
 - Development of downstream purification methods.
 - BIOSept line of wound treatment products



Contact:
Dr. Christian Hautmann

Lessingstr. 14
D-80336 München
Phone: +49 (0) 89 209120-0
Fax: +49 (0) 89 209120-30
E-Mail:
c.hautmann@gkm-therapieforschung.de
Internet: www.gkm-therapieforschung.de



Contact:
Claudia Kubacki

Theresienhöhe 11
D-80339 München
Phone: +49 (0) 89 360440
Fax: +49 (0) 89 360448000
E-Mail: service.info@gsk.com
Internet: www.gsk.com



Contact:
Peter Paul Schikora

Mühlfeld 9
D-83324 Ruhpolding
Phone: +49 (0) 8663 41800-0
Fax: +49 (0) 8663 41800-99
E-Mail: info@glucometrix.de
Internet: www.glucometrix.de



Contact:
Dr. Heike Naserke

Albrechtstr. 14
D-80636 München
Phone: +49 (0) 89 126680-0
Fax: +49 (0) 89 126680-2444
E-Mail: Heike.Naserke@harrison-cro.com
Internet: www.harrisonclinical.com



Contact:
Dr. Dr. Stefan Bertsch

Professor-Messerschmitt-Str. 3
D-85579 Neubiberg
Phone: +49 (0) 89 6008761-0
Fax: +49 (0) 89 6008761-24
E-Mail: bertsch@hematris.de
Internet: www.hematris.de



Contact:
PD Dr. Bernhard Kreymann

Agnes-Pockels-Bogen 1
D-80992 München
Phone: +49 (0) 89 4111842-0
Fax: +49 (0) 89 4111842-09
Internet: www.hepawash.com

Harrison Clinical Research Deutschland GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Metabolic Diseases, Nephrology, Oncology, Pain, Clinical Research, Monitoring

Harrison Clinical Research is an independent ISO 9001 certified CRO founded in 1987 in Munich with offices in UK, Belgium, Israel, Spain, Italy, France, Austria, Poland, Ukraine, Russia, USA and partners in Asia and Australia. Our team comprises more than 300 research professionals. We offer all services required for the clinical development and registration of new pharmaceutical products/medical devices: International project management, monitoring, data management, statistics, medical writing, auditing, training and outsourcing.

Apart from conduct of standard Phase I studies, our Phase I/IIa clinic is specialised on proof-of-concept studies in special patient populations and efficacy studies in various indications. For more information please visit www.harrisonclinical.com

Hematris Wound Care GmbH

MEDTECH

Keywords: Devices

Hematris Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding.

We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area.

Hepa Wash GmbH

MEDTECH

Keywords: Hepatology, Devices

The Hepa Wash GmbH is a medical device company developing a new liver assist device for the treatment of patient with life-threatening liver disease. Main features of Hepa Washes extracorporeal technology are its highly efficiency albumin-dialysis and its innovative albumin regeneration circuit. Hepa Wash is dedicated to developing a therapy that is several times more effective than currently available treatments and to significantly increase the survival rate and quality of live of patients with life-threatening liver disease.

hepacult GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Analytical Chemistry, Drug Development, Tissue Engineering / Cell Culture, Clinical Research, Toxicology, Analysis

hepacult develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used to prognose the metabolism of novel drugs and for the in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products hepacult provides to the scientific community and pharmaceutical industry an outstanding in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extent. Results gained during the preclinical stage with hepatocytes show a better prognostic value. Partially even the cost-intensive clinical experiments on humans and related risks to humans can be reduced.

Hexal AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Peptide/Protein, Pharmacokinetics, 3 D Structural Analysis, Clinical Research

HEXAL is the leading German generic manufacturer and belongs to the worldwide Sandoz Group with its headquarters in Holzkirchen, Bavaria. HEXAL brings biosimilars to the German market. Biosimilars are high-differentiated products, based on very complex biological molecules. Biologics, or biopharmaceuticals, are medicines produced from living organisms using biotechnology techniques. Many biologics are recombinant proteins and are manufactured using „recombinant DNA“ technology, a process that involves inserting a specific gene into a host cell to produce a particular protein. These complex state-of-the-art molecules represent a distinct regulatory class of medicine compared to traditional, chemically synthesized medicines. In Germany HEXAL employs more than 4.000 people at six sites. The company was founded in 1986 and merged with Sandoz in 2006.

HTI bio-X GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation

HTI bio-X GmbH is a innovative company and is focussing on products and customer service for biotechnological and pharmaceutical laboratories as well as Life Science industry. We develop products from the simple lab device to complex automated solutions. Our service is focused on engineering tasks and technical support, project management, technical and management consulting. Our current product portfolio covers consumables and instruments (e.g. cleavage machines) for DNA-synthesis as well as for microarray techniques (e.g. hybridization chambers). We also provide instruments for the dosage of powder as well as a complete robotic platform and devices for sample preparation and DNA extraction. Our biomagnetic workstation X-Tract facilitates all kinds of magnetic beads applications.

hepacult

Contact:
Kurt Martin

Postfach 1351
D-85767 Unterföhring
Phone: +49 (0) 89 95001711
Fax: +49 (0) 89 9612087
E-Mail: Kurt.Martin@hepacult.de
Internet: www.hepacult.de



Contact:
Isabell Remus

Industriestr. 18
D-83607 Holzkirchen
Phone: +49 (0) 8024 908-0
E-Mail: isabell.remus@sandoz.com
Internet: www.hexal.de



Contact:
Ditte Heimberg

Anzinger Str. 7
D-85560 Ebersberg
Phone: +49 (0) 8092 2092-0
Fax: +49 (0) 8092 2092-28
E-Mail: info@hti-bio-x.com
Internet: www.hti-bio-x.com



creative bioscience solutions

Contact:
Dr. Wolfgang Mutter

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9060-0
Fax: +49 (0) 8158 9060-210
E-Mail: info@hyglos.de
Internet: www.hyglos.de



Contact:
Prof. Dr. Markus Veit

Fraunhoferstr. 18b
D-82152 Martinsried
Phone: +49 (0) 89 856536-50
Fax: +49 (0) 89 856536-66
E-Mail: info@i-dras.com
Internet: www.i-dras.com



Contact:
Simon Herzog

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 800 001111-28
Fax: +49 (0) 800 001111-29
E-Mail: sherzog@ibidi.de
Internet: www.ibidi.de

Hyglos GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Proteomics, Infectious Diseases, Peptide/Protein, Clinical Diagnostics

Hyglos' core competency is to exploit the principles of bacteriophage biology and the expert use of the proprietary phage-protein technology for diagnostics, antimicrobial and research applications. Hyglos' products and services are supplied to well known pharmaceutical and biotech companies as well as research institutes. Hyglos product portfolio includes EndoLisa[®], Endotrap[®], EndoGrade[®], reagents for food diagnostics, Bacteria Capture Kits. Furthermore, Hyglos offers customized services using state-of-the-art technology; Endotoxin Detection Service, Endotoxin removal Service, From Gene to Protein Service. Hyglos GmbH is certified according to ISO 9001:2008 and ISO 13485:2003 + AC:2007.

i.DRAS GmbH – international Drug Regulatory Affairs Services

CRO

Keywords: Drug Development, Analytical Chemistry, Small Molecules, Analysis, Medical Writing, Pharmacology, Toxicology

i.DRAS is a consultancy company for international drug regulatory affairs. i.DRAS offers strategic support and services for human and veterinary medicinal products from the preclinical/early clinical development stages to the first submission of the MA dossier throughout post marketing activities, covering the whole product life cycle. Services provided cover new and established drug substances and the corresponding drug products, including herbal and biological/biotechnological medicinal products. If requested i.DRAS takes over the project management for complex projects with further partners who may be assigned through us or our clients. Furthermore, i.DRAS provides and organises in-house training and education, covering all topics related to the services offered by i.DRAS.

ibidi GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Tissue Engineering / Cell Culture, Chip / Array Technology, Microscopy

ibidi develops, produces and distributes cell-culture biochips (μ -Slides) and devices for functional cell-based assays. An extensive line of μ -Slides and μ -Dishes offers solutions for immunofluorescence and basic cell culture, plus the following complex assays: angiogenesis, chemotaxis, wound healing, shear stress and flow. The company also specializes in instruments such as heating and incubation units, and a unique perfusion system that provides continuous flow for the simulation of blood vessels. The high optical quality of the μ -Slides allows microscopic cell investigations, using phase contrast or DIC, fluorescence and also confocal microscopy. The new F-actin marker LifeAct makes it possible to keep track of the development and movement of F-actin structures in living cells. All of the products are offered world-wide through a variety of distributors.

IKINOWO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Analytical Chemistry, Aptamer Technology, Chip / Array Technology, Proteomics, Oncology

The main goal of the *IKINOWO GmbH* is to develop diagnostic tools for human diseases and cell profiling concerned with ribonuclease, expression defects and codon usage.

IKINOWO GmbH has been funded by the German government:

Federal Ministry of Education and Research (BMBF) in the framework of the program „EXIST SEED“ promoting business start ups from university research.

IMG M Laboratories GmbH – your partner for genomic services

BIOTECH

Keywords: Analysis, Pharmacogenetics, Chip / Array Technology, Genomics, Laboratory, PCR

Munich based IMG M Laboratories offers advanced genomic services to customers from pharma, diagnostics, academia and biotech. IMG M is accredited according to DIN EN ISO/IEC 17025 including gene expression analysis based on Agilent microarrays and qPCR. IMG M offers a full range of first-class Next Generation Sequencing (NGS) services based on Roche 454 and LifeTech SOLiD platforms. ■ Our service portfolio covers the areas of [RNA SERVICES], [DNA SERVICES], [BIOINFORMATICS] and [CONSULTING].

■ At IMG M, we combine state-of-the-art technology with complex data analysis to deliver meaningful results in an easy-to-understand format.

■ For more information, please visit [www.imgm.com].

immatics biotechnologies GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Genomics, Proteomics, Peptide/Protein, Vaccines, Immune Therapy, Oncology

immatics biotechnologies is a clinical-stage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer. immatics' lead product, IMA901 has completed a Phase II trial in renal cell carcinoma. immatics' pipeline also includes IMA910, in Phase II for colorectal cancer, and IMA950 which is being developed for glioma.

immatics' technology platform rapidly generates defined therapeutic cancer vaccines which are based on multiple tumour-associated peptides (TUMAPs) with the ability to specifically stimulate the immune system against cancer cells. These vaccines - comprising multiple peptides confirmed to be naturally presented by real tumour tissue - offer the prospect of greater effectiveness than existing cancer vaccine approaches. immatics' products are 'drug like' with stable, off-the-shelf formulations and robust easily scalable manufacturing.

immatics is based in Tuebingen and Munich, Germany, and has raised more than € 54 million (US\$ 72million) in private equity in two financing rounds.



Contact:
Dr. Merold Müller

Lise-Meitner-Str. 30
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 206962
Fax: +49 (0) 8161 9363876
E-Mail: info@ikinowo.com
Internet: www.ikinowo.com



Contact:
Dr. Ralph Oehlmann

Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 8955784-0
Fax: +49 (0) 89 8955784-1
E-Mail: info@imgm.com
Internet: www.imgm.com



i m m a t i c s

Contact:
Dr. Bettina Kipp

Fraunhoferstr. 18b
D-82152 Martinsried
Phone: +49 (0) 89 309041-0
Fax: +49 (0) 89 309041-55
E-Mail: info@immatics.com
Internet: www.immatics.com



Contact:
Wolfgang Mayer

Karlstr. 46
D-80333 München
Phone: +49 (0) 89 5432177-89
Fax: +49 (0) 89 5432177-92
E-Mail: info@immumed.de
Internet: www.immumed.de



Contact:
Martin Sahiri

Schatzbogen 52
D-81829 München
Phone: +49 (0) 89 7263718-0
Fax: +49 (0) 89 7263718-51
E-Mail: info@implen.de
Internet: www.implen.de



Contact:
Ilka Rother

Lärchenstr. 3
D-82166 Gräfelfing
Phone: +49 (0) 89 89665425
Fax: +49 (0) 89 82084607
E-Mail: info@imr-partner.de
Internet: www.imr-partner.de

Immumed GmbH – Gesellschaft für angewandte Immunologie

BIOTECH PRECLINICAL SERVICES

Keywords: Analysis, Laboratory, Inflammation, ELISA / EIA, Clinical
Diagnostics

Applied Immunology - Testing Services

We offer testing services for human, mouse or rat samples:

- Analysis of cytokines, chemokines and phosphoproteins
- Cell-characterization ■ Cell-separation ■ Cytotoxicity

Our team is specialized in measuring multiplex-parameter analysis with Luminex-Technology in various samples like serum, cell cultures, saliva, urine.

We perform every application for flow-cytometry analysis, for example cell phenotyping, intracellular cytokine detection or cytotoxicity assays as well as positive or negative selection of cells with magnetic-bead technology.

Implen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Nanobiotechnology, Genomics, Chip / Array
Technology, Automation, Devices

Implen GmbH is a leading supplier for system solutions for the analysis and processing of small volumes. We develop and distribute key technologies to optimize processes needed for molecular biological as well as cytogenetic applications. Together with our partners we combine customized complete-solutions and bring them to the market worldwide.

IMR Partner International GmbH

CRO

IMR – International Medical Research – Partner GmbH was incorporated in 2003 as a family owned business in Gräfelfing (Munich) Germany. The company provides consulting services including temporary or part time management in the area of clinical research, regulatory affairs, quality management and pharmacovigilance. It serves as the service partner for pharma, biotech and medical device companies, venture capital funds and CRO's. Therapeutic area expertise includes pain, inflammation, neurology, psychiatry, dermatology/allergy, internal and musculoskeletal medicine.

Inamed Research GmbH & Co. KG

CRO

Keywords: Drug Delivery, Clinical Research, Monitoring, Medical Writing, Respiratory Diseases

Inamed GmbH – „THE Respiratory CRO“

INAMED was founded in 1998 and is an experienced, independent, privately owned and managed CRO with its headquarters located at the periphery of Munich, and with its roots in basic research and clinical medicine.

We are an international contract research organization with true respiratory expertise. Complementing our solid experience in conducting clinical trials, INAMED's team of inhalation and clinical experts provides our sponsors with a unique spectrum of services.

Besides our clinical trial operations at all phases of development and our fully staffed, in-house Phase I-IIa unit with twenty beds, INAMED performs *in-vitro* studies in our own labs and is the only CRO in continental Europe able and approved to perform radio-labeling studies. Our studies deliver the highest quality data and can enhance your clinical trials and development projects for drugs and inhalation devices. INAMED offers an opportunity for sponsors to get their products to market more successfully.

Infors GmbH

BIOTECH DEVICES & REAGENTS

Infors is specialised in marketing and maintenance of fermenters and shakers. As a subsidiary of Infors AG in Basel, Switzerland, it not only sees itself as a trading and service company but also cooperates with researchers in order to develop new equipment used in the field of microbiology and cell culture.

Ingenium Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Medicinal Chemistry, Inflammation, Cardiovascular Diseases, Neurology, Pharmacology

Ingenium Pharmaceuticals GmbH, founded in 1998, is a subsidiary of Probiodrug (Halle/S. and Martinsried, Germany). Probiodrug is a privately held biopharmaceutical company focused on the development of innovative small molecule drugs. Probiodrug is pioneering an industrialized approach for making innovative targets pharmacologically accessible. Its core competence is the elucidation of the structure, biochemistry, and biology as well as the pathophysiology of regulatory peptides and enzymes modifying the activity of specific proteins and pathways.

Based on this expertise, the Company is developing inhibitors and ligands targeting key enzymes such as proteases and kinases. The most promising compounds are then developed by Probiodrug as drug candidates for the treatment of major diseases such as Alzheimer's disease or chronic inflammatory disorders. In Alzheimer's disorder, Probiodrug's expertise in metabolic enzymes has led to the discovery of an entirely new mechanism of action which is involved in the seeding of the typical depositions found in the brain of AD patients and also explains their neurotoxicity.



Contact:
Patrick McManus

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 893569-0
Fax: +49 (0) 89 893569-22
E-Mail: request@inamed-cro.com
Internet: www.inamed-cro.com



Contact:
Dr. Burkhard J. Feigel

Dachauer Str. 6
D-85254 Einsbach
Phone: +49 (0) 8135 8333
Fax: +49 (0) 8135 8320
E-Mail: infors.de@infors-ht.com
Internet: www.infors-ht.com



Contact:
Susanne Imssel

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 8565-2300
Fax: +49 (0) 89 8565-2305
E-Mail: info@ingenium-pharmaceuticals.com
Internet: www.ingenium-ag.com



Contact:
Prof. Dr. Toni Lindl

Balanstr. 6
D-81669 München
Phone: +49 (0) 89 48777-4
Fax: +49 (0) 89 48777-2
E-Mail: info@I-A-Z-zellkultur.de
Internet: www.I-A-Z-zellkultur.de



virion\serion

Contact:
Dr. Gerhard Hermann

Friedrich-Bergius-Ring 19
D-97076 Würzburg
Phone: +49 (0) 931 3045-0
Fax: +49 (0) 931 3045-100
E-Mail: dialog@virion-serion.de
Internet: www.virion-serion.de



Contact:
Dr. Frank Becker

Lochhamer Str. 29a
D-82152 Martinsried
Phone: +49 (0) 89 895572-80
Fax: +49 (0) 89 895572-81
E-Mail: info@intana.de
Internet: www.intana-bioscience.de

Institut für angewandte Zellkultur Dr. Toni Lindl GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody Production Service, Tissue Engineering / Cell Culture

The Institut für angewandte Zellkultur Dr. Toni Lindl offers services in the area of cell culture and tissue culture, training in cell culture work, distribution of cell lines, consulting in cell culture, molecular biology, genetic engineering and development of monoclonal antibodies and in vitro processes. The core competences cover cell culture services and genetic engineering with a product range of recombinant human interleukin-2 and human monoclonal antibodies against rabies. Partnerships are sought with university research institutes in immunology and virology, where know-how in cell culture and in vitro technologies can be transferred.

Institut Virion\Serion GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Automation, Respiratory Diseases, Infectious Diseases, Autoimmune Diseases, ELISA / EIA, Clinical Diagnostics

Institut Virion\Serion GmbH is a German *in-vitro* diagnostic company with more than 30 years of experience in the international market. The extensive high-quality product portfolio for the diagnosis of infectious diseases contains SERION ELISA *classic* tests recommended for quantified antibody detection in human serum, plasma, and, if necessary, in cerebrospinal fluid, against various viral, bacterial, fungal and parasitic infections. SERION ELISA *antigen* tests enable a direct antigen detection of pathogens. Our Complement Fixation Tests are featuring more than 50 different antigens. The latest developments of our particle-based SERION Multianalyt™ products allow simultaneous antibody detection against multiple antigens using flow cytometry. Parallel to immunoassays we have introduced the Immunomat™ for automated processing and analysis of SERION ELISA *classic* and SERION ELISA *antigen* tests.

Intana Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Microscopy, Antibody, Peptide/Protein, Small Molecules

Intana Bioscience GmbH, founded 2008, is a privately owned service provider company. Understanding the selectivity profile and the binding characteristics of a candidate drug has been shown to be essential for downstream optimization. Intana Bioscience GmbH offers interaction analysis based on a single molecule sensitive spectroscopic approach called fluorescence cross correlation spectroscopy (FCCS). FCCS can be applied in cellular lysates to determine the binding and rate constants of biomolecular interaction and represents a highly efficient approach to develop selective inhibitors for targeted therapies. Customers benefit from short assay development time, in depth interaction analysis and assay conditions that mimic the natural environment of a drug.

INTERLAB central lab services – worldwide GmbH

CRO

Keywords: Analytical Chemistry, Clinical Diagnostics, Logistics, Clinical Research

INTERLAB is an independent central laboratory supporting clinical trials for pharmaceutical and biotechnology companies covering Europe, North and South America, Australia, Africa and Asia. The international head office is in Munich, Germany. INTERLAB performs routine and esoteric testing on a daily basis: over 25.000 samples daily: clinical chemistry, hematology, endocrinology, genetics, PCR, microbiology, virology, immunology, serology, histopathology, cytology, toxicology, drug assays, incl. LC-MS/MS. Additional services: professional project managers, flexible data management and transfer, cost-effective shipment logistics worldwide, EN 45,000, ISO 9001 and EC/ISO/EN 15189 (17025).

IRIS Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Natural Compounds, Combinatorial Chemistry, Medicinal Chemistry, Drug Delivery, Drug Development, Peptide/Protein

2011 – Celebrating 10 Years in Business:

1. Starting Materials for Peptide Synthesis, Peptidomimetic and Medicinal Chemistry (Protected Amino Acids, Coupling reagents, Linkers, resins)
2. Reagents for PEGylation (improving solubility and pharmacokinetic properties of biopharmaceuticals and organic drug molecules)
3. Reagents for Life Science Research (substrates for Drug Interaction Studies, Natural Products with biological & pharmacological activity, Amino Acid and Carbohydrates derivatives as enzyme substrates)
4. Biocatalysis (immobilised enzymes, enzyme carriers, unusual and innovative enzymes for modern biocatalytic synthesis of fine chemicals, optical resolution of racemic mixtures; lipases and esterases for food industry and biodiesel production)
5. Contract Manufacturing of unusual derivatives with one or several chiral centres.

ITG Isotope Technologies Garching GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Drug Delivery, Devices, Peptide/Protein, Small Molecules

ITG Isotope Technologies Garching GmbH is responsible for all radio-isotope related development, production and logistics and provides products and services to customers in medicine, industry and its sister companies within the ITM Group. ITG is managing the isotope sourcing from the global reactor network, operates the isotope processing facilities in Garching and holds the „radioactive materials production license“. ITG provides products such as: Lutetium-177 n.c.a., Rhenium-188, Gallium-68, Ge-68/Ga-68 Generator, W-188/Re-188 Generator, Ac-225/Bi-213 Generator.



Contact:
Dr. Hermann Schulz

Bayerstr. 53
D-80335 München
Phone: +49 (0) 89 741393-0
Fax: +49 (0) 89 741393-39
E-Mail: CEO.Schulz@INTERLAB.de
Internet: www.INTERLAB.de



Contact:
Dr. Thomas Bruckdorfer

Waldershof Str. 49-51
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-73
Fax: +49 (0) 9231 9619-99
E-Mail: info@iris-biotech.de
Internet: www.iris-biotech.de



Contact:
Dr. Richard Henkelmann

Lichtenbergstr. 1
D-85748 Garching
Phone: +49 (0) 89 289139-46
Fax: +49 (0) 89 289139-29
E-Mail: info@itg-garching.de
Internet: www.itg-garching.de



Contact:
Christian Wiest

Ingolstädter Landstr. 1
D-85764 Neuherberg
Phone: +49 (0) 89 3187-3973
Fax: +49 (0) 89 3187-4170
E-Mail: christian.wiest@ithera-medical.com
Internet: www.ithera-medical.com



Contact:
Oliver Buck

Lichtenbergstr. 1
D-85748 Garching
Phone: +49 (0) 8651 7678-0
Fax: +49 (0) 8651 7678-20
E-Mail: info@itm.ag
Internet: www.itm.ag



Contact:
Dr. Günter Schumacher

Lichtenbergstr. 1
D-85748 Garching
Phone: +49 (0) 89 2891-3905
Fax: +49 (0) 89 6283-6811
E-Mail: info@radiopharmacy-munich.com

iThera Medical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Drug Development, Devices, Cardiovascular Diseases, Inflammation, Oncology

iThera Medical develops and markets a novel in-vivo biomedical imaging technology, MSOT = multi-spectral opto-acoustic tomography. MSOT utilizes the photo-acoustic effect to visualize and quantify anatomical, functional and molecular information of living tissue. Today, MSOT allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardiovascular problems). For the future, MSOT also promises to become a valuable tool for clinical diagnostics.

ITM Isotopen Technologien München AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Drug Delivery, New Materials, Devices, Automation, Chip / Array Technology, Cardiovascular Diseases

Setting Standards with New Generation Therapies! The ITM Group provides a new generation of highly effective radioisotope therapies and integrated application systems to those oncological and endovascular patients who are currently very difficult or impossible to treat with conventional methods:

- ITM-Rhenium-SCT[®]: Skin cancer patients with large and difficult to treat lesions
- ITM-Rhenium-PTA[®]: Patients with progressed peripheral endovascular disease, and cardiovascular patients with recurring in-stent restenosis
- ITM-PRRT: Peptide Receptor Radioisotope Therapies: Oncological patients with metastatic disease.

ITM RP-München GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Cardiovascular Diseases, Small Molecules, Peptide/Protein, Devices, Drug Delivery, Clinical Diagnostics, Drug Development

ITM RP-München GmbH - Radiopharmazie München™ – is responsible for the development of the portfolio and pipeline of radiopharmaceutical products in oncology/personalized medicine.

RPMs main focus are the so called Targeted or Peptide Receptor Radioisotope Therapies, which have already proven their medical effectiveness and commercial viability in the treatment of various metastatic tumors. In this context an innovative peptide with a multistage targeting and internalization mechanism has been licensed and has been brought into pre-clinical development by RPM. First promising results in a wide variety of vascularized tumors and metastatic melanoma could be obtained.

KantarHealth GmbH – Clinical Research

CRO

Keywords: Logistics, Clinical Research, Pharmacovigilance, Oncology, Medical Writing, Monitoring, Analysis

KantarHealth GmbH Clinical Research conducts phase I-IV clinical trials as well as NIS world-wide. Our operations span local agencies in over seventy countries in Europe. KantarHealth GmbH combines more than 25 years of CRO expertise in drug research with the development of innovative web-based applications in project and data management (InTrial and InDrums). Our services include: protocol and CRF design, eCRF solutions, feasibility and site selection, investigators training, handling and completion of legal and ethical requirements, monitoring and site management, project management, implementation of risk management programs, data management, medical coding, quality assurance, statistical planning and analysis, medical writing.

Kendle GmbH

CRO

Keywords: Clinical Research, Monitoring, Allergy, Diabetics, Medical Writing, Pharmacology, Oncology

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of clinical development services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Please find more information about Kendle at www.kendle.com

KLIFOVET AG

CRO

Keywords: Logistics, Monitoring, Medical Writing, Analysis, Clinical Research

KLIFOVET is the provider of high quality services for the Animal Health Industry and Animal Nutrition Industry in Europe regarding the registration and marketing of products. Strategic advice on licensing products, regulatory affairs consultancy, but also full CRO for conducting efficacy studies in any animal species is our business. We are in command of well organized logistics, a highly motivated team, a comprehensive net of co-operators and skilled investigators throughout Europe and US. We can handle large multi-national projects as well as run studies locally, in Europe or globally according to the demanding standards of FDA, EMA and/or the client. We perform this efficacy studies, field safety studies, marketing studies and palatability studies for veterinary medicinal products and feed additives.



Contact:
Siegfried Freytag


Landsberger Str. 284
D-80687 München
Phone: +49 (0) 89 5600-1421
Fax: +49 (0) 89 5600-1590
E-Mail: siegfried.freytag@kantarhealth.com
Internet: www.kantarhealth.com



Real people. Real results.™

Contact:
Isabel Tarazona

Stefan-George-Ring 6
D-81929 München
Phone: +49 (0) 89 993913-0
Fax: +49 (0) 89 993913-160
E-Mail: info.muc@kendle.com
Internet: www.kendle.com



Contact:
Dr. Klaus Hellmann

Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 580082-0
Fax: +49 (0) 89 580082-15
E-Mail: info@klifovet.com
Internet: www.klifovet.com



Contact:
Michael Miller

Ferdinand-Zwack-Str. 39
D-85354 Freising
Phone: +49 (0) 08161 205957
E-Mail: info@kmbioservices.de
Internet: www.kmbioservices.de



Contact:
Dr. Elisabeth Müller

Steubenstr. 4
D-97688 Bad Kissingen
Phone: +49 (0) 971 7202-0
Fax: +49 (0) 971 68546
E-Mail: mueller@laboklin.de
Internet: www.laboklin.com

Labor L+S AG

Contact:
Dr. Frank Böttcher

Mangelsfeld 4
D-97708 Bad Bocklet-Großenbrach
Phone: +49 (0) 9708 9100-0
Fax: +49 (0) 9708 9100-36
E-Mail: labor@labor-ls.de
Internet: www.labor-ls.de

kmbs

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, PCR

kmbs is your service partner for organismic studies e. g. in Conservation Biology, Zoology, Phylogeny, Taxonomy, and Molecular Biology to clear up specimens' identities by means of molecular/genetic analyses (Sample preparation, PCR, DNA sequencing, Gene Fragment analysis) for purposes like resolving species relationships, detecting sibling species, delimiting species boundaries, investigating population structure and integrity, a.s.o. In addition, we are experienced in making microscopic preparations, carrying out outdoor services like mapping species inventories or searching for special organisms within a given habitat including the collection of organisms on demand, and acting as project manager and consultants.

Laboklin GmbH & Co KG – Unternehmensbereich Labogen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing.) Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more.

Labor L+S AG

BIOTECH

Keywords: Medicinal Chemistry, Allergy, Clinical Diagnostics

Labor L+S AG is a service provider who understands the language of the future: Achievement, service, quality. With L+S AG there is no separation from advisors and practitioners. More than 500 customers from the pharmaceutical, cosmetics, food and feed industry trust our know-how. Our range of services: Microbiological, molecular-biological, biological, chemical and physicochemical tests of pharmaceuticals, medicinal products, food and feed, cosmetics as well as related raw materials and intermediate goods, Industrial hygiene, Clinical-microbiological diagnostic as well as diagnostic of food intolerances and allergies. In our state of the art laboratory (5100 sqm) 250 employees carefully handle more than 100.000 samples/year.

LAT GmbH Dr. Tittel – Institut für Pharma-Analytik

CRO

Keywords: Pharmacology, Pharmacovigilance, Regulatory Affairs, Laboratory, Analytical Chemistry, Analysis, Medical Writing

LAT has more than 30 years experience both in routine testing and method development. We offer a wide range of services: Pharmacopeial Tests (Ph. Eur., USP, BP, Ph. Eur.), Characterisation of Raw Material, writing of DMF (Drug Master Files), Characterisation of Reference Standards, writing of Monographs, Development of analytical methods (identity, assay, related substances, dissolution), Validation of analytical methods according to ICH guidelines, Analysis of residual solvents, ethylene oxide, unknown peaks. Stability testing according to ICH-guidelines, Compilation and revision of marketing authorisation dossiers (CTD, eCTD, IMPD, ASMF/US-DMF).
Compilation of dossiers for CEP application at the EDQM.

Leon-nanodrugs GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Drug Delivery, Nanobiotechnology, Antibody, Antisense/Nucleotides, Peptide/Protein, Small Molecules

Leon-nanodrugs GmbH is an innovative contract drug development company specialized in the production of API-specific nanoparticles and complex drug-delivery-systems for generic and original products up to market approval, including pre-clinical and clinical development and the drug specific manufacturing patents. The APIs range from small molecules to proteins and hormones. The patented MJR-technology enables the realization of line extensions and drug combinations which were up to now impossible. Based on its interdisciplinary expertise the company provides unique tools for proactive life cycle management for the pharmaceutical and biotech industry.

LEUKOCARE AG

BIOTECH DEVICES & REAGENTS

Keywords: Inflammation, Immune Therapy, Peptide/Protein, Antibody, Clinical Research, New Materials, Clinical Diagnostics

LEUKOCARE is a privately owned, product-focused, clinical-stage biotechnology company headquartered in Martinsried near Munich, Germany. LEUKOCARE's proprietary Stabilizing and Protecting Solutions (SPS) allow to extend shelflife of biologics (proteins, vaccines, nucleic acids) in dehydrated state and to retain functionality following terminal sterilization of biologics by gamma-, or beta-irradiation or ethylene oxide. LEUKOCARE collaborates with partners in the fields of biopharmaceuticals, medical devices and diagnostics. Partnering with LEUKOCARE also grants access to our well established physiological, biochemical, and immunological expertise.



Contact:
Dr. Franz Kelnhofer

Am Haag 4
D-82166 Gräfelfing
Phone: +49 (0) 89 858967-0
Fax: +49 (0) 89 858967-111
E-Mail: info@lat-gmbh.de
Internet: www.lat-gmbh.de



Contact:
Cornelia Beier

Lucile-Grahn-Str. 47
D-81675 München
Phone: +49 (0) 89 4142488-96
Fax: +49 (0) 89 982722-7
E-Mail: info@leon-nanodrugs.com
Internet: www.leon-nanodrugs.com



Contact:
Michael Scholl

Am Klopferspitz 19
D-82152 Martinsried/Munich
Phone: +49 (0) 89 7801665-0
Fax: +49 (0) 89 7801665-11
E-Mail: info@leukocare.com
Internet: www.leukocare.com



Contact:
Dr. Fritz Huber

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 69809-100
Fax: +49 (0) 941 69809-101
E-Mail: info@lipofit.de
Internet: www.lipofit.de



Contact:
Prof. Dr. Matthias Schieker

Truhenseeweg 8
D-82319 Starnberg
Phone: +49 (0) 8151 5590291
Fax: +49 (0) 8151 917922
E-Mail: info@livimplant.de
Internet: www.livimplant.de



Contact:
Dr. Caroline Freye-Minks

Mühlweg 2a
D-82054 Sauerlach
Phone: +49 (0) 8104 616-20
Fax: +49 (0) 8104 616-48
E-Mail: service@loewe-info.com
Internet: www.loewe-info.com

LipoFIT Analytic GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Analysis, Nephrology, Metabolic Diseases, Pharmacokinetics, Fine Chemicals / Reagents, Agrobiotechnology

LipoFIT: NMR analytics for clinical laboratories, the pharmaceutical and agrochemical industry. For current unsolved analytical challenges, the NMR technology may offer a solution. LipoFIT offers and develops tests based on NMR and tailor made statistical procedures for multi-parameter tests.

Examples are:

- Products for safety testing: A precise multi-parametric NMR screening test for detecting nephrotoxicity caused by any substance (e.g. NECs)
- Purity testing of chemical compounds: Distinction of analogues, causing severe auto immune reactions
- Products used in the agrochemical industry: Quality tests of plants and seeds as raw materials and for breeding purposes.

LipoFIT is certified (EN ISO 13485:2003 and ISO 9001:2000) and holds the Statement of GMP Compliance.

LivImplant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Bone / Joint Diseases, Cell Therapy, Tissue Engineering / Cell Culture

LivImplant GmbH develops and sells innovative cell based therapies for lesions and diseases of tendons, joints, cartilage and bones, focusing on stimulating the self-healing powers of the body by applying stem cells and growth factors. As a spin off from the Experimental Surgery and Regenerative Medicine department of the Ludwig-Maximilians-University of Munich (www.experimed.de) and a close collaboration with the Veterinary Clinic of the University of Giessen LivImplant benefits from the latest scientific proceedings. First applications are available for curing lameness with horses and dogs.

Loewe® Biochemica GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Agrobiotechnology, ELISA / EIA

LOEWE is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nematodes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR).

Lophius Biosciences GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

The Lophius Biosciences GmbH, which was founded in the year 2002, is a spin-off of the Institute for Medical Microbiology and Hygiene and the Department of Internal Medicine I, University of Regensburg, Germany.

The core business of Lophius is R&D for innovative diagnostic and therapeutic products in T-cell immunology and immunotherapy.

Lophius offers clinical sample-testing services based on a broad repertoire of immunological routine assays. In addition, Lophius uses its proprietary technology for the highly sensitive detection and characterization of active T cells.

MAB Discovery GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Antibody, Drug Development

MAB Discovery is an antibody discovery company. Founded in October 2010 it started its operations in January 2011. The company provides an integrated discovery concept based on in vivo and in vitro mab generation platforms as well as different lead optimization concepts.

The company currently has formed a strategic alliance with BioDuro Biologics, a CRO company with operations in Shanghai, China. The main shareholder of BioDuro Biologics is PPD an US based leading global CRO organization.

medicomp GmbH

CRO

medicomp GmbH was founded in 1985 and has developed ever since into a full service CRO. We offer a wide range of services for phase I-IV trials, PMS and medical devices: medical and biometrical planning, protocol and CRF design, project management, data management, monitoring, statistical analysis and medical writing. medicomp is a member of the Bundesverband Medizinischer Auftragsinstitute (BVMA), which implies regular independent system audits. Furthermore, medicomp is a founding member of Pharmaceutical Service Network (PSN), a network of independent European CROs, which allows us to offer services for studies conducted on a European scope in collaboration with our partners.



Contact:
Dr. Ludwig Deml

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 6309197-0
Fax: +49 (0) 941 6309197-9
E-Mail: info@lophius.de
Internet: www.lophius.de



Contact:
Dr. Stephan Fischer

Forstenrieder Str. 8-14
D-82061 Neuried
Phone: +49 (0) 89 990178-0
Fax: +49 (0) 89 990178-199
E-Mail: info@mabdiscovery.com
Internet: www.mabdiscovery.com



Contact:
Dr. med. vet. Michael Gierend

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 895286-0
Fax: +49 (0) 89 895286-66
E-Mail: medicomp@medicomp-cro.de
Internet: www.medicomp-cro.de

MediCliPha Ltd

Contact:
Prof. Dr. Peter Schlieper

Bergstr. 7
D-86926 Greifenberg
Phone: +49 (0) 8192 9336-0
Fax: +49 (0) 8192 9336-17
E-Mail: info@medicore.de
Internet: www.medicore.de

MediGene

Contact:
Dr. Nadja Wolf

Lochamer Str. 11
D-82152 Martinsried
Phone: +49 (0) 89 856529-0
Fax: +49 (0) 89 856529-20
E-Mail: medigene@medigene.com
Internet: www.medigene.com

MEDPACE

Contact:
Katrin Stedtler

Gmunder Str. 53
D-81379 München
Phone: +49 (0) 89 8955718-0
Fax: +49 (0) 89 8955718-100
E-Mail: K.Stedtler@medpace.com
Internet: www.medpace.de

medicore International AG / MeDiPha-Holding AG

CRO

Keywords: Drug Development, Clinical Research, Monitoring, Medical Writing

medicore International AG was founded in 1992 and is a contract research organisation (CRO) with services for biotech- and pharmaceutical companies. Recently, a close cooperation was formed with MeDiPha AG. The full-service concept includes consultations in drug development (from the active principle to marketing approval), clinical trials (phase II to IV, phase I in co-operation), data management, biostatistics, quality assurance (audits of different type), expert reports (pharmacology/ toxicology and clinical), medical writing, marketing surveillance studies, regulatory affairs, medical information and drug safety. Both companies offer full service packages or a modular approach. The reputation is based on competent staff, on GCP-conformance, on strict keeping timelines and budget.

MediGene AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Dermatology, Autoimmune Diseases, Oncology, Drug Development, Immune Therapy

MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG, TecDax) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market which are distributed by partner companies. It has several drug candidates in clinical development and possesses innovative platform technologies. MediGene focuses on clinical research and development of novel drugs with focus on oncology.

Medpace Germany GmbH

CRO

Keywords: Monitoring, Oncology, Metabolic Diseases, Cardiovascular Diseases, Clinical Research

Medpace, established in 1992, is a full-service Contract Research Organization (CRO), who partners with leading pharmaceutical and biotech organizations to bring promising new drugs to market. Medpace combines comprehensive regulatory consulting with efficient clinical trial management to provide sponsors with exceptional support in drug development. Proven leaders in medical and scientific research monitor every project. Medpace physicians have first-hand experience working with regulatory agencies to successfully guide projects through the complexities of the regulatory process. The medical expertise and regulatory guidance provided by Medpace leads to reduced costs and increased efficiencies for our valued customers.

MedPharmTec-Services

CRO

MedPharmTec-Services is a Pharmaceutical Contract Service Organisation providing expert assistance in drug development, clinical research (phase II through IV), medical information, regulatory affairs and drug safety to pharmaceutical and biotechnology companies. Our clinical research services range from protocol planning, CRF design, trial management, monitoring and auditing up to data management, biometrics and report writing. Further areas of MedPharmTec-Services activities include medical information, i.e. medical and scientific translations, proof-reading, writing/designing of brochures, publications and scientific literature searches as well as consulting and services in terms of regulatory affairs and drug safety.

Merck KGaA; Merck Serono – Institute of Drug Metabolism and Pharmacokinetics

PHARMA & CHEMICAL INDUSTRY

Keywords: Small Molecules, Antibody, Pharmacokinetics, ELISA / EIA, Drug Development

The Institute of Drug Metabolism and Pharmacokinetics (DMPK) is located in Grafing near Munich and is part of Global Research of Merck Serono, Geneva. The institute was established in 1969 and has grown considerably over the years. Currently 80 people are working at Grafing. The scope of the Institute of DMPK includes ADME studies of NCEs and NBEs in laboratory animals during drug discovery and development phases. Support is given to toxicology (toxicokinetics) and to clinical R&D by providing bioanalytical data and information about the metabolism in humans. The institute is equipped with state of the art instruments (e.g. LC-MS/MS, NMR, biacore, phosphor-imaging systems) and laboratories for radiolabelling of drugs with various radioisotopes (e.g. C-14, H-3, J-125).

metabion

BIOTECH DEVICES & REAGENTS

Keywords: Analysis, Antibody Production Service, RNAi & Antisense, Genomics, Proteomics, PCR

metabION is one of the globally leading suppliers of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality products and services. Founded in 1997 in Munich/Martinsried, metabion keeps on expanding its product portfolio from the production of a wide range of synthetic DNA and RNA oligonucleotides according to customers' needs to the supply of standard life science products. Successfully translating highest quality standards into daily practice is the core of metabion's business philosophy and key to its popularity at the same time. Careful evaluation and implementation of new and promising technologies and products are complementing metabion's progressive and innovative approach within a healthy and sound business setup.



Contact:
Dr. Horst H. Langenbahn

Olschewskibogen 7
D-80935 München
Phone: +49 (0) 89 354998-0
Fax: +49 (0) 89 354998-199
E-Mail: office@MedPharmTec.de
Internet: www.MedPharmTec.de



Contact:
Dr. Bernhard Ladstetter

Am Feld 32
D-85567 Grafing
Phone: +49 (0) 8092 7008-0
Fax: +49 (0) 8092 7008-99
E-Mail: bernhard.ladstetter@merck.de
Internet: www.merck.de



Contact:
Dr. Andreas Berghammer

Lena-Christ-Str. 44
D-82152 Martinsried
Phone: +49 (0) 89 899363-0
Fax: +49 (0) 89 899363-11
E-Mail: metabion@metabion.com
Internet: www.metabion.com



Contact:
Dieter Meyer

Paul-Gerhardt-Allee 42
D-81245 München
Phone: +49 (0) 89 829265-100
Fax: +49 (0) 89 829265-099
E-Mail: info@metronomia.net
Internet: www.metronomia.net



Contact:
Dr. Erwin Soutschek

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 700 5050-2002
Fax: +49 (0) 700 5050-2003
E-Mail: info@microbionix.com
Internet: www.microbionix.com



Contact:
Dr. Günter Müller

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9981-0
Fax: +49 (0) 8158 9981-10
E-Mail: info@microcoat.de
Internet: www.microcoat-biotechnologie.de

Metronomia Clinical Research GmbH

CRO

Keywords: Clinical Research, Logistics, Monitoring, Medical Writing, Drug Development, Oncology

Metronomia Clinical Research is a mid-size European CRO, providing full- or tailored services in clinical trials phase I - IV and NIS, with special focus on e-clinical, data management and biostatistics. Metronomia's mission statement is to improve and accelerate drug development by bringing together cutting-edge e-clinical technologies, well accepted study designs and pronounced customer orientation. Since more than 20 years our customers particularly esteem the high-quality and reliability of our data, our commitment to best service and outstanding flexibility, our stable project teams and the competitive cost-benefit ratio. Metronomia has a proven track record in all major therapeutic areas (core indications: oncology, dermatology, transplantation, nephrology and pulmonary diseases).

MICROBIONIX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Research, Analysis, Infectious Diseases, Clinical Diagnostics

MICROBIONIX specializes in the development of Multiplex Assay Systems. The basis of all our applications is Luminex „xMAP-Technology“, a bead-based multiplex platform technology for rapid and cost-efficient analysis. MICROBIONIX offers Multiplex Testing Services for analytes relevant to biomarker studies, hormone-analytic, cellular signal transduction and pathways:

- Quantification of Cytokines, Chemokines and Growths Factors
- Activity Assays for Protein-Kinases
- Activity State Assays for Signalling Proteins
- Binding-Assays for Transcription Factors
- Immunglobulin Isotyping
- MMP-Analysis

MicroCoat Biotechnologie GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, ELISA / EIA, PCR, Analytical Chemistry

Founded in 1992, MicroCoat is a biotechnology company focused on the field of Immune- and Nucleic acid-Diagnostics.

The major work areas are

- Coating of various biological reagents (streptavidin; antibodies; nucleic acids; and others) on solid phases (e.g. microtiterplates, tubes, chips)
- Development and manufacturing of diagnostic assays,
- Service in the field of Immune and Nucleic acid-Diagnostics like: measurement of samples, also for clinical trials; method comparison of assays; configuration and handling of „sample panels“; system verification and validation.

MicroCoat has been certified for EN ISO 13485:2003 (9001/EN 46001).

Micromet AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Immune Therapy, Antibody, Drug Development

Micromet puts novel concepts in immunotherapy to work. Using proprietary technologies, the Company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. Two candidates are currently in clinical trials. The Company has established a powerful drug development platform: BiTE™ („Bispecific T cell engagers“), a unique drug format that leverages the outstanding cytotoxic potential of T cells to precisely eliminate pathogenic cells. In addition, Micromet is exploiting the potential of SCAs (single-chain antibodies) for the development of novel drug candidates. The Company has attracted both top-tier life science investors and corporate partners such as MedImmune, Inc., Enzon Pharmaceuticals, Inc., and Serono.

MIKROGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA / EIA, Infectious Diseases, Automation, Autoimmune Diseases, Chip / Array Technology

Founded in 1989 MIKROGEN GmbH offers innovative solutions for medical laboratories. The company's scope is the development and production of clinical diagnostic test systems based on recombinant antigens, with the focus on bacterial, viral, parasitic and autoimmune diseases. MIKROGEN's core competencies covers genetic engineering and the scientific quality of research and development, which is reflected in various patent applications and publications in international journals. The key success factors of the company are consistent customer orientation, the strong product competence and highly skilled employees. MIKROGEN meets ongoing market demands by emphasising its activities on automation and standardisation in the in-vitro diagnostics, to improve processes in medical laboratories.

MLL Münchner Leukämie Labor GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Chip / Array Technology, Genomics, PCR, Hematology, Oncology

MLL Munich Leukemia Laboratory is working as a reference laboratory for the diagnosis of hematologic malignancies focussing on leukemia and lymphoma. All 100 coworkers (physicians, molecular biologists, and technicians) have outstanding reputation in the field of comprehensive diagnostics. In parallel, cytomorphology, cytochemistry, immunophenotyping, cytogenetics, FISH, and molecular genetic techniques such as PCR are performed. The seven day available work-flow is orientated to the clinical needs of patients and physicians. MLL is testing new techniques such as next-generation sequencing. We serve as a reference laboratory for German and European leukemia studies and are a SME-member in the European Leukemia Network (ELN). Education programmes are provided for physicians and technicians.



Contact:
Angela Lucks

Staffelseestr. 2
D-81477 München
Phone: +49 (0) 89 895277-0
Fax: +49 (0) 89 895277-105
E-Mail: info@micromet.de
Internet: www.micromet.de



Contact:
Dr. Erwin Soutschek

Floriensbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 54801-0
Fax: +49 (0) 89 54801-100
E-Mail: mikrogen@mikrogen.de
Internet: www.mikrogen.de



Contact:
Prof. Dr. Dr. Torsten Haferlach

Max-Lebsche-Platz 31
D-81377 München
Phone: +49 (0) 89 99017-0
Fax: +49 (0) 89 99017-111
E-Mail: info@mll.com
Internet: www.mll.com



Molecular Networks
Inspiring Chemical Discovery

Contact:
Dr. Oliver Sacher

IZMP, Henkestr. 91
D-91052 Erlangen
Phone: +49 (0) 9131 8156-68
Fax: +49 (0) 9131 8156-69
E-Mail: info@molecular-networks.com
Internet: www.molecular-networks.com



Contact:
Dr. Jorge Garcia

Gut Keferloh 1c
D-85630 Grasbrunn b. München
Phone: +49 (0) 89 456729-0
Fax: +49 (0) 89 456729-18
E-Mail: mailto@mzd.de
Internet: www.MZD.de



Contact:
Dr. Claudia Gutjahr-Löser

Lena-Christ-Str. 48
D-82152 Martinsried
Phone: +49 (0) 89 89927-0
Fax: +49 (0) 89 89927-222
E-Mail: info@morphosys.com
Internet: www.morphosys.com

Molecular Networks GmbH

BIOTECH BIOINFORMATICS

Keywords: [Small Molecules](#), [Molecular Modelling](#)

Molecular Networks offers innovative chemoinformatics software products, consulting, development and research services to increase the quality and productivity of discoveries in chemical, pharmaceutical and biotechnology R&D. Founded in 1997, the company established international business relationships and Molecular Networks' technology is utilized in major industrial and academic discovery laboratories worldwide to design and optimize chemical products and processes. Molecular Networks' product portfolio comprises a variety of software tools, databases and decision support applications for the design and the synthesis of chemical compounds, the prediction of their chemical, physical and biological properties, their chemical reactivity and metabolic or environmental fate.

Monitor Zentrale Deutschland

CRO

Monitor Zentrale Deutschland (MZD) a department of Geelen & Geelen GmbH, is a clinical research service provider, located in Grasbrunn near Munich. It started in 1994 as a monitoring service and has become an agency for the recruitment (out- and in-sourcing) of temporary experienced freelance clinical research professionals for the R&D sector (e.g. CRAs, Study Nurses, Project Managers, Medical Writers, Regulatory Affairs and Drug Safety Managers, Clinical Trials Administrators or Coordinators, Data Managers. Besides this Geelen & Geelen is the publisher of the German Magazine of Clinical Research (Deutsche Zeitschrift für Klinische Forschung www.dzkgf.de).

MorphoSys AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: [CNS](#), [Oncology](#), [Infectious Diseases](#), [Dermatology](#), [Antibody](#), [Antibody Production Service](#), [Drug Development](#)

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. By successfully applying HuCAL[®] and other proprietary technologies, MorphoSys has become a leader in the field of human therapeutic antibodies. Through its alliances with some of the world's most important pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Via its business unit AbD Serotec, MorphoSys is expanding its reach in the diagnostics and research markets.

MSD SHARP & DOHME GMBH

PHARMA & CHEMICAL INDUSTRY

Keywords: Cardiovascular Diseases, Dermatology, Diabetics, Oncology, Ophthalmology, Respiratory Diseases, Rheumatology

MSD SHARP & DOHME GMBH is the German subsidiary of Merck & Co., Inc., a research-driven, worldwide acting pharmaceutical company based in the US, which develops, produces and distributes medicines and vaccines in different therapeutic fields. MSD wants to contribute to medical care in order to guarantee and improve access to urgently needed medicines worldwide. Thus, MSD supports numerous poor countries with donations of pharmaceuticals. For more than 100 years MSD publishes the renowned „MSD-Manual“, a standard publication for physicians and pharmacists (www.msd.de/msdmanual/). Medical knowledge and advice for the public is published in the „MSD-Manual Handbuch Gesundheit“. MSD Germany has more than 1,200 employees. The company is situated in Haar near Munich.

MSOURCE Medical Development GmbH

CRO

Keywords: Monitoring, Analysis, Clinical Research, Oncology, Infectious Diseases, CNS, Cardiovascular Diseases

As a rapidly expanding ISO 9002 certified full-service CRO organization, MSOURCE has provided a range of clinical development and professional services to the pharmaceutical, biotechnology and medical device industries since 1994.

Through a strong focus on client needs, our people, processes and continued emphasis on quality, MSOURCE has built services to address: Clinical Trial Management, Clinical Data Services, Clinical Contract Hire and Quality Assurance Consulting.

multimmune GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Antibody, Cell Therapy, Vaccines, Oncology

multimmune is a biopharmaceutical company dedicated to the discovery and development of new products for the treatment of cancer. The company focuses on the development of drug candidates to treat heat shock protein 70 (Hsp70) positive tumors, as surface-bound Hsp70 is a tumor-specific marker expressed on about 50-75% of various cancer entities, e.g. lung, breast, colon, pancreas.

Currently, four approaches are being explored to destroy cancer cells: (1) by extracorporeal activation of Natural Killer (NK) cells with a synthetic peptide (ready to go into phase II), (2) by using an antibody against Hsp70 (preclinical), (3) by inducing tumor specific apoptosis with a recombinant human serine protease (preclinical), (4) by direct infusion of an Hsp70 peptide (preclinical).



Contact:
Kurt Leidner

Lindenplatz 1
D-85540 Haar
Phone: +49 (0) 89 4561-1130
Fax: +49 (0) 89 4561-1329
E-Mail: kurt_leidner@msd.de
Internet: www.msd.de



A member of TÜV SÜD Group.

Contact:
Christine Wurm

Rüdesheimerstr. 15/3
D-80686 München
Phone: +49 (0) 89 21019-10
Fax: +49 (0) 89 21019-150
E-Mail: cwurm@msource-cro.com
Internet: www.msource-cro.com



Contact:
Dr. Claus Botzler

Arnulfstr. 197
D-80634 München
Phone: +49 (0) 89 4520-7707
Fax: +49 (0) 89 4140-4299
E-Mail: info@multimmune.de
Internet: www.multimmune.de



Contact:
Dr. Christian Simmet

Hauptstr. 41
D-84184 Tiefenbach
Phone: +49 (0) 8709 9229-664
Fax: +49 (0) 8709 9229-82664
E-Mail: csimmet@minitube.de



Contact:
Dr. Niels Fertig

Gabrielenstr. 9
D-80636 München
Phone: +49 (0) 89 2189979-72
Fax: +49 (0) 89 2189979-60
E-Mail: info@nanion.de
Internet: www.nanion.de



Contact:
Dr. Philipp Baaske

Amalienstr. 54
D-80799 München
Phone: +49 (0) 89 21802833
Fax: +49 (0) 89 21802050
E-Mail: info@nanotemper.de
Internet: www.nanotemper.de

MWM Biomodels GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Pharmacokinetics, Transgenic Animals, Cardiovascular Diseases, Diabetics, Respiratory Diseases

MWM Biomodels GmbH is a spin-off company of the LMU Munich and Minitube, specialized in the development and characterization of transgenic large animal models for biomedical research. Current projects are focused on genetically modified pigs for xenotransplantation as well as transgenic pig models of diabetes mellitus, muscular dystrophy and immunodeficiency. MWM Biomodels offers support starting from the design of a project, the development of expression and targeting vectors, the generation of genetically modified large animals, their phenotypic characterization and the performance of preclinical studies.

Nanion Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Devices

Nanion Technologies is a spin-off from the Center for Nanoscience (CeNS) of the Ludwig-Maximilians-University of Munich (LMU). Nanion combines bio- and microtechnology in a company serving the life sciences industry by offering products and services which will dramatically increase the speed and efficiency of the drug discovery process in an important segment of the pharmaceutical market. Nanion bases its business on a proprietary chip technology and will design and develop High Throughput Screening (HTS) systems for ion channel active drugs (ICADs). Ion channels are prime targets for innovative medicines aimed at many important diseases.

NanoTemper Technologies GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Nanobiotechnology, Peptide/Protein, Small Molecules

The NanoTemper Technologies GmbH provides services and instruments for the pharmaceutical and biotechnological industry and is also developing products for medical diagnostics. The NanoTemper® Technology „Micro Scale Thermophoresis“ allows to probe the affinity, size, stability and conformation of drug candidates/biomolecules in close to real conditions: freely moving in aqueous solutions and especially in biological liquids like cell lysate or blood.

For example the affinities of antibodies, aptamers, small molecules, proteins and oligonucleotides can be quantified, as well as the interactions of nanoparticles, microbeads or drug delivery systems with body fluids.

NDA Regulatory Service GmbH

CRO

Keywords: Regulatory Affairs, Pharmacovigilance, Drug Development

NDA is one of the leading Regulatory Affairs consultancies in Europe. With ~85 employees and offices in Sweden, UK and Germany, NDA has successfully provided Regulatory Support throughout Europe for over 10 years. NDA Regulatory Service GmbH in Munich was founded by a core group of regulatory experts from the European headquarter of an international pharmaceutical company. Our consultants are experienced professionals who offer expert knowledge and understanding of European regulations, guidelines and procedures. They are proficient in all regulatory activities associated with small molecules, biologicals and advanced therapies. We are dedicated to guide our clients smoothly through product development and registration in Europe.

Neaspec GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Analytical Chemistry, Microscopy, Nanobiotechnology

Neaspec is dedicated to delivering innovative solutions for nanoscale optical imaging & spectroscopy for research laboratories in industry and academic institutions. After 15 years of R&D, Neaspec now introduces the NeaSNOM microscopy platform – the only commercially available microscope that enables optical imaging and spectroscopy with a lateral resolution of better than 20 nm within the material fingerprint region in the infrared, visible and terahertz spectral region. As the ultimate nanoanalytic tool for material research and photonics, NeaSNOM has a high application potential in many disciplines such as Semiconductor Technology, Chemistry, Photonics, Polymer Science and Life-Sciences.

NeuroProfile GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets (disease-related genes or proteins) for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for forthcoming drug generations with new mechanisms of action that not only ameliorate the disease symptoms, but potentially prevent or block progression of the disease.

Several patent pending target candidates are run in preclinical validation projects.



Contact:
Dr. Rainer Paffenholz

Weihenstephaner Str. 28
D-81673 München
Phone: +49 (0) 89 427299-4000
Fax: +49 (0) 89 427299-4010
E-Mail: munich@ndareg.com
Internet: www.ndareg.com



Contact:
Dr. Stefan Schiefer

Bunsenstr. 5
D-82152 Martinsried
Phone: +49 (0) 89 787939-78
Fax: +49 (0) 89 787939-79
E-Mail: info@neaspec.com
Internet: www.neaspec.com



Contact:
Dr. Thomas Rohrmeier

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 7853690
Fax: +49 (0) 941 7853699
E-Mail: info@neuroprofile.com
Internet: www.neuroprofile.com

NIGU

AlzChem Group

Contact:
Dr. Frank Fleischer

Beuthener Str. 2
D-84478 Waldkraiburg
Phone: +49 (0) 8638 962-0
Fax: +49 (0) 8638 962-287
E-Mail: info@nigu.de
Internet: www.nigu.de



Contact:
Dr. Klaus-Peter Stengele

Beuthenerstr. 2
D-84478 Waldkraiburg
Phone: +49 (0) 8638 98420
Fax: +49 (0) 8638 984211
E-Mail: stengele@nimblegen.de
Internet: www.nimblegen.de



Contact:
Martin Bischof

Zielstattstr. 40
D-81379 München
Phone: +49 (0) 89 7877-0
Fax: +49 (0) 89 7877-250
E-Mail: communications.munich_de@novartis.com
Internet: www.novartis-consumerhealth.de

NIGU Chemie GmbH

PHARMA & CHEMICAL INDUSTRY

Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies. Guanidine thiocyanate for nucleic acid based diagnostics is another integral part of the portfolio. A typical example is to provide guanidine-salts and recycling of used solutions as a complete package to the biopharmaceutical industry.

NimbleGen Systems GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Genomics, Chip / Array Technology, Fine Chemicals / Reagents, Clinical Diagnostics

NimbleGen Systems, the leading supplier of flexible high-density microarray products and services, is enabling a new era of High-Definition Genomics (SM). NimbleGen uniquely produces high-density arrays of isothermal long oligos that provide superior results for advanced genomic analysis methods such as CGH, ChIP, microbial Comparative Genome Sequencing, and expression tiling. NimbleGen's High-Definition Genomics enables scientists to obtain and integrate complex genomic data sets not previously accessible, providing a much clearer understanding of genome structure and function, and how this relates to biology and medicine.

NimbleGen Systems GmbH is the wholly owned German subsidiary of Nimblegen Systems Inc and the chemistry arm of NimbleGen.

Novartis Consumer Health GmbH

PHARMA & CHEMICAL INDUSTRY

Novartis Consumer Health, located in Munich, merchandises and distributes OTC and prescription drugs for self-medication.

Nuvisan GmbH

CRO

Keywords: Oncology, Small Molecules, Peptide/Protein, Pharmacokinetics, PCR, ELISA / EIA, Clinical Research

Nuvisan Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. We deliver services ranging from a single test to fully integrated drug development programs.

Together with Focus we are pleased to offer our sponsors the complete spectrum of drug development services and assist the sponsor in bringing safe and effective pharmaceutical products to market.

Octapharma Biopharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Hematology, Drug Development

Octapharma Biopharmaceuticals GmbH (foundation 1997) is a product-oriented R&D company with 37 employees located in Martinsried. The emphasis of our work is the development of recombinant pharmaceuticals as a modern alternative to plasma products. Our recombinant proteins produced in a human cell line show human-identical properties and improved tolerance in patients compared to hamster cell - derived products is expected. Our recombinant FVIII is already successfully running in Clinical Phase II in patients. Fresenius Kabi and Octapharma Group entered into an Exclusive License, Development and Supply Agreement to develop a HESylated recombinant protein. These combined technologies are intended to generate a therapeutic protein with superior product profile in respect of half-life prolongation – increased quality of life for the patient.

Omegamatrix GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Prof. W.S. Harris, Sanford University – USA, and Prof. C. von Schacky, University of Munich, invented and defined the HS-Omega-3 Index in 2004. Then, in 2006 Schacky founded Omegamatrix GmbH, as a Laboratory, to deal with the ever growing number of research projects, applications and samples. Initially proposed as a risk factor for sudden cardiac death, it now indicates cardiovascular risk as well. First studies have shown its association to life expectancy in general. Other applications, still in development, range from psychiatric diseases to pregnancy and lactation.



Contact:
Dr. Karl Michaelis

Wegenerstr. 13
D-89231 Neu-Ulm
Phone: +49 (0) 731 9840-0
Fax: +49 (0) 731 9840-280
E-Mail: karl.michaelis@nuvisan.com
Internet: www.nuvisan.com



For the safe and optimal use of human proteins

Contact:
Carola Schröder

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 700769-60
Fax: +49 (0) 89 700769-61
E-Mail: info-munich@octapharma.com
Internet:
www.octapharma-biopharmaceuticals.com

Omegamatrix GmbH


Contact:
Adrian Passow

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 55063007
Fax: +49 (0) 89 55063008
E-Mail: info@omegamatrix.eu
Internet: www.omegamatrix.eu/



Contact:
Prof. Dr. Lutz Eichacker

Adelbergweg 14
D-82234 Wessling
Phone: +49 (0) 8153 908785-3
Fax: +49 (0) 8153 908785-4
E-Mail: info@omx-online.com
Internet: www.omx-online.com



Contact:
Dr. Igor Ivanov

Fraunhoferstr. 20
D-82152 Martinsried
Phone: +49 (0) 89 38012215-0
Fax: +49 (0) 89 38012215-9
E-Mail: request4more@oncolead.com
Internet: www.oncolead.com

Oncology Services GmbH

Contact:
Dr. Wolfgang Beier

Lucile-Grahn-Str. 47
D-81675 München
Phone: +49 (0) 89 4142488-92
E-Mail: bd@os-europe.com
Internet: www.oncology-services.com

OMX GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Analysis, Peptide/Protein, Proteomics

The OMX GmbH develops and markets innovative technology and offers mass spectrometry services in proteomics.

Products facilitate new work flows for laboratory routines to yield highest quality results.

The laboratory disposable OMX-S has been established to ease protein sample preparation from polyacrylamide gels. The all in one device OMX-S facilitates a four step protocol in an aqueous buffer to yield highest quality peptides in one hour. Peptides are ready for MALDI- or ESI- based mass spectrometry analysis.

With OMX-MS, customers pick a single protein with OMX-S, and send the device by ordinary mail to OMX or to any laboratory to perform the sample preparation and mass spectrometry analysis.

OncoLead GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Tissue Engineering / Cell Culture, Cell Therapy, Oncology

OncoLead offers cellular screens designed to accelerate the decision making process for the development of anticancer drugs. Its information driven cell panel screen is to help scientists from all sectors to discover and develop novel and innovative anticancer medicines faster.

Oncology Services GmbH

CRO

Keywords: Oncology, Cell Therapy, Gene Therapy, Immune Therapy, Toxicology, Pharmacology, Clinical Research

Oncology Services is a full service CRO specialised in the field of Oncology. OS can provide an organically grown international network of international investigator sites and opinion leaders. From Phase I to Phase IV OS offers a range of services to assist the pharmaceutical and biotech industries in executing their clinical studies. Our services include: study planning, medical writing, patient and investigator recruitment, data management, biostatistics, site monitoring, in-house monitoring, project management, study reporting and much more. OS has clinical expertise with different drugs like: antibodies, antisense cytotoxics, hormones, radio-sensitizer, small molecules, proteins, vaccines and biologicals.

origenis GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Small Molecules, Molecular Modelling, Combinatorics, Automation, Medicinal Chemistry, Combinatorial Chemistry

origenis is a contract research organisation offering services in drug design, synthesis, and characterisation. origenis has implemented a novel drug design and discovery platform, MOREsystem® and MolMind®, based on a multi-disciplinary approach, which integrates state of the art

- molecular modelling ■ chemo-informatics ■ innovative chemistry
- high throughput secondary screening

into a seamless, fast and cost-effective process.

This interdisciplinary process is built to design and discover promising and novel target focussed compound series, with optimized properties for their pre-defined therapeutic use.

Orion Clinical Services GmbH

CRO

Keywords: Drug Development, Medical Writing, Monitoring, Clinical Research

ORION Clinical Services is a full-service clinical development organisation performing all aspects of clinical trials internationally. The company is a dynamic, proactive, multicultural CRO, offering a high quality, customised and flexible service.

ORION s European operations are managed from offices in the United Kingdom, France and Germany, while North America is managed from the USA, and Australasia from Australia. These central hubs are augmented by regional staff – who are particularly important in providing coverage of central and Eastern Europe.

Founded in 1997, ORION Clinical Services has steadily built a reputation built on quality and reliability.

Otsuka Novel Products GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Clinical Diagnostics, Antibiotics, Infectious Diseases

Otsuka Novel Products GmbH (ONPG) was founded in 2011 in Munich, as an Otsuka group company. With an international network of 145 subsidiaries and 39,000 employees in 23 countries, and regions across Europe, Asia-pacific, America and the Middle East, Otsuka researches, develops, manufactures and markets innovative and original products with a focus on pharmaceutical products for the treatment of diseases. ONPG will initially focus on infectious diseases, working in collaboration with other group companies to develop improved diagnostic tools and novel products for the treatment of tuberculosis.

origenis

Contact:
Michael Almstetter

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7801676-0
Fax: +49 (0) 89 7801676-777
E-Mail: info@origenis.de
Internet: www.origenis.de



Contact:
Dr. Jörg Rennecke

Elsenheimerstr. 61
D-80667 München
Phone: +49 (0) 2241 97398-201
Fax: +49 (0) 2241 97398-200
E-Mail: Joerg.Rennecke@orioncro.com
Internet: www.orioncro.com



Otsuka Novel Products GmbH

Contact:
Dr. Katharina Thiele

Maximilianstr. 35 a
D-80539 München
Phone: +49 (0) 162 2752199
E-Mail: kthiele@otsuka.de



Contact:
Dr. Axel F. Wenzel

Kreillerstr. 65
D-81673 München
Phone: +49 (0) 89 922003-0
Fax: +49 (0) 89 922003-90
E-Mail: office@p-ss-t.de
Internet: www.p-ss-t.de



Contact:
Dr. Martin Riffeser

Larezhausen 3
D-86567 Hilgertshausen
Phone: +49 (0) 8250 92790 10
Fax: +49 (0) 8250 92790 19
E-Mail: info@paktis.de
Internet: www.paktis.de



Contact:
Prof. Dr. Michael Wiechmann

Gewerbepark 13
D-94501 Aidenbach
Phone: +49 (0) 8543 601630
Fax: +49 (0) 8543 601649
E-Mail: info@pan-biotech.de
Internet: www.pan-biotech.de

P.S.S.T Pharma Scientific Services Team

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Devices, Nutraceuticals, Antibiotics

P.S.S.T is a small international consultancy and service provider for pharmaceutical and related industries. We accompany your drug / medical device development projects with advise and services in:

- regulatory affairs (from Clinical trials to Marketing authorisation filings, strategies+services including e.g. eCTD, User testing for PILs)
 - drug dev. project management organisation+services, quality management
 - clinical dev. (incl. scientific writing, protocol development, EUDRACT filings, IMPD etc.)
 - general services and consultancy
 - training and information provision
- P.S.S.T's range includes scientific services for all sections of pharmaceutical, medical and healthcare industry. For support in other countries we established partnerships with local CROs and consultant.

PAKTIS Antibody Service GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Transgenic Animals, Xenotransplantation, Antibody Production Service, Drug Development, Agrobiotechnology

Paktis offers business development services, providing strategic consulting and active management support to diagnostic, material and life science companies. This includes business plan evaluation, due diligence services, interim management, corporate development as well as sales and marketing. We support companies dealing with:

- Special TypiFix® ear tags for farm animals that allow easy and convenient taking of tissue samples for further analyses (Scapie, Bovine Virus, Diarrhea) or for identification of meat's origin.
- One-step ultra-quick DNA-purification columns (Nexttec).
- Polyclonal antibody production using rabbits.
- Large scale production of industrial proteins with transgenic farm animals (sheep, cattle).

PAN Biotech GmbH

BIOTECH DEVICES & REAGENTS

PAN-Biotech GmbH is a modern and innovative company with its headquarters in Aidenbach/Germany.

PAN-Biotech was founded in 1988 and is today a major producer of biotechnological products which are worldwide distributed and used in research and industry.

The product range includes new serum- and proteinfree media, sera (FCS) from different countries of origin including important special variants and a broad variety of media for cell culture. Important new product areas are our automated cell culture systems for research and industry as well as new services all around the cell culture and cell processing.

As a specialist for cell culture we can offer you nearly the complete range of products and services that you need for your successful cell culture.

PARI Pharma GmbH

MEDTECH, PHARMA INDUSTRY

Keywords: Drug Development, Drug Delivery, Analytical Chemistry, Liposomes, Antibiotics, Infectious Diseases, Respiratory Diseases

PARI Pharma focuses on the development of aerosol delivery devices and comprehensive inhalation drug development to advance aerosol therapies where drug and device can be optimized together. Based on PARI's 100-year history working with aerosols, PARI Pharma develops treatments for pulmonary and nasal administration customized with advanced delivery platforms, such as eFlow (lower respiratory) and Vibrent (upper respiratory) Technologies. PARI Pharma partners with pharmaceutical companies to develop new or improved therapies. PARI Pharma has several clinical development programs ongoing, either partnered or on its own, for cystic fibrosis, asthma, COPD, respiratory syncytial virus (RSV) infection, and treatments for lung transplant patients among other indications. PARI Pharma, a PARI Medical Holding company, is located near Munich, Germany with a major presence in the United States.

Patrys GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Infectious Diseases, Antibody, Drug Development

Patrys – the natural human antibody based company. Patrys Limited (ASX: PAB) is an Australian public company committed to the development of novel treatments for cancer and other diseases, including the commercialisation of a unique natural human antibody based therapies for the treatment of lung, pancreatic, gastric and colon cancers.

The company has the world-wide and exclusive rights to technologies that have been developed over 25 collective years of research and development and which uniquely allow for the capture, development and production of natural human antibodies for potential therapeutic applications. The technologies, and resulting deep product pipeline, have achieved positive results in animal studies in the treatment of human lung, pancreatic, gastric and colon cancers.

Patrys also currently benefits from the prior establishment of drug development collaborations with three large pharmaceutical companies.

In addition to its internal drug development projects and existing collaborations, the company has also acquired a substantial preferred equity holding in Acceptys, Inc., an American company developing the platform natural human antibody technology for the treatment of infectious diseases, including Hepatitis C, Hepatitis B, Pneumonia and Staph A.

Patrys' commercial strategy is to blend the internal development of lead product candidates while simultaneously benefiting from partnerships and collaborations aimed at developing additional product candidates from the company's deep product pipeline.



Contact:
Michael Hahn

Lochhamer Schlag 21
D-82166 Gräfelfing
Phone: +49 (0) 89 742846-831
Fax: +49 (0) 8151 279-6331
E-Mail: m.hahn@pari.de
Internet: www.pari-pharma.com



Contact:
Dr. Frank Hensel

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 230795-0
Fax: +49 (0) 931 230795-19
E-Mail: info@patrys.com
Internet: www.patrys.com



International Research Organization

Contact:

Birgit Hennecke-Janzer

Landsberger Str. 408

D-81241 München

Phone: +49 (0) 89 9999-7733

Fax: +49 (0) 89 9999-7744

E-Mail: birgit.hennecke-janzer@pfc-cro.com

Internet: www.pfc-cro.com



Contact:

Dr. Peter Remiger

Heinrich-Mack-Str. 35

D-89257 Illertissen

Phone: +49 (0) 7303 12-0

Fax: +49 (0) 7303 12-387

E-Mail: peter.remiger@pfizer.com

Internet: www.pfizer.com



Contact:

Dipl. Stat. Holger Stammer

Neumarkter Str. 18

D-81673 München

Phone: +49 (0) 89 544637-0

Fax: +49 (0) 89 544637-50

E-Mail: pharmalog@pharmalog.com

Internet: www.pharmalog.com

PFC Deutschland GmbH

CRO

Keywords: Drug Development, Endocrinology, Oncology, Rheumatology, Clinical Research, Monitoring, Medical Writing

PFC Pharma Focus (1992) is a privately owned International Research Organization located in Switzerland (HQ), Germany, Israel and India. Our core competencies are

■ Concept Development ■ Clinical Drug Development ■ International Project Management ■ Regulatory & Medical Affairs ■ Quality Assurance (QA) Services ■ Training

The combination of our service portfolio, our flexible & highly trained teams and our structured network enables the adaptation to the specific requirements of each project.

Pfizer Manufacturing Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pain, Infectious Diseases, CNS, Cardiovascular Diseases, Automation

Pfizer is a leading pharmaceutical company with headquarters in the US which develops, produces and distributes medicines and vaccines in different therapeutic fields. The product portfolio of the Pfizer Illertissen manufacturing site is specialized in solid dosage forms sold globally. We stand for a high degree of automation, system integration and innovation with an excellent supply performance. We provide innovative concepts and services in Containment Manufacturing and Wallet Packaging with a proven high quality and high service level at competitive costs. The unique expertise is proven by renowned awards achieved: Overall „Facility of the Year Award“ from „International Society for Pharmaceutical Engineering“ (ISPE) in 2008 for the fully automated containment manufacturing facility and „Healthcare Compliance Packaging Council (HCPC)-Columbus Award 2011“ for innovative compliance packaging solutions realized with wallet cards.

PHARMALOG – Institut für klinische Forschung GmbH

CRO

Pharmalog acts as a European full service CRO with an excellent reputation in clinical trials Phase I - IV since 1983. Our staff of 50 colleagues (incl. central field based monitors) conducts clinical and non-interventional trials in Germany and all EU/EEU-countries, using our pool of 9,800 investigators in clinics/ practices. Special advantages: Fast patient recruitment, motivated investigators, local monitors are native speakers. We have performed about 300 clinical trials in all medical indications for medical products/- devices/biotechnology products according to ICH- and FDA-Standards for 50 nat./internat. pharmaceutical companies. We offer full service or modular approach (e.g. monitoring, data management/statistics), reasonable pricing due to short contact ways and low overhead costs.

Pharm-Olam International Deutschland GmbH

CRO

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries.

Our global network, including the emerging markets of Central Eastern Europe, Latin America, and India enables us to recruit patients on-time for even the most challenging studies. By accelerating enrolment, we reduce costs for our sponsors and take trials to the next Phase faster.

From pre-clinical to Phase IV, POI is focused on delivering the highest quality data, achieving targeted enrolment and meeting projected timelines.

Phenoquest AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Small Molecules, Antibody, Drug Development, Pharmacology, CNS

Phenoquest is a recently founded biopharmaceutical company dedicated to the development of innovative medications for the treatment of psychiatric diseases. The lead project focuses on the development of antibody-based therapeutics for depressive disorders. Scientists at Phenoquest combine profound knowledge in the fields of neurobiology and behavioural pharmacology with substantial experience in drug-development processes in industry. Making use of this combination, Phenoquest offers services ranging from the performance of basic experiments to a multi-faceted evaluation of drug candidates.

Phytochem Referenzsubstanzen GbRmbH

BIOTECH DNA/PROTEIN ANALYTICS

Phytochem develops, produces and markets high purified substances for the pharmaceutical industry, research, analytics and authorities (main focus over 3,000 Natural Compounds). Phytochem synthesizes or isolates also Degradation products and Impurities in remedies or other rare drugs especially for customers needs with best equipment and experience. Lot specific testing is guaranteed. Phytochem products were used as Reference Standards for research and development: (Identity standard Data File: IDF) also for quality control as Primary Standards (Reference Substance Masterfile: RMF) and full documented Method Validation. Additional products and consulting services in the fields of Funcional Foods, Dietary Supplements, Food Additionals and Cosmetics are new focuses from Phytochem.



Contact:
Dr. Peter Sonner

Ingolstädter Str. 20
D-80807 München
Phone: +49 (0) 89 3750899-0
Fax: +49 (0) 89 3750899-20
E-Mail: german.office@pharm-olam.com
Internet: www.pharm-olam.com



Contact:
Dr. Markus Henniger

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 8932811-109
Fax: +49 (0) 89 8932811-111
E-Mail: service@phenoquest.com
Internet: www.phenoquest.com



Contact:
Hans Rausch

Krumbacherstr. 9
D-89335 Ichenhausen
Phone: +49 (0) 731 97205-45
Fax: +49 (0) 731 97205-46
E-Mail: phytochem@t-online.de
Internet: www.phytochem-standards.de



Contact:
Rita Fischer

Lise-Meitner-Str. 30
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 1411400
Fax: +49 (0) 8161 1411444
E-Mail: info@pieris-ag.com
Internet: www.pieris-ag.com



Contact:
Dr. Gudrun Vogeser

Hohenwarter Str. 100
D-85276 Pfaffenhofen
Phone: +49 (0) 8441 87948-30
Fax: +49 (0) 8441 87948-31
E-Mail: info@pika-weihenstephan.de
Internet: www.pika-weihenstephan.de



Contact:
Markus Fischer

St. Veit-Weg 2
D-93051 Regensburg
Phone: +49 (0) 941 69818-10
Fax: +49 (0) 941 69818-28
E-Mail: info@polyquant.com
Internet: www.polyquant.com

Pieris AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Drug Development

Pieris AG is a biopharmaceutical company engaged in the discovery and development of Anticalins® for the diagnosis and treatment of life-threatening human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of its Anticalin® candidates. Recognizing the enormous market potential of protein-based drugs, Pieris is committed to becoming an integrated drug discovery and development company.

PIKA Weihenstephan GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: PCR, Analysis, Analytical Chemistry, New Materials, Agrobiotechnology

PIKA Weihenstephan was founded in 2000 as a spin-off from the Technical University of Munich-Weihenstephan. Our focus is the fast detection and identification of microorganisms which may occur as spoilers during the production process of beer and beverages, but also in a diversity of other applications. Besides offering analyses for customers, PIKA Weihenstephan is producing and selling enrichment media and kits to be used for fast and specific process control. We are specialists in microbiology, both in conventional and in DNA analyses, especially PCR based methods. All processes at PIKA Weihenstephan are certified according to DIN EN ISO 9001:2008.

PolyQuant GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, ELISA / EIA, Analysis, Clinical Diagnostics, Proteomics, Clinical Research

Based on an innovative platform technology for the absolute multiplex quantitation of proteins, PolyQuant offers cost-effective products and services for proteomics and pharma. The technology allows large-scale acquisition of protein levels, which can be leveraged in drug discovery and biomarker validation. The QconCAT technology is particularly well suited for the rapid development of protein assays, which typically takes 12 weeks and less. QconCAT-based reference standards for a wide range of topics, such as disease states or metabolic pathways, are in the pipeline or can be custom designed on request. PolyQuant offers a full protein analytical service from arbitrary samples such as cell extracts or blood serum. Alternatively, protein quantitation products are offered for the implementation of analytical workflows at the customer. A convenient license path exists for adaptation of PolyQuant technologies to large scale customer projects.

Postnova Analytics GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices

Postnova Analytics provides complete analytical solutions for the characterization of proteins, biopolymers, macromolecules and nanoparticles (1000 Da – 10¹² Da, 10 nm – 100 µm). Postnova's products are used by all major global companies and institutions in the field of biotechnology, pharma, polymer and environmental research, e.g. DOW, BASF, Roche, MIT, TUM. Postnova's product portfolio includes systems, supplies and services based on its proprietary patented FFF technology for protein-virus, aggregate characterization, polymer-rubber characterization, nanoparticle characterization and preparative micron particle separation. Postnova has two locations in Landsberg, Germany (headquarters) and Salt Lake City, Utah, USA.

PPD Germany GmbH & Co. KG – Branch office

CRO

Keywords: Drug Development, Devices, Clinical Research, Logistics, Monitoring, Medical Writing

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppd.com

PreSens Precision Sensing GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Drug Development, Tissue Engineering / Cell Culture, Analytical Chemistry

PreSens is a world leader in the field of chemical-optical sensors. It develops, manufactures and distributes sensor systems for Biotech & Pharma, Food & Beverage, Scientific Applications and Medical Devices. PreSens focuses on parameters which are essential for life: oxygen, pH and carbon dioxide. Over the last 14 years, we have delivered our special microsensors and our non-invasive systems for various applications such as respirometry, biology, or medical research. We also offer imaging Solutions: 2D-sensing of oxygen-, pH- and CO₂-distributions. PreSens is certified EN ISO 13485:2003 + AC:2007 and ISO 9001:2008. Together with its partners it offers full service in Europe, USA and Asia.



Contact:
Dr. Thorsten Klein

Max-Planck-Str. 14
D-86899 Landsberg a. L.
Phone: +49 (0) 8191 428181
Fax: +49 (0) 8191 428175
E-Mail: info@postnova.com
Internet: www.postnova.com



Contact:
Dr. Peter Oberosler

Hansastr. 32
D-80686 München
Phone: +49 (0) 89 57877-0
Fax: +49 (0) 89 57877-400
E-Mail: genl.info@ppdi.com
Internet: www.ppd.com



Contact:
Achim Stangelmayer

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 94272-100
Fax: +49 (0) 941 94272-111
E-Mail: info@presens.de
Internet: www.presens.de



Contact:
Dr. Christoph Burdack

Gmunder Str. 37-37a
D-81379 München
Phone: +49 (0) 89 4521308-0
Fax: +49 (0) 89 4521308-22
E-Mail: contact@priaxon.com
Internet: www.priaxon.com



Contact:
Esther Gleede

Am Klopferspitz 19
D-82152 Martinsried/München
Phone: +49 (0) 89 5173949-0
Fax: +49 (0) 89 5173949-9
E-Mail: info@prionics.de
Internet: www.prionics.de



Contact:
Dr. Christian Philipp

Ernsbergerstr. 5a
D-81241 München
Phone: +49 (0) 89 580081-20
Fax: +49 (0) 89 580081-22
E-Mail: info@probior.com
Internet: www.probior.com

Priaxon AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Peptide/Protein, Oncology, Proteomics, Small Molecules, Drug Delivery, Drug Development

Priaxon is an emerging pharmaceutical company building a pipeline of novel drug candidates in different therapeutic fields, but mainly focusing on protein-protein interactions in oncology and other diseases. The goal is to discover and develop candidates for validated but hard-to-drug targets using two orthogonal drug discovery platforms. In January 2009 a collaboration agreement for the development of mdm2/p53-inhibitors with Boehringer Ingelheim was signed.

We open up a new dimension in drug discovery by a unique combination of proprietary chemoinformatic tools with innovative synthetic chemistries. As a result Priaxon rationalizes and accelerates the whole drug discovery process.

PRIONICS DEUTSCHLAND GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Clinical Diagnostics, Agrobiotechnology, ELISA / EIA, Infectious Diseases

PRIONICS DEUTSCHLAND GmbH, founded in September 2005, is responsible for the marketing, sales and technical support of innovative tests for the early detection of important zoonotic diseases of production animals. The company provides its customers in Germany and Austria with a portfolio of more than 50 diagnostic kits, accessories and biochemicals.

PRIONICS offers diagnostic solutions for all major animal disease areas including TSE, BVDV, FMD, TB, ParaTB, CSF, Salmonella, Trichinella and Blue Tongue. PRIONICS is also the distributor for all Ingenasa products.

The parent company Prionics AG, Switzerland, is one of the world's leading providers of farm animal diagnostics and a recognized centre of expertise in BSE and prion diseases.

probior GmbH

BIOTECH DEVICES & REAGENTS

probior distributes products for biotechnology, medicine and pharmacy. We carry a wide selection of high quality reagents and assay kits for High Throughput Screening manufactured by our Japanese partner Dojindo.

We offer fast and convenient assay kits for protein labeling, DNA/RNA isolation, cell viability/cytotoxicity and oxidative stress. There are also high-purity reagents available e.g. for cell staining, NO research, diagnostic analysis, and also Self Assembled Monolayer, HPLC reagents, detergents, good's buffer.

Project Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Small Molecules, Peptide/Protein, Antibody, Liposomes, Drug Delivery, Drug Development

Project Pharmaceuticals transforms proteins, peptides and delicate small molecules into pioneering drugs. PJP adds value to client's bio-therapeutics by applying an innovative concept of development called Advaceutics. Based on the Advaceutics concept, PJP designs optimized formulations and delivery systems that are stable, convenient and safe. Tailored to these optimized systems the company develops cost-effective manufacturing processes and transfers those from its own pilot labs to large-scale manufacturing. PJP makes sure that investigational products, biogenerics as well as „bio-better“ are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing.

Proteros biostructures GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: 3 D Structural Analysis, Fine Chemicals / Reagents, Small Molecules, Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Oncology

Proteros is Europe's most experienced and largest biotechnology company in the field of X-ray protein structure analysis and a leading service partner for fully integrated lead discovery. Successful in business since 1998, Proteros collaborates with more than 80 international pharma, biotech and agricultural companies. Focusing on services, Proteros provides protein crystallography, a tailor-made compound library in conjunction with unique assay technologies and medicinal chemistry capabilities to generate novel lead compounds for a variety of therapeutically relevant target proteins. Flexible business models, no royalty requirements, and the transfer of Intellectual Property to the customer, renders Proteros an ideal partner of the Pharmaceutical and Biotech Industry.

QinLAB Diagnostik GbR

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Medicinal Chemistry, Automation, Diabetics, Hematology

QinLAB diagnostics was founded in January 2008 as Baier & Dr. Schlüter GbR Vertriebsgesellschaft Life Sciences. Vision of the new company is to establish high-quality in-house laboratory diagnostics in small hospitals, clinics and larger private medical centers (MVZs). An overall lab concept is built that includes the customers wishes and needs and that result in innovative, economic and patient-friendly diagnostics on a high level. Besides the classical clinical chemistry and drugs-of-abuse assay systems Qinlab develops and offers innovative single test assays which are suitable for the point-of-care (POCT)-market.



Contact:
Dr. Andreas Schütz

Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 452289-700
Fax: +49 (0) 89 452289-717
E-Mail: info@project-pharmaceutics.com
Internet: www.project-pharmaceutics.com



Contact:
Dr. Torsten Neufeind

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700761-0
Fax: +49 (0) 89 700761-15
E-Mail: business@proteros.com
Internet: www.proteros.com



Contact:
Dr. Volker Schlüter

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 326051-66
Fax: +49 (0) 89 326051-67
E-Mail: info@qinlab.de
Internet: www.qinlab.de



Contact:
Dr. Bernhard Schirm

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 700763-16
Fax: +49 (0) 89 700763-29
E-Mail: info@quattro-research.com
Internet: www.quattro-research.com



Contact:
Stefan Schöffel

Mühlweg 2
D-82054 Sauerlach
Phone: +49 (0) 8104 8980-13
Fax: +49 (0) 8104 8980-99
E-Mail: stefan.schoeffel@quintiles.com
Internet: www.quintiles.de



Contact:
Dr. Gerd Juhl

Zuccalistr. 19
D-80639 München
Phone: +49 (0) 89 17850012
E-Mail: gerdjuhl@t-online.de
Internet: www.quintiles.com

quattro research GmbH

BIOTECH BIOINFORMATICS

quattro research GmbH develops and markets software solutions for the management and analysis of chemical and biological data in drug discovery and development. quattro's suite of products contains solutions for registering new chemical substances, for managing biological assay data, for stock management particularly for research laboratories, and an electronic laboratory notebook. The efficiency of the quattro products is a result of the integrated Chemistry Engine, which facilitates work with chemical structures in all areas of the software package. The quattro's suite has been developed under realistic conditions, in close collaboration between quattro research's developer team and scientists in the laboratory. In addition to the quattro's suite, quattro research also offers its customers consultancy services and specific system solutions to manage chemical and biological data.

QUINTILES GmbH

CRO

Keywords: [Monitoring](#), [Medical Writing](#), [Clinical Research](#)

Quintiles' Product Development, Commercialization and Novaquest Development divisions help improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has about 17,000 employees in offices in 50 countries and is the world's leading pharmaceutical services organization. For more information visit the company's Website at www.quintiles.com

QUINTILES Consulting

CRO

Quintiles is a leading international consultancy and CRO offering comprehensive services to the worldwide medical device industry. Our services include regulatory affairs, quality assurance, standards, pricing and reimbursement, authorized representation, clinical trial management, languages and labeling, etc. These services are provided by highly experienced, locally based consultants coming from competent authorities, notified bodies, European Commission, and the health care industry. They have academic qualifications in medicine, pharmacy, chemistry, law, engineering, languages, business management, etc. Many of the consultants are among the top EC experts on certain issues and have contributed to the development of the European directives and guidelines in such areas as vigilance, drug/device borderline issues, classification, and animal and human origin materials. Quintiles key strength is being able to understand the issues of small and start up companies, the needs of large multinational corporations, and to provide a customized approach to both. Quintiles offices are in B, D, F, I, S, UK and AUS. Quintiles is represented in 30 countries.

R&D Biopharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Small Molecules, Natural Compounds, Drug Development

R&D-Biopharmaceuticals is a biopharmaceutical company focusing on the pre-clinical and clinical development of unique small molecules deriving from natural products for diseases with unmet medical need. The Company has exclusive access to the natural product class of the Tubulysins discovered by Prof. Höfle and Prof. Reichenbach from the Gesellschaft für Biotechnologische Forschung in Braunschweig and to proprietary second generation Epothilones, a highly promising new drug class for the treatment of cancer. The Company is pursuing an active partnering strategy for further development of these compound classes. They are suited especially for conjugation and targeting approaches.

RadPharm Europe GmbH

CRO

Keywords: Drug Development, Clinical Research, Oncology

RadPharm is an imaging core lab, managing the complete imaging segment of clinical trials for the global pharmaceutical, biotechnology and medical device industries. Our expertise spans Phase I through IV and all major therapeutic areas. We are specialized in oncology trials but also do cardiovascular, musculoskeletal, CNS and medical device studies. Our radiologists, nuclear physicians and medical oncologists interpret data from all major modalities, including CT, MRI, X-ray, SPECT, Ultrasound, PET and PET/CT in a centralized and independent way. We assist in planning, tracking and implementation of studies and provide medical expertise, regulatory know-how and validated technologies.

RAPID Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Research, Devices, Bone / Joint Diseases, Cardiovascular Diseases, CNS, Oncology

RAPID Biomedical GmbH is specialised in the development of probeheads for MRI and NMR spectroscopy. The company cooperates with research institutes, hospitals and MR system manufacturers worldwide. Our products include 1H MR coils for clinical studies at all magnetic field strengths and for all organs. We supply multi-nuclear MR-probeheads for combined MRI and MRS in clinical and basic science investigations. This development has been extended to a 7T whole body scanner.

Our recent work concentrates on multi array coils for parallel MRI both for human as well as for animal studies.

Our sister company RAPID MR International, LLC (www.rapidmri.com), situated in Columbus, Ohio, is contact partner for customers from the United States, Canada and South America.

Whenever you need an optimised MRI coil for your application, please contact us and we will come up with a proposal.



Contact:
Dr. Wolfgang Richter

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700764-90
Fax: +49 (0) 89 700764-99
E-Mail: wolfgang.richter@rdbiopharma.de
Internet: www.rdbiopharma.de



Contact:
Dr. Karoline Meures

Ottostr. 3
D-80333 München
Phone: +49 (0) 89 20244497-0
Fax: +49 (0) 89 20244497-9
E-Mail: meures@radpharm.com
Internet: www.radpharm.com



Contact:
Ulrike Haase

Ketteler-Str. 3-11
D-97222 Rimpar
Phone: +49 (0) 9365 8826-0
Fax: +49 (0) 9365 8826-99
E-Mail: info@rapidbiomed.de
Internet: www.rapidbiomed.de



Contact:
Dr. Albrecht Pfahler

Münchner Freiheit 18
D-80802 München
Phone: +49 (0) 89 33039921-0
Fax: +49 (0) 89 33039221-30
E-Mail: info@remark-pharma.de
Internet: www.remark-pharma.de



Contact:
Dr. Ortwin Faff

Carl-von-Linde-Str. 40
D-85716 Unterschleißheim
Phone: +49 (0) 89 321419-60
Fax: +49 (0) 89 321419-59
E-Mail: info@retrotech-online.de
Internet: www.retrotech-online.de



Contact:
Jörg Rothgänger

Sedanstr. 27
D-97082 Würzburg
Phone: +49 (0) 931 4173329
Fax: +49 (0) 931 4173348
E-Mail: info@ridom.de
Internet: www.ridom.de

REMARK GmbH Pharmservices & Consulting

CRO

Keywords: Drug Development, Clinical Research, Medical Writing

REMARK is a privately owned pharma services and consulting company founded in 1999. Quality and speed are the decisive factors in the success of a company involved in the healthcare market. To reach your goals our business unit Clinical Research offers the following services:

- Strategic Consulting ■ Project Management ■ Quality Assurance
- Pharmacovigilance Services ■ Training / Coaching ■ Medical Writing
- Due Diligence

Together with our unit Pharma Marketing, REMARK bridges the gap between development and marketing. For more information visit our web site at www.remark-pharma.com

Retro-Tech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Small Molecules, Xenotransplantation, Natural Compounds, Automation, Devices, Infectious Diseases, Clinical Diagnostics

Retro-Tech focuses on technology and product development based on magnetic beads (core technology) for diagnostics of retroviruses (HIV, HTLV, MLV, Hepatitis, other) and therapy of viral diseases (AIDS, Leukemia, Hepatitis, Autoimmune), with special focus on retroviral enzymes (reverse transcriptase, integrase), receptors (CD4, chemokine) and regulatory proteins. Services offered include Biosafety & Quality testing of bio-pharmaceuticals, organs, cell banks, blood products, antiviral drug screening by cellular and biochemical assays, toxicity testing, kinetic and inhibition studies on mechanism of action.

The products currently offered are retroviral diagnostic kits, reagents & accessories, e.g. assay kits for reverse transcriptase (RTA), magnetic bead separation and handling devices.

Ridom GmbH

BIOTECH BIOINFORMATICS

Ridom supplies highly customized and therefore extremely user-friendly software for DNA sequence-based diagnostics.

The company was started in January 2003 by research scientists who still have close links to the University. Therefore, the company's motto is „from scientists for scientists“. As a highly specialized company, which is owned by the founders, Ridom reacts flexible and fast to their customers needs.

Major products are Ridom SeqSphere and Ridom StaphType.

Ritter GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Pharmacogenetics, PCR, Genomics, ELISA / EIA, Automation, Devices

As a very productive brand-supplier, Ritter provides over 40 years of know-how in developing and producing fine high-precision plastic parts. Ritter produces in accordance to the local quality standards only in own production plants. The company is DIN ISO 9001:2000 certified and works according the DIN EN ISO 13485:2003. The 200 employees are engaged to provide packaging solution for construction chemicals (cartridges), laboratory and medical products (liquid handling systems, products for dialysis and robotic systems).

Roche Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Automation, ELISA / EIA, PCR, Antibody, Peptide/Protein

Roche Diagnostics GmbH is part of Roche, Switzerland. Roche is a world leader in in-vitro diagnostics, medicines for cancer, transplantation and a market leader in virology. At Penzberg, Roche operates one of the largest biotechnology facilities in Europe for research, development and production of biotechnology based diagnostics and active pharmaceutical ingredients. The portfolio comprises test systems for the life science market, diagnosis, patient stratification and therapy monitoring. Pharma specializes in therapeutic human proteins with focus on monoclonal antibodies and biomarkers for oncology. Recently, stem cell research was added to the site portfolio.

Sandoz Biopharmaceuticals

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, 3 D Structural Analysis, Pharmacokinetics, Peptide/Protein, Clinical Research

Sandoz, the generic pharmaceuticals division of Novartis, is a worldwide leader in generics. Sandoz is also the pioneer and global leader in the rapidly emerging market for biosimilars, also known as follow-on biologics (or biopharmaceuticals). Sandoz developed and launched both, the first-ever biosimilar product in the EU (recombinant human growth hormone in 2006) and the first complex - glycosylated - biosimilar (recombinant human erythropoietin alfa) a year later. With the EU approval and launch in 2009 of biosimilar G-CSF (filgrastim), Sandoz is the only company with three products on the market in Europe. Sandoz currently employs more than 23.000 people in over 130 countries across the globe. The company's global headquarters is based in Holzkirchen/Bavaria, in the south of Munich.



Contact:
Kerstin Lenke

Kaufbeurer Str. 55
D-86830 Schwabmünchen
Phone: +49 (0) 8232 5003-0
Fax: +49 (0) 8232 5003-10
E-Mail: info@ritter-online.de
Internet: www.ritter-medicalcare.de



Contact:
Barbara Jopp-Heins

Nonnenwald 2
D-82377 Penzberg
Phone: +49 (0) 8856 60-0
Fax: +49 (0) 8856 60-3896
E-Mail: barbara.jopp-heins@roche.com
Internet: www.roche.de



Contact:
Isabell Remus

Industriestr. 18
D-83607 Holzkirchen
Phone: +49 (0) 8024 908-0
E-Mail: isabell.remus@sandoz.com
Internet: www.sandoz-biosimilars.com



Contact:
Iris Margraf

Fraunhoferstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 8565-1800
Fax: +49 (0) 89 8565-1819
E-Mail: info@sciltechnology.com
Internet: www.sciltechnology.com



Contact:
Dr. Marcus Meyr

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 455799-0
Fax: +49 (0) 821 455799-22
E-Mail: info@sension.eu
Internet: www.sension.eu



Contact:
Eva Metzger

Joh.-Seb.-Bach-Str. 7
D-85591 Vaterstetten
Phone: +49 (0) 8106 8887
Fax: +49 (0) 8106 301565
E-Mail: service@sequiserve.de
Internet: www.sequiserve.de

Scil Technology GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Drug Delivery, Peptide/Protein, Bone / Joint Diseases

Scil Technology develops products for bone and cartilage regeneration in dental and orthopaedic indications. Scil's products consist of growth-stimulating biomolecules (protein-based growth factors) and biomaterials being completely biodegradable and biocompatible. These innovative products are tailor-made to meet the specific requirements of each target indication and will be applied locally to induce or enhance tissue regeneration. In the dental field, Scil Technology develops products for dental bone augmentation, periodontal disease and dental implantology. Orthopaedic products are developed for spinal fusion, trauma, cartilage defects and osteoarthritis.

Sension GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Antibody, Autoimmune Diseases, ELISA / EIA, Clinical Diagnostics

Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medical diagnostics, reproductive management in agriculture, and in the monitoring of samples for mold.

Also technologies for label production to prevent products from counterfeiting are realized.

Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required.

SequiServe GmbH

BIOTECH DNA/PROTEIN ANALYTICS

SequiServe offers the following custom services in molecular biology: DNA-sequencing (plasmids, PCR-products, BACs, PACs, primer-walking). Purification of PCR products.

SERVIER Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Pharma Industry Drug Development, Clinical Research, Bone / Joint Diseases, Cardiovascular Diseases, CNS, Diabetics

Following its international success, SERVIER Deutschland GmbH has established an independent branch in Munich since 1996. SERVIER is one of the very dynamic pharmaceutical companies in Germany, experiencing a growth-rate in double figures on average. The reason for this is not only the approved and merchandised drugs but also new, innovative products. The success of the new drugs is supported by the SERVIER Forschung und Pharma-Entwicklung GmbH (also in Munich), which manages many different projects throughout the German-speaking region.

SGS M-Scan GmbH – Mass Spectrometry Consultants and Analysts

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Analysis, Analytical Chemistry, Peptide/Protein, Antibody, Proteomics, Pharmacokinetics

SGS M-Scan, the world leaders in the application of advanced mass spectrometry techniques for protein and carbohydrate structural analysis, comprises of four analytical laboratories in Europe and the US. The German Laboratory SGS M-Scan GmbH is based in the „Biotech Park“ Freiburg. The SGS M-Scan laboratories provide GLP/GMP compliant analyses for bio/pharmaceuticals, from small molecules/NME's through to peptides, proteins and glycoproteins such as monoclonal antibodies, including biosimilar products at all stages of the product development pipeline. Analyses range from impurity analysis, de-novo sequence determination, to full characterisation to appropriate FDA/ICH guidelines (ICH Q6B).

Sigma-Aldrich Chemie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Antibody, Genomics, CNS, Small Molecules, Knock Out, PCR

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide.



Contact:
Horst Stemmer

Elsenheimer Str. 53
D-80687 München
Phone: +49 (0) 89 57095-01
Fax: +49 (0) 89 57095-126
E-Mail: info@de.netgrs.com
Internet: www.servier.de



Contact:
Dr. Jörg Müller

Hauptstr. 68
D-82008 Unterhaching
Phone: +49 (0) 89 665084-52
Fax: +49 (0) 89 665084-54
E-Mail: services.de@m-scan.com
Internet: www.m-scan.de

SIGMA-ALDRICH®

Contact:
Dr. Udo Sticher

Eschenstr. 5
D-82024 Taufkirchen
Phone: +49 (0) 89 6513-1504
Fax: +49 (0) 89 6513-1399
E-Mail: udo.sticher@sial.com
Internet: www.sigma-aldrich.com




Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: kerek@sinatur.net
Internet: www.sinatur.net



Contact:
Dr. Christian Thirion

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700961-999
Fax: +49 (0) 89 700961-998
E-Mail: info@sirion-biotech.de
Internet: www.sirion-biotech.com



Contact:
Dipl. Ing. Ulrich Schubert

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 854665-13
Fax: +49 (0) 89 854665-15
E-Mail: ulrichschubert@smartecbio.de
Internet: www.smartecbio.de

SiNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Diabetics, Metabolic Diseases

SiNatur owns the patent rights for the structure, preparation and medicinal applications Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biologically active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC50 in the nanomolar range.

Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact.

SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity.

SIRION BIOTECH GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Gene Transfer, Drug Development, Drug Delivery, Knock Out, RNAi & Antisense

SIRION BIOTECH GmbH is a biotech company that produces genetically modified cells and is a technology provider in the area of viral vector systems. The company founded in 2006 is located in the Innovations- und Gründerzentrum Biotechnologie IZB in Martinsried near Munich. The expert in RNAi technology offers a wide range of more than 100 products and services. Using state-of-the-art techniques and assay systems the company offers reliable lead-through service projects in target validation, screening and drug discovery. With its strong expertise in primary cell handling isolation, and cell line generation SIRION BIOTECH serves as a partner for optimized drug development for pharmaceutical and biotech companies.

SMARTEC IngenieurBüro

BIOTECH DEVICES & REAGENTS, MEDTECH

Keywords: Devices, Automation, Chip / Array Technology, PCR, Tissue Engineering / Cell Culture

Smartec IngenieurBüro is your competent partner for individual system approaches and instrument development in the biological laboratory. Smartec IngenieurBüro convinces with know-how within the ranges biotechnology, analytics, genetic engineering, micro technology as well as micro fluidic. Smartec IngenieurBüro solves tasks of instrumentation for molecular and immunological process engineering. Smartec IngenieurBüro supports you from the idea to all stages of the product. Smartec IngenieurBüro offers complete solutions, consisting of mechanics, optics, electronics, as well as firm- and software of a hand. Smartec IngenieurBüro consists of engineers and physicists which are predominantly settled in the ranges Research and Development (R&D) of bioanalytic systems.

SpheroTec GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Tissue Engineering / Cell Culture

SpheroTec is a biotech company using 3D cell-culture systems that have similar properties to microtumors in cancer patients. On this basis, SpheroTec offers pharmaceutical and biotech companies the opportunity to conduct functional tests of drug candidates for oncology in close to real conditions. This permits the early identification of promising substances and gives a broad profile of the effects of substances. The process also allows the definition of the kinds of tumors for which a substance or a combination of substances has the best clinical efficacy.

SSS International Clinical Research GmbH

CRO

Keywords: Clinical Research, Medical Writing, Monitoring, Respiratory Diseases, Oncology, Cardiovascular Diseases, Hematology

SSS International Clinical Research provides cost-effective, high quality, comprehensive, and internationally integrated services to develop and commercialize the products of our clients throughout Europe in the pharmaceutical and biotechnology industries. From experienced project planning and clinical trials management to innovative web-based monitoring tools and expert consulting, our products and services have been proven for more than a decade and through many successful projects. From Phase II dose-finding studies to Phase IV post-marketing studies, and everything in between, we offer a broad range of therapeutic expertise to meet your clinical trial needs. We have the international experience and local presence to promote your success.

Süd-Chemie AG

CHEMICAL INDUSTRY & INDUSTRIAL BIOTECHNOLOGY

Süd-Chemie is a global leading specialty chemicals company. The common denominator of all Süd-Chemie products is the efficient use of natural resources to enhance the quality of life for humans and the environment. Key markets served by its Adsorbents Division include the consumer goods, packaging and foundry industries, as well water treatment. Products manufactured by the Catalysts Division offer solutions for the chemical, petrochemical and refinery industries, for energy storage, hydrogen production and off-gas purification. The main focus of Süd-Chemie's industrial biotechnology activities is on bio-catalysis and bio-refining. The company develops energy-efficient processes for the manufacture of biomass-based chemicals and fuels. Süd-Chemie has for instance developed a process which uses enzymatic hydrolysis followed by fermentation to produce second generation cellulosic bio-ethanol from wheat straw or other agricultural production residue.



Contact:
Annika Jäger

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 5404134-0
Fax: +49 (0) 89 5404134-20
E-Mail: ajaeger@spherotec.com
Internet: www.spherotec.com



Contact:
Dr. Michael Sigmund

Landsberger Str. 23/25
D-82110 Germering
Phone: +49 (0) 89 8006500
Fax: +49 (0) 89 800650555
E-Mail: michael.sigmund@cro-sss.eu
Internet: www.cro-sss.eu



Contact:
Dr. Andre Koltermann

Staffelseestr. 6
D-81477 München
Phone: +49 (0) 89 710661-0
Fax: +49 (0) 89 710661-122
E-Mail: info.crd@sud-chemie.com
Internet: www.sud-chemie.com

SuppreMol

Contact:
Prof. Dr. Peter Buckel

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 30905068-0
Fax: +49 (0) 89 30905068-68
E-Mail: info@suppremol.com
Internet: www.suppremol.com

Syntacoll

Contact:
Dr. Alexandra Dietrich

Donaustr. 24
D-93342 Saal/Donau
Phone: +49 (0) 9441 68600
Fax: +49 (0) 9441 686030
E-Mail: info@syntacoll.de
Internet: www.innocoll.de



TEMMLER

Contact:
Dr. Claudio Lorck

Weihenstephaner Str. 28
D-81673 München
Phone: +49 (0) 89 427299-01
Fax: +49 (0) 89 427299-1000
E-Mail: info@temmler.eu
Internet: www.temmler.de

SuppreMol GmbH

BIOTECHTHERAPEUTICS & DIAGNOSTICS

Keywords: Autoimmune Diseases, Rheumatology, Antibody, Drug Development, Peptide/Protein

SuppreMol is a clinical stage biotech company developing first-in-class biopharmaceutical drugs based on a new therapeutic principle. Development candidates comprise therapeutic proteins and antibodies with the potential to cure autoimmune diseases instead of only treating symptoms.

SuppreMol is developing its lead product SM101 in proof-of-concept studies in Primary Immune Thrombocytopenia (ITP), an orphan disease, as well as Systemic Lupus Erythematosus (SLE). The company is further evaluating more common and mainstream diseases such as Rheumatoid Arthritis, Multiple Sclerosis (MS), and Chronic Obstructive Pulmonary Disease (COPD). SuppreMol is a spin-off from the laboratories of the Nobel Laureate Prof. Robert Huber of the Max Planck Institute of Biochemistry in Martinsried, Germany.

Syntacoll GmbH

PHARMA & CHEMICAL INDUSTRY

Syntacoll is the manufacturing division of Innocoll, Inc. and produces clinical supply or commercial product to its marketing partners and to Innocoll's two other divisions, Innocoll Technologies and Innocoll Pharmaceuticals.

Using proprietary manufacturing processes, Syntacoll converts raw collagen material and incorporates medicinal compounds yielding finished pharmaceutical product in the form of a sponge or membrane. This system forms the basis of Innocoll's lead collagen-based technology, CollaRx. The sponge or membrane product format is a unique way to locally deliver a wide variety of medicinal compounds and is fully biodegradable and resorbable. The sponge and the membrane formats can be implanted at the time of surgery or applied topically to a chronic, acute or traumatic wound. Delivering drug locally to the site of action has a number of benefits, including the safe delivery of higher doses than could be achieved through systemic routes and avoidance of systemic side effects.

Temmler Werke GmbH

PHARMA & CHEMICAL INDUSTRY

The Temmler Group, with its 7 production sites in Europe, is one of the largest providers of contract services in the pharmaceutical environment. Temmler has a wide experience in formulation development of finished solid, semi-solid and liquid dosage forms, in manufacture, packaging, blinding, distribution and return handling of clinical trial supplies, in the optimization of established manufacturing processes as well as in the contract manufacture of medicinal products with marketing authorization, supplemented by Quality Control and Analytical services.

Temmler offers services from stand-alone processes according to customer specifications, to strategic services comprising the entire supply chain.

THERMOSOME GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Liposomes, Oncology

Founded in 2010, Thermosome is a biotech company developing new drug delivery systems for therapeutic and diagnostic agents based on temperature-sensitive liposomes.

The company is using a novel liposome technology based on synthetic phosphatidyloligoglycerols that provides liposomes with prolonged circulation half-life and ultra-fast release properties. Drug release shall be triggered by the application of energy from an exogenous or endogenous device (e.g. regional hyperthermia, high intensity focused ultrasound) to the patient receiving the treatment. Thermosome will make use of its platform technology in order to not only enhance the efficacy of the drug but also to reduce systemic side effects.

TILL Photonics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Microscopy, Automation

TILL Photonics GmbH, founded in 1993, develops and markets live cell fluorescence microscopes for research applications as well as routine, applied science and diagnostics. The microscopes based on patented technology for confocal and conventional fluorescence microscopy, were developed in collaboration with the Bioluminescence Zentrum (BIZ) at the Ludwig-Maximilians-Universität (LMU) in Munich and are manufactured in Germany. The success of TILL Photonics in the scientific as well as the routine markets is based on a competent and experienced team providing reliable instrumentation for automated routine applications as well as collaboration with international research institutions.

TILL provides extremely flexible, modular systems for all current and future microscopy standards – and complete turnkey solutions for imaging and photometry systems. The majority of TILL's customers are found in the fields of neurobiology, cell biology, biomedicine and pharmacology.

The company's headquarters are located in the Munich BioRegio (Germany), TILL Photonics' US operation is based in Rochester, NY.

THERMOSOME GmbH

Contact:
PD Dr. Lars Lindner

Silberblattstr. 18a
D-81377 München
Phone: +49 (0) 179 5368303
Fax: +49 (0) 89 71668340
E-Mail: info@thermosome.com
Internet: www.thermosome.com



Contact:
Erika Weber

Lochamer Schlag 21
D-82166 Gräfelfing
Phone: +49 (0) 89 895662-0
Fax: +49 (0) 89 895662-101
E-Mail: info@till-photonics.com
Internet: www.till-photonics.com



Contact:
Dr. Elfriede Müller

Fraunhoferstr. 18a
D-82152 Martinsried
Phone: +49 (0) 89 856512-83
Fax: +49 (0) 89 856512-86
E-Mail: info@toplab.de
Internet: www.toplab.de

TRANSCATHETER TECHNOLOGIES

Contact:
Dr. Wolfgang Goetz

Josef-Engert-Str. 11
D-93051 Regensburg
Phone: +49 (0) 170 63099-20
Fax: +49 (0) 941 63099-897
E-Mail:
wolfgang.goetz@transcatheter-
technologies.com
Internet: www.transcatheter-technologies.com



Contact:
Brigitte Stempfer

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 324266-0
Fax: +49 (0) 89 324266-199
E-Mail: mail@trionpharma.de
Internet: www.trionpharma.de

TopLab GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Analysis, Proteomics

TOPLAB GmbH is a leading ISO 9001 certified service provider with high end research facilities for proteomics, protein analytics, target and biomarker discovery and validation. The company has outstanding expertise in proteome analysis, protein identification and characterisation with more than 15 years experience. A portfolio of proprietary technologies has been developed and/or licensed that is able to significantly enhance the rate of discovery of potential biomarkers and novel therapeutic targets. The vision of TOPLAB is to support our clients from pharma, biotech and academia with highest quality standards, modern technologies and an experienced and highly motivated team, to achieve confident results in compliance with the timelines of our customers with calculable costs.

Transcatheter Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Cardiovascular Diseases

TRANSCATHETER TECHNOLOGIES develops medical devices aimed at reducing the trauma of open-heart valve surgeries. Its re-positionable transcatheter aortic valve system TRINITY is at the forefront of next generation valve implantation technology. The new technology makes it possible to implant aortic valve prostheses without the need for traumatic open-heart surgery.

Key features of TRINITY allow the physician to reposition the valve during implantation. ZERO PRESSURE CRIMPING™ technology protects the fragile biological leaflets when the stent is folded and expanded. This will increase the safety and durability of the valve prosthesis and will allow for implantation in younger patients.

TRION Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Immune Therapy, Antibody, Drug Development

TRION Pharma GmbH is a privately held biopharmaceutical company that has established a novel approach to cancer immunotherapy. The Company's unique family of trifunctional therapeutic antibodies, called Triomab®, simultaneously activates multiple immune defense mechanisms against cancer. Removab® (catumaxomab), the most advanced candidate of the Triomab® family, received EU market approval for the intraperitoneal treatment of malignant ascites. Removab® is not only the first drug indicated for the treatment of malignant ascites, but also the first approved bispecific, trifunctional antibody worldwide. TRION employs about 90 people in Munich for development and cGMP-manufacturing of its antibody products.

TRION Research GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Drug Development, Antibody Production Service, Immune Therapy

TRION Research GmbH, founded in 1998, is a Biotech research company and a strategic partner of TRION Pharma GmbH focusing on the generation of novel Triomab® antibody candidates and the support of non-clinical and clinical development of Triomab® antibodies. The company offers Immunomonitoring Service, special antibody conjugation support, additional analytical service in tumor biology and further analytical support for reagent control to investigators, study sponsors and CROs.

The core competences of the company are:

- Immunomonitoring and logistical support for clinical and non-clinical studies
- Supply of purified antibodies (labeled and unlabeled)
- Development of immunological assays

Tripes International

BIOTECH BIOINFORMATICS

Keywords: Molecular Modelling, 3 D Structural Analysis, Medicinal Chemistry, Combinatorial Chemistry

Tripes International is a global leader in innovative scientific solutions that enable life science researchers to improve the efficiency of their molecular discovery efforts. Established in 1979, Tripes was the first company to bring scientific computational drug discovery capabilities to the pharmaceutical, chemical and food design industries, and today helps a broad range of companies and research facilities accelerate the identification and optimization of new compounds that have the potential to become new products in the drug, food, flavoring and fragrance markets. Headquartered in St. Louis, Missouri, Tripes International serves more than 1,000 customers spanning over 46 countries. Tripes is wholly owned by Vector Capital, a San Francisco-based private equity boutique.

U3 Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Antibody, Drug Development

U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Established in July 2001, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Professor Axel Ullrich. Since May 2008 U3 Pharma belongs to DAIICHI Sankyo Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide and no. 3 in Japan. Being part of this global environment, U3 Pharma is striving to provide patients around the world with innovative antibody-based therapeutics.



Contact:
Brigitte Stempfer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700766-0
Fax: +49 (0) 89 700766-11
E-Mail: mail@trionresearch.de
Internet: www.trionresearch.com



Contact:
Dr. Ulrike Uhrig

Martin-Kollar-Str. 17
D-81829 München
Phone: +49 (0) 89 451030-0
Fax: +49 (0) 89 451030-30
E-Mail: ulrike.uhrig@certara.com
Internet: www.tripes.com



Contact:
Dr. Johannes Bange

Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 8103-9100
Fax: +49 (0) 89 8103-9199
E-Mail: information@u3pharma.com
Internet: www.u3pharma.com



Contact:
A. N. Kraupa

Fraunhoferstr. 11
D-82152 Martinsried
Phone: +49 (0) 89 8575200
Fax: +49 (0) 89 8561304
E-Mail: info@uniequip.de
Internet: www.uniequip.com



Contact:
Dr. Reinhard Zeidler

Marchioninstr. 25
D-81377 München
Phone: +49 (0) 89 70992-96
Fax: +49 (0) 89 70992-25
E-Mail: info@vaecgene.de
Internet: www.vaecgene.de



Contact:
Christian Wandersee

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 359099-0
Fax: +49 (0) 931 359099-12
E-Mail: office@vasopharm.com
Internet: www.vasopharm.com

UniEquip Laborgerätebau & Vertrieb GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices

UniEquip provides production and distribution of biotech instruments, e.g. AutoGen (fully automated nucleic acid extraction), highly advanced gel documentation systems, nucleic acid purification kits, ThermoCycler and most typical laboratory equipment for molecular biology.

Vaecgene Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Proteomics, Drug Development, Immune Therapy, Infectious Diseases, Oncology

Vaecgene focuses on the research and development of novel therapeutics and in vitro diagnostics. Core competence and proprietary technology are the development of viral vectors that helped Vaecgene to establish a broad portfolio including individual drugs for immunological treatment of tumors and infectious diseases. Recently, Vaecgene has developed a new intelligent technology, AMIDA, for functional proteomics for fast and efficient identification and validation of tumor markers for early detection of cancer. In addition, the company offers services related to Epstein-Barr-Virus. The company has also extensive experience in monitoring and quantitating the immune competence in patients and non-human primates.

vasopharm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the bioavailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury. www.vasopharm.com

vermicon AG

BIOTECH AGRO, FOOD, ENVIRONMENT

vermicon AG offers solutions for microbiology. The company develops and markets products and services for the detection and analysis of microorganisms. Additionally the company offers microbiological consulting. Its approach is new and non-conventional. Our portfolio comprises: The products - our detection systems for industrial and private customers. The services - extensive analyses for microbiology. Microbiological consulting – the unique link between microbiology and consulting. The power of the technology portfolio combined with a strong and innovative team consisting of microbiologists and chemists allows us to explore completely new and exciting ways.

vertis Biotechnologie AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Chip / Array Technology, Genomics, PCR, Analysis

VERTIS was established in 2000 as a spin off from Technical University Munich-Weihenstephan, Germany. The company offers highest quality and fast turn-around molecular biology services in the field of functional genomics. VERTIS has developed an innovative technology platform which significantly accelerates gene discovery projects. VERTIS products and services can be broadly grouped into the following categories:

- cDNA synthesis ■ Full-length cDNA cloning ■ cDNA library construction
- Cloning and analysis of small non-coding RNA (sncRNA, the prototype of which is microRNA) ■ Profiling of gene expression using novel ultra high throughput MPSS DNA sequencing technology

VERUM.de GmbH

CRO

Keywords: Cardiovascular Diseases, Clinical Research, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases

VERUM is a CRO highly specialised in monitoring in Central and Eastern Europe, with experienced and well established monitoring units in the Czech Republic (since 1992), Hungary, Romania and in the Ukraine (all since 1996). VERUM also cover Slovakia and Kazakhstan. All 26 CRAs are highly educated (23 MDs), well trained and permanently employed. A long tradition combined with an excellent relationship to authorities and a broad experience from some 50 international projects guarantee the smooth conduct of a trial and high quality of the data. Client related key functions like reporting, contracting or invoicing as well as project and quality management are provided by the German head offices. The 40 Europe wide employees of VERUM have handled trials with up to 1200 patients per study. In addition to its core business, monitoring in CEE and performing of audits, VERUM offers a full CRO service to the client via an established network (PSN), including monitoring in Western Europe and all data management and statistics services.



Contact:
Barbara Roderus

Emmy-Noether-Str. 2
D-80992 München
Phone: +49 (0) 89 15882-0
Fax: +49 (0) 89 15882-100
E-Mail: info@vermicon.com
Internet: www.vermicon.com



Contact:
PD Dr. Fritz Thümmeler

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 1411211
Fax: +49 (0) 8161 1411212
E-Mail: info@vertis-biotech.com
Internet: www.vertis-biotech.com



Contact:
Christian Sacher

Sembdnerstr. 5
D-82110 Germering
Phone: +49 (0) 89 800777-60
Fax: +49 (0) 89 800777-88
E-Mail: verum@verum.de
Internet: www.verum.de



Contact:
Dr. Ludwig Furtmayr

Behringstr. 11
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 899336
Fax: +49 (0) 89 8599949
E-Mail: viramed@viramed.de
Internet: www.viramed.de



Contact:
Karl Appelmann

Henkestr. 91
D-91052 Erlangen
Phone: +49 (0) 9131 974434-0
Fax: +49 (0) 9131 974434-43
E-Mail: info@virologik.com
Internet: www.virologik.de



Contact:
Dr. Katja Wosikowski

Grillparzerstr. 25
D-81675 München
Phone: + 49 (0) 89 552797-590
Fax: + 49 (0) 89 552797-599
E-Mail: info@vivopharm.eu
Internet: www.vivoPharm.eu

Viramed Biotech AG

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, ELISA / EIA, Infectious Diseases

Based on 20 successful years on the German IVD-Market, Viramed Biotech AG produces and markets IVD-Products, based on its proprietary research and development. The company focuses on Westernblot-, Stripe- and Elisa-test kits for serological screening and confirmation of infectious and autoimmune diseases. The major products are Westernblot tests for *Borrelia* sp., *Yersinia*, *Heliobacter* p., Epstein-Barr-Virus, *Bordetella pertussis*, ENA and autoimmune liver diseases. New analytics based on purified and recombinant antigens are under development. The development of antigens and test kits for specific analytics are offered as service. The company aims to intensify export of existing products worldwide and appreciates further distribution contacts.

ViroLogik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Infectious Diseases

ViroLogik develops innovative drugs for treatment of viral diseases with a focus on Hepatitis C, HIV and Influenza.

ViroLogik devised a novel strategy to overcome the formation of drug-resistance. The approach aims at the inhibition of highly conserved host cell factors mandatory for viral replication. This is in contrast to many current drugs that target fast changing viral proteins and, hence, are prone to formation of drug resistance.

ViroLogik obtained a licence for a highly promising drug candidate and owns a broad panel of patents and patent applications. Comprehensive partnerships with leading research institutions, hospitals and pharmaceutical companies secure access to valuable expertise, networks and resources.

vivoPharm Europe Ltd

CRO

Keywords: Bone / Joint Diseases, Metabolic Diseases, Oncology, Drug Development, Medical Writing, Pharmacology, Toxicology

vivoPharm is a contract research organisation (CRO) based in Australia. It offers integrated preclinical services to the biotechnology and pharmaceutical industries, which include in vitro and in vivo efficacy, safety, toxicology (GLP), pharmacodynamic and pharmacokinetic analyses.

The company's advanced animal facilities, laboratories and corporate headquarters are located in Adelaide, Australia. Its European office is based in Munich, Germany. vivoPharm works closely with its clients to develop a flexible experimental design to best serve each customer's individual needs. vivoPharm operations are GLP compliant and meet the highest industrial standards, acknowledged by customers worldwide.

Wacker Chemie AG

CHEMICAL INDUSTRY & INDUSTRIAL BIOTECHNOLOGY

Keywords: Nutraceuticals, Peptide/Protein, Antibody Production Service, Fine Chemicals / Reagents

WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Its products are required in countless high-growth end-user sectors such as photovoltaics, electronics, pharmaceuticals and household/personal care products.

Within its bio division, WACKER uses advanced biotech processes to offer innovative and tailored solutions and biotech products for the pharma and the food & nutrition industry. Its products include pharmaceutical proteins, cyclodextrins and fermentation-grade cysteine. The division focuses on developing customized solutions for growth sectors such as food additives and pharmaceutical actives.

Wilex AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Small Molecules, Oncology

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the company has a broad portfolio of near-to-market therapeutic and diagnostic products for the targeted treatment and specific detection of various types of cancer. The company's therapeutic product candidates are based on antibodies and small molecules. Through its US subsidiary WILEX Inc. in Cambridge, MA, WILEX markets a portfolio of oncological biomarker tests under the brand Oncogene Science. These biomarkers can be used as companion diagnostics in clinical trials and for therapy monitoring. Furthermore, the acquisition of Heidelberg Pharma AG is set to give WILEX access to an attractive and highly promising antibody drug conjugate technology platform and a pre-clinical service business. The business model of WILEX covers the entire value chain in the oncology market and comprises research, technology, development collaboration as well as sales and marketing. WILEX's customers and partners include leading international pharmaceutical companies. Website: <http://www.WILEX.com>, ISIN DE0006614720 / WKN 661472 / Symbol WL6



Contact:
Rachela Mohr

Hanns-Seidel-Platz 4
D-81737 München
Phone: +49 (0) 89 6279-0
Fax: +49 (0) 89 6279-1770
E-Mail: info@wacker.com
Internet: www.wacker.com



Contact:
Katja Arnold

Grillparzerstr. 10
D-81675 München
Phone: +49 (0) 89 413138-0
Fax: +49 (0) 89 413138-99
E-Mail: investors@wilex.com
Internet: www.wilex.com



Contact:
Kilian Schramm

Karlstr. 55
D-80333 München
Phone: +49 (0) 89 4524466-0
Fax: +49 (0) 89 4254466-50
E-Mail: kilian.schramm@wimasis.com
Internet: www.wimasis.com



Contact:
Susanne Roth

Deuschherrnstr. 15-19
D-90429 Nürnberg
Phone: +49 (0) 911 926800
Fax: +49 (0) 911 9268039
E-Mail: wn@winicker-norimed.de
Internet: www.winicker-norimed.de



Contact:
Prof. Dr. Arne Skerra

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 53730-90
Fax: +49 (0) 8161 53730-99
E-Mail: info@xl-protein.com
Internet: www.xl-protein.com

Wimasis GmbH

BIOTECH BIOINFORMATICS

Keywords: Inflammation, Dermatology, Cardiovascular Diseases, Microscopy, Automation, Devices

Wimasis is an image analysis servicer in the field of life science, preclinical and clinical research. It's focus lies in the automation of image analysis tasks via an intuitive, web-based interface, that allows access to large scall computing power. With multiple fully automated solutions in the life sciences (Scratch, Tube Formation, Chemotaxis Assays, etc.), Wimasis has grown a worldwide userbase from Australia to Zypress. Besides the ongoing development projects in the field of cell-based assays, many custom solutions are continuously being developed for *in vitro* and *in vivo* analysis. If you are looking at cells, tissue or data generated from clinical imaging modalities, Wimasis can help you solve the automation task with cost efficient tools.

Winicker Norimed GmbH – Medizinische Forschung

CRO

Winicker Norimed, established in 1993, is a full service Contract Research Organization, located in Southern Germany in the center of Nuremberg. Our highly skilled personnel has many years of professional experience in clinical research and consists of physicians, life scientists, psychologists, statisticians and other specialists with medical background. Our reputation is based on professionalism, personal commitment and an efficient client-oriented cooperation. We deliver quality by exclusively working according to internationally accepted standards, Good Clinical Practice and by following our or our clients' Standard Operating Procedures. Winicker Norimed offers a full range of services in clinical research, from planning through reporting. We manage and conduct phase II-IV clinical trials, non-interventional trials, epidemiological studies and registers.

XL-protein GmbH

BIOTECH

Keywords: Peptide/Protein, Pharmacokinetics, Drug Development

XL-protein is a biopharmaceutical company utilizing its proprietary 'PASylation' technology to develop second generation biopharmaceuticals with prolonged plasma half-life. PASylation of therapeutic proteins allows less frequent and lower dosing combined with better tolerability, also opening perspectives for follow-on products of approved biopharmaceuticals. 'PASylation' – the genetic fusion with conformationally disordered polypeptide sequences composed of the amino acids Pro, Ala, and Ser – provides a superior way to attach a solvated random chain with large hydrodynamic volume to a biologically active protein. Thus, its typically rapid clearance via kidney filtration can be retarded by one to two orders of magnitude while the PAS moiety is biochemically inert and easily degradable.

X-Pert Med GmbH

CRO

Keywords: Clinical Research

X-pert Med GmbH is a family owned and operated CRO/SMO with a focus in pain, musculoskeletal medicine and dermatology. The company is managing clinical trials and development programs like a CRO with a focus on services that require an M.D. since 5 of the 20 employees are M.D's (e.g. medical monitoring, pharmacovigilance). In addition, we serve as investigators for both sponsor and investigator sponsored clinical trials. This helps us to translate experiences from daily care of patients into clinical trials protocols or development programs. We have access to validated clinical surrogate models to test concepts in the early stages of clinical development, e.g. UVB induced pain and inflammation, muscle pain induced by eccentric contraction, psoriasis plaque test, UVB irritation/sensitization.

Xvir Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. Such cancer therapies are based on the use of oncolytic adenoviruses restoring drug sensitivity and radiation-sensitivity, respectively, of the tumors. Experimental evidence for the efficacy of Xvir's therapeutic approach has been provided in several animal studies. Xvir's therapeutic approach is covered by proprietary patents and patent applications, respectively.

Zentrum für Humangenetik und Laboratoriumsmedizin Dr. Klein und Dr. Rost GbR

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: ELISA / EIA, Chip / Array Technology, Genomics, Microscopy, PCR, Pharmacogenomics, Pharmacogenetics

The Center for Human Genetics und Laboratory Medicine Dr. Klein and Dr. Rost in Martinsried was founded in 1998 and is accredited according to DIN EN ISO/IEC 17025 and ISO 15189. The facility provides quality genetic services in diagnostics, prevention and management of hereditary disorders as well as birth defects affecting the fetus, the newborn, the child and adults. The laboratory provides DNA/RNA testing for more than 200 diseases, continuously developing new tests and implementing state-of-the-art technologies such as array-CGH and Next Generation Sequencing (NGS).



Contact:
Dr. med. habil. Matthias Rother

Lärchenstr. 3-3a
D-82166 Gräfelfing
Phone: +49 (0) 89 89665425
Fax: +49 (0) 89 82084607
E-Mail: info@x-pert-med.de
Internet: www.x-pert-med.de



Contact:
Dr. Per Sonne Holm

Nymphenburger Str. 1
D-80335 München
Phone: +49 (0) 89 99317446
Fax: +49 (0) 89 51556413
E-Mail: info@xvir.com
Internet: www.xvir.com



Contact:
Dr. Hanns-Georg Klein

Lochamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 895578-0
Fax: +49 (0) 89 895578-78
E-Mail: info@medizinische-genetik.de
Internet: www.medizinische-genetik.de

Biotech Incubators in Bavaria

www.igz.wuerzburg.de

www.izmp-erlangen.de

www.bioregio-regensburg.de



Würzburg

Bayreuth

Erlangen

Nuremberg

Regensburg

Straubing

Freising

Munich

Martinsried

www.straubing-sand.de/biocampus

www.izb-online.de



Er erkennt, was bei wem am besten wirkt.

Jeder Mensch ist anders – auch genetisch. Deshalb setzen wir auf Personalisierte Medizin: Unsere Bereiche Pharma und Diagnostics arbeiten gemeinsam an Tests und Wirkstoffen, um Therapien besser auf die Bedürfnisse von Patienten abzustimmen.

Unsere Innovationen helfen Millionen Menschen, indem sie Leid lindern und Lebensqualität verbessern. Wir geben Hoffnung.

www.roche.de



Innovation für die Gesundheit

Life Sciences

Creative legal services for your success

Life Sciences is an innovation-driven field with an enormous potential for growth. Our future-oriented legal services accelerate your strategic, tax, organizational and regulatory decisions. Let us support you with creativity, knowledge and efficiency.

Find out more:

Raupach & Wollert-Elmendorff

Peter Homberg

phomberg@raupach.de

Franklinstraße 48

60486 Frankfurt am Main

Phone: +49 (0)69 71 91 884-0

Fax: +49 (0)69 71 91 884-4

www.raupach.de

**Raupach
& Wollert-Elmendorff**

Rechtsanwaltsgesellschaft mbH

Berlin Düsseldorf Frankfurt/Main Hamburg
Hannover München Stuttgart